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Summary 
The potential of respiration measurements, metabolomics and 13C metabolic flux analysis (13C-
MFA) for the determination of drug-induced cardiotoxicity was analysed. Two cardiac in vitro 
models, namely murine HL-1 cells and human embryonic stem cell derived cardiomyocytes 
(hESC-CM) were applied for this purpose. 
Respiration measurement in HL-1 cells upon drug treatment revealed distinct EC50 profiles. The 
toxicity occurred either fast or with a delay. This effect was dependant on the mechanism of 
toxicity of the respective drugs. 
Metabolite profiling of HL-1 cells in response to sub-toxic drug concentrations was carried out 
by using HPLC. The considered metabolites included glucose, lactate, pyruvate and amino acids. 
The metabolic profiles were drug class dependant, as shown by multivariate statistics, thereby 
allowing classification of drugs according to their mechanisms of action. 
13C-MFA was carried out to determine the effect of Ca2+ channel blocker verapamil and the 
cytostatic drug doxorubicin on the central metabolism at concentrations which were clinically 
relevant and non-toxic. Verapamil-treatment resulted in a highly efficient glucose metabolism in 
HL-1 cells. In both HL-1 cell and hESC-CM, doxorubicin-treatment resulted in an increased 
oxidative metabolism, most likely to avoid ATP-depletion. 
The obtained results potentially have pharmacological relevancy, but also provide novel 
strategies for preclinical toxicity determination of new drug compounds. 
Zusammenfassung 
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Zusammenfassung 
In dieser Arbeit wurde das Potential von Respirationsmessungen, Metabolomics-Anwendungen 
und 13C basierten metabolischen Flussanalysen (13C-MFA) zur Bestimmung von Medikamenten-
induzierter Kardiotoxizität untersucht. Es wurden HL-1 Kardiomyozyten sowie aus humanen 
embryonalen Stammzellen gewonnene Herzzellen (hESC-CM) als in vitro Modelle verwendet. 
Die Respirationsmessungen an HL-1 Zellen ergaben je nach Medikament sehr unterschiedliche 
EC50-Dynamiken. Der toxische Effekt trat entweder sehr schnell oder mit einer zeitlichen 
Verzögerung ein. Die EC50-Dynamiken waren von den Toxizitätsmechanismen der 
entsprechenden Medikamente abhängig. 
Die Erstellung von Metabolit-Profilen in HL-1 Zellen wurde nach Gabe von subtoxischen 
Medikamentenkonzentrationen mittels HPLC durchgeführt. Es wurden Glukose, Laktat, Pyruvat 
sowie 20 Aminosäuren gemessen. Mit Hilfe multivariater statistischer Methoden konnten 
Medikamentenklassen-abhängige Metabolit-Profile bestimmt werden.  
13C-MFA wurde angewandt, um den Einfluss des Kalziumkanal-Blockers Verapamil sowie des 
Zytostatikums Doxorubicin auf den Zentralstoffwechsel zu bestimmen. Die betrachteten 
Konzentrationen der Wirkstoffe waren sowohl klinisch relevant also auch nicht toxisch. Die 
Behandlung von HL-1 Zellen mit Verapamil resultierte in einer deutlich höheren Effizienz in der 
Glukosenutzung. Sowohl in hESC-CM als auch in HL-1 Zellen resultierte die Doxorubicin-
Behandlung in einer Zunahme des oxidativen Stoffwechsels, welche wahrscheinlich der 
Aufrechterhaltung der intrazellulären ATP-Konzentration dient. 
Die erzielten Ergebnisse haben pharmakologische Relevanz und zeigen des Weiteren auch neue 
Strategien für präklinische Kardiotoxizitäts-Messungen von neuen Wirkstoffen. 
Introduction 
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Chapter 1 
Introduction 
 
Drug induced cardiotoxicity and the need for predictive in vitro models and 
assays 
Drug induced cardiotoxicity may emerge as altered cardiac contractility, changes of cardiac 
rhythm or ischemia (Mandenius et al., 2011). These potentially life threatening side effects still 
challenge the pharmaceutical industry as well as drug regulatory agencies (Darpo, 2007) and 
have resulted in drug withdrawal from the market in the past several years (Gwathmey et al., 
2009). The withdrawal of several cardiac and non-cardiac drugs due to cardiotoxic effects in 
man, while toxicity was observed in animals (Lasser et al., 2002; Lexchin, 2005; Redfern et al., 
2003), has led to extended requirements by regulatory authorities concerning cardiotoxicity 
testing. Determination of cardiotoxicity in preclincial studies is therefore of high importance in 
the regulatory procedure. Cardiotoxicity assessment should be oriented on guidelines regarding 
repeated dose studies as well as cardiac safety pharmacology ((ICH) S4 guideline (ICH, 1997), 
EMEA (EMA, 2008; ICH, 2005). These guidelines suggest electrophysiological aspects in vitro 
and in vivo such as repolarisation and conduction abnormalities, heart rate and ECG. In addition, 
the assessment of endpoints such as blood pressure, heart rate or cardiac output is recommended.  
Preclinical in vitro determination of cardiac side effects mainly comprises electrophysiological 
measurements in canine or rabbit Purkinje fibers and cell lines which express the hERG ion 
channel (Braam et al., 2010). Drug induced prolongation of the QT interval in an 
electrocardiogram (ECG) potentially produces a risk of cardiac arrhythmia, such as Torsades de 
Pointes (TdP), which can result in sudden death. In an ECG the QT-interval is defined as the time 
span between the start of the QRS-complex and the termination of the T-wave (Braam et al., 
2010).  
Reliable electrophysiological measurements require appropriate cell models. The major drawback 
of animal models is the low predictability of cardiotoxic outcome in humans. Ideally, primary 
human cardiomyocytes represent a convenient cardiac model, as they possess all relevant ion 
channels. However, the use of primary human cardiomyocytes is limited by a shortage of 
available cells. Irrespective of the cardiac cell model, predictions of cardiotoxic outcome merely 
Introduction 
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based on electrophysiological measurements seem insufficient since molecular and energetic 
aspects of cardiotoxicity might be neglected. Characterization of functional parameters such as 
substrate usage and metabolic fluxes by using state of the art analysis on reliable cardiac cell 
types, such as hESC-CM may greatly improve the prediction potential of a test system, thus 
providing a more reliable test system. 
 
Cardiac in vitro models for preclinical drug testing 
Determination of potential cardiac effects of new chemical entities (NCE) in man necessitates 
cardiac in vitro models which closely mimic the terminally differentiated, adult cardiomyocyte in 
terms of concerted ion channel activity (Mandenius et al., 2011) but also in terms of the substrate 
spectrum for ATP generation. Ideally, such an in vitro model is of human origin which would 
circumvent interspecies variability, especially when considering the low predictive power of 
animal models. The use of human cardiomyocytes ex vivo is rather limited for drug testing 
purposes, since these cells are non-proliferating and their availibilty is very limited for obvious 
reasons. Human embryonic stem cells (ESCs) can be differentiated into spontaneously 
contracting cells with characteristics of cardiomyocytes (Jensen et al., 2009; Kehat et al., 2001; 
Synnergren et al., 2008). It has been suggested that cardiomyocytes derived from human 
embryonic stem cells (hESC-CM) may be used as in vitro cardiac test models since their 
functionality makes them attractive and applicable for drug discovery and drug testing (Jensen et 
al., 2009). To date the physiology of hESC-CM has been extensively characterised. One main 
advantage of hESC-CM over primary cardiomyocytes is that they can be maintained in culture 
while keeping a contractile phenotype. Besides that, functional synchronisation of contraction can 
be observed both in monolayer culture and in larger cell aggregates. In addition, gene expression 
levels of voltage-gated potassium channels (hERG) are similar as compared with human cardiac 
tissue (Asp et al., 2010; Mandenius et al., 2011). The presence of hERG channels is of high 
importance since drug-induced QT-prolongation can be the result of interaction with the hERG 
ion channel (Moss and Kass, 2005). Recent work on hESC-CM demonstrated the potential of 
these cells for predictive in vitro drug testing by using multielectrode arrays (MEA) (Braam et 
al., 2010; Caspi et al., 2009), a system which allows much higher and less costly throughput as 
compared with conventional patch clamp techniques using single cells.  
Besides hESC-CM other animal cardiac cell models are available for use either for interspecies 
comparison, method optimisation or method validation. Primary cells from either chicken or rats 
Introduction 
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are widely used as a cardiac in vitro model. Murine HL-1 cardiomyocytes, a cardiac muscle cell 
line, derived from an atrial mouse tumour lineage (Claycomb et al., 1998), represent a very 
convenient alternative to neonatal chicken heart cells or rat cardiomyocytes. These cells can be 
serially passaged, without loosing their ability to contract. Besides, HL-1 cells maintain a 
differentiated cardiac phenotype, regarding biochemical and electrophysiological properties 
(Claycomb et al., 1998; White et al., 2004). HL-1 cells have been shown to be quite useful for 
studying cardiac physiology (Claycomb et al., 1998; White et al., 2004) since they express many 
genes typical for differentiated adult cardiomyocytes (Claycomb et al., 1998). HL-1 
cardiomyocytes express several cardiac ion channels, such as L-and T-Type Ca2+ channels (Xia 
et al., 2004), ATP-sensitive K+ channels (Fox et al., 2005) and inward rectifier K+ channels 
(Goldoni et al., 2010). These properties make them attractive for preclinical studies on drug 
induced cardiotoxicity.  
Nevertheless, the non-human origin of both HL-1 cells and animal derived primary cells might 
not allow any reproductive conclusions in man, as they do not mimic human cardiomyocytes 
(Mandenius et al., 2010). Besides, HL-1 cells are highly relying on glycolysis (Monge et al., 
2009), while the adult human myocardium mainly relies on oxidative metabolism.  
 
Respiration measurement in cardiac cells using oxygen sensitive sensors 
The healthy and resting human myocardium covers 70-80% of its energy demand by oxidation of 
fatty acids. The remainder is covered by catabolism of glucose and organic acids. This 
distribution is owed to the high amount of ATP which can be gained from oxidation of one mole 
of fatty acids. The stepwise process of ß-oxidation of fatty acids leads to the formation of actyl-
CoA which enters the TCA-cycle to gain NADH+H+ and FADH2. The reduction equivalents 
enter the respiratory chain in the inner mitochondrial membrane where they are oxidized at 
respiratory complex I or II. The electrons are transferred to molecular oxygen, a process which is 
coupled to phosphorylation of ADP to yield ATP. The rather high workload of the contracting 
cardiac tissue highly depends on oxidative metabolism. In ischemic heart disease altered cardiac 
respiration is the result of insufficient bloodflow and thus oxygen supply, which may result in 
energy deprivation. Besides cardiac disease, drug induced alterations of cardiac respiration can be 
the result of altered cardiac substrate usage. Changes in substrate metabolism may lead to 
contractile dysfunction (Stanley et al., 2005). Both altered substrate usage and respiration have 
been observed in case of some drugs with potential or known cardiac risk.  
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Measuring cardiac respiration in response to new chemical entities (NCE) both in vivo and in 
vitro might reflect the cardiac energy status and thus provide information of potential cardiac 
risk. Determination of cardiac oxygen consumption might therefore complement well established 
preclinical measurements of cardiac electrophysiological of either single cells or isolated animal 
hearts.  
Several methods for the determination of oxygen consumption are available, such as Clark 
electrodes or electrochemical cells (Ramamoorthy et al., 2003). Clark electrodes are most 
commonly used. Though, the major drawback of this method is the oxygen consumption by the 
electrode (Ramamoorthy et al., 2003; Wilson et al., 1987). In addition, they are not easily 
applicable for high throughput measurements since several cost-intensive electrodes would be 
required. In preclinical in vitro drug testing on cardiac models, the use of non-invasive 
immobilised fluorescence based sensors  (Bambot et al., 1994; John et al., 2003) would provide a 
convenient solution for high throughput drug testing, since they are now broadly available in high 
density well formats. 
Use of oxygen sensitive optodes in drug screening has been shown to be very reliable (Beckers et 
al., 2009; Deshpande et al., 2005; Hynes et al., 2003; Wodnicka et al., 2000) On top of that, 
optodes allow the determination of dynamic toxic effects, as shown recently (Beckers et al., 
2009; Noor et al., 2009; Wolf et al., 2011).  
 
Metabolomics in cardiac research 
Metabolomics or metabolite profiling includes the quantitative and qualitative analysis of the 
complete set of small molecules in a certain biological system, e.g. in prokaryotic or eukaryotic 
cells, body fluids and tissues (Koek et al., 2011). Metabolome analysis involves quantitative or 
qualitative measurement of extracellular and/or intracellular metabolites. Most frequently, 
chromatographic techniques combined with mass spectrometry are applied, such as GC/MS or 
LC/MS. The measurement of small molecules potentially allows conclusions about alterations of 
metabolic pathways upon perturbation by either disease or pharmacological intervention. The 
metabolome may be more tractable than the proteome, due to its lower complexity (Lewis et al., 
2008). It is assumed that the human metabolome consists of approximately 3000 metabolites, 
while the complexity of post-transtranslational modifications of proteins might give 106 protein 
species. The metabolome comprises many different compound classes, including metabolites 
which are anionic and cationic as well as lipophilic and hydrophilic (Lewis et al., 2008). 
Introduction 
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Presently, several different strategies are applied in metabolomics research, i.e. metabolic target 
analysis, metabolic profiling, metabolic fingerprinting and metabolomics (Koek et al., 2011). 
According to Koeck et al. metabolic target analysis can be summarized as the quantitative 
(absolute or relative) analysis of one or only a few metabolites. Metabolic profiling refers to the 
quantitative and qualitative analysis of metabolically or analytically related metabolites. 
Metabolic fingerprinting was defined as the screening of samples to provide sample 
classification. Metabolomics aims at quantification and qualitative analysis of the total set of 
metabolites in a biological matrix (Koeck et al., 2011).  
Most metabolomics related studies result in high dimensional data sets. For the proper analysis of 
potential differences in the metabolite concentrations between healthy/untreated control groups 
and diseased/treated groups the respective sample or patient groups should be large enough to 
allow statistical reliability and furthermore necessitate proper statistical tools which allow 
analysis of multivariate data. These tools comprise either unsupervised or supervised algorithms 
(Blekherman et al., 2011). Principal component analysis (PCA) is an unsupervised data analysis 
method which is used for dimension reduction and data visualisation, preferably in a 2-
dimensional space. Other common unsupervised methods are hierarchical clustering and self-
organizing maps. Supervised statistical methods are mainly used for generating classification 
models (healthy vs. diseased) based on observed sample readings, e.g. by linear regression in 
order to find the best linear predictor of a class (Blekherman et al., 2011). Most popular 
supervised methods in metabolomic studies include ANOVA, partial-least square discriminant 
analysis (PLS-DA) and discriminant function analysis (DFA). 
The use of metabolomic techniques and appropriate data analysis potentially allows the 
identification of novel biomarkers of drug induced cardiotoxicity and the respective mechanism 
of toxicity. Many cardiac diseases are related to alterations of cardiac substrate utilisation and 
energy deprivation (Ashrafian and Neubauer, 2009; Griffin et al., 2011; Mayr, 2008; Stanley et 
al., 2005). Thus, the number of metabolomic studies carried out in plasma and body fluids have 
increased in the past several years. Recently, MS–based  measurement of metabolic changes in 
plasma/serum of patients in whom ischemia was either induced by stress or due to cardiac 
surgery were determined (Sabatine et al., 2005; Turer et al., 2009). Both studies suggested 
significant alterations of TCA-cycle activity in the course of ischemia and potentially provided 
targeted optimization in patients undergoing cardiac surgery.   
Introduction 
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Besides biomarker identification of cardiac diseases, it has also been used in toxicity assessments 
of drugs. By using 1H-NMR spectroscopy the effect of 3,4-methylenedioxymethamphetamine on 
the metabolism in rat hearts was determined (Perrine et al., 2009). In addition, the effect of 
doxorubicin, an anticancer drug with high cardiotoxic side effects, has been assessed similarly 
(Andreadou et al., 2009).  
It can be assumed that metabolomic studies have high potential in preclinical studies on 
cardiotoxic side effects of new chemical entities. By mapping metabolic effects of compounds 
with known cardiac effects in humans, preferably by using hESC-CM, the risk of new chemical 
entities/pharmaceuticals for cardiac side effects might be reliably assessed, e.g. by applying 
pattern recognition techniques on the basis of clinically observed side effects, such as QT-
prolongation or cardiac arrest.  
 
13C metabolic flux analysis  
The quantification of cellular metabolism is of great interest in several fields of biotechnological 
research (Kohlstedt et al., 2010; Niklas and Heinzle, 2011; Niklas et al., 2010; Quek et al., 2010; 
Wittmann, 2007; Zupke et al., 1997). By applying metabolic flux analysis quantitative 
information on enzyme activity as well as substrate utilisation can be obtained (Vo and Palsson, 
2006). Estimation of intracellular fluxes relies on both experimental measurements but also 
computational approaches. Metabolic fluxes can be determined either by flux balance analysis 
(Lee et al., 2006) (FBA, metabolite balancing) or by applying 13C-labelled substrates (Lee et al., 
2006; Schmidt et al., 1998) (13C metabolic flux analysis). Determination of metabolic fluxes by 
using FBA is the least complicated method among all MFA methods in terms of both 
experimental and computational techniques. Experimentally, it mainly necessitates measurement 
of metabolite uptake and production rates of a cell population. A set of linear mass balance 
equations around intracellular metabolites is set up and the information in the metabolic network 
is stored in a stoichiometric matrix. This matrix contains information of known fluxes (measured 
extracellular uptake and production fluxes) and unknown intracellular fluxes. In case of 
determined systems the set of equations can easily be solved. In case of underdetermined 
systems, linear programming tools help finding an optimal solution space, depending on the 
defined objective function.  
Introduction 
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The main assumption in FBA is usually a metabolic steady-state, i.e. constant concentrations of 
intracellular metabolites. FBA has been successfully applied to study mammalian cell 
metabolism (Niklas et al., 2009; Niklas et al., 2010; Sidorenko et al., 2008).  
The major drawback of FBA is that it does not allow to resolve reversible, parallel or circular 
reactions (Niklas et al., 2010). These drawbacks can be tackled with 13C metabolic flux analysis 
approaches. The use of 13C tracers (e.g. 13C-labelled glucose) combined with the GC/MS based 
analysis of 13C-enrichment in intra- or extracellular metabolites or in monomers from cellular 
polymers (e.g. amino acids in proteins) allows a more reliable determination of intracellular 
fluxes. For 13C metabolic flux analysis several modelling approaches have been established. 
These approaches are mainly optimization-based and fit an intracellular flux distribution to the 
measured 13C labelling pattern of the considered metabolites. These concepts mainly make use of 
atom mapping matrices (Zupke et al., 1997) and isotopomer mapping matrices (IMM) (Schmidt 
et al., 1997), which allow to track the carbon transfer in individual enzymatic reactions.  
While metabolic flux analysis in prokaryotic cells is a well established procedure, e.g. in the field 
of metabolic engineering, application of this methodology in eukaryotic cells is still very limited, 
mainly due to compartmentation in these cells but also due to necessary biological conditions, 
such as metabolic and/or isotopically steady state, which are rather hard to achieve in these 
systems (Niklas et al., 2010). 
Nevertheless, metabolic flux analysis has been used for the analysis of mammalian metabolism 
mainly in the areas of cell culture technology as reviewed recently (Niklas et al., 2010). Other 
applications include the physiological characterization of animal cell lines, such as hybridomas 
(Bonarius et al., 2001), CHO-cells (Goudar et al., 2010), human production cell lines (Henry et 
al., 2011; Niklas et al., 2011), hepatocytes (Maier et al., 2009), kidney cells (Sidorenko et al., 
2008), the analysis of effects of drugs (Niklas et al., 2009).  
13C tracer studies have been carried out to determine the substrate metabolism and anaplerosis in 
the heart (Cohen and Bergman, 1997; Comte et al., 1997a; Comte et al., 1997b; Malloy et al., 
1996; Malloy et al., 1987; Panchal et al., 2001). In most of the studies the fluxes were 
analytically derived. It has been suggested that such analytical solutions are only applicable for 
small network models and not obtainable for some pathway structures (Vo and Palsson, 2006).  
A 13C-based analysis of carbon substrate metabolism in the perfused mouse heart applying the 
IMM concept was recently described (Vo and Palsson, 2006). Detailed studies on the effect of 
cardiotoxic drugs on the cardiac metabolism by means of metabolic flux analysis hasn´t been 
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carried out and is rather limited to toxicological studies in hepatic cell models (Maier et al., 2009; 
Niklas et al., 2009). Given that the failing heart changes its substrate spectrum (Stanley et al., 
2005), metabolic flux analysis using systemic approaches, as recently described (Vo and Palsson, 
2006) might potentially be useful for the preclinical determination of a drug candidates influence 
on cardiac energy metabolism. Ideally, such studies would make use of reliable in vitro cell 
models, such as human embryonic stem cells derived cardiomyocytes. 
 
Objective of the thesis 
The main objective of this thesis is to determine the potential of 1. dynamic respiration 
measurement systems, 2. metabolite profiling (metabolomics) and 3. 13C-metabolic flux analysis 
in preclinical in vitro cardiotoxicity testing of drug compounds. Two different cardiac in vitro 
models were used, namely HL-1 cardiomyocytes and cardiomyocytes derived from human 
embryonic stem cells (hESC-CM). For the assessment of the applicability of each method and in 
vitro model for drug testing a set of drugs with known pharmacology and cardiotoxic risk in man 
were considered. The applied drugs comprised several pharmacological classes such as 
antiarrhythmics, cytostatics, antihistamines and psychoactive drugs. Each of the methods was 
optimized by using HL-1 cardiomyocytes prior to the use of hESC-CM, since HL-1 cells are 
easier to maintain and their availability is not limited, due to their proliferating phenotype. 
The first part of this thesis mainly consists of cytotoxicity screening of model drugs with known 
pharmacological effects. This cytotoxicity screening was carried out by applying dynamic 
respiration measurement in HL-1 cells or hESC-CM using oxygen sensitive optodes. Since the 
dynamic aspect of respiration measurement using optodes seems to have a high potential, 
corresponding dynamics of drugs tested on HL-1 cells and hESC-CM were established and 
compared. In addition, determination and comparison of EC50 dynamics of cardioactive drugs, 
oxygen measurement based cytotoxicity screening provided essential information for subsequent 
metabolomic and fluxomic studies, since it gave information on the toxicity range of a 
compound.  
The second main objective was to assess whether metabolite profiling on HL-1 cells and hESC-
CM allows the determination of potential cardiotoxic side effects of new drug compounds.  
Significant alterations in the metabolome at drug concentrations significantly below EC50 values 
where common toxicity screening assays fail to suggest potential harm in in vitro assays would 
illustrate the benefit of metabolomics as in additional tool for in vitro drug testing. This part of 
Introduction 
 11
the work comprised the exposure of HL-1 cells to drugs, analysis of the metabolome in the 
respective culture medium and finally the data evaluation using multivariate statistics, which are 
commonly used in this field. For this kind of analysis drug concentrations were considered which 
showed no significant alteration of cell respiration, as determined in the first part of the thesis.  
The third main objective of the thesis was the determine whether 13C metabolic flux analysis on 
HL-1 cells and hESC-CM allows the determination of drug induced changes of fluxes in central 
metabolic pathways, such as glycolysis and TCA-cycle. Similar to the metabolite profiling 
approach, 13C MFA was carried out at drug concentrations which did not result in alterations of 
cell viability i.e. at sub-toxic concentrations.   
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Chapter 2 
EC50 dynamics for a better understanding of toxicity 
Abstract 
Determination of the EC50 dynamic of a drug can give valuable information on the mechanism of 
its toxicity. Recent studies have reported the applicability of dynamic measurement of parameters 
such as dissolved oxygen or pH, as possible estimators of cellular respiration or metabolic 
activity. However, a direct comparison of EC50 dynamics obtained from reported approaches with 
corresponding dynamics of common cytotoxicity assays hasn’t been carried out yet. In addition, 
variability of EC50 dynamics of drugs from the same and from different pharmacological classes 
has not been determined yet. 
First, we assessed the performance of a recently described dynamic screening system (24 – well 
OxoDishes) by comparing time dependant EC50 values with values obtained from two common 
cytotoxicity assays (SRB- and LDH assay) by screening four different drugs (amiodarone, 
desipramine, doxorubicin, terfenadine) on HL-1 cardiomyocytes. Secondly, we assessed to what 
extent EC50 dynamics obtained from oxygen measurement were differing between model drugs 
belonging to different pharmacological classes. For this purpose, another five drugs from similar 
classes were screened by oxygen measurement and the data of nine different EC50 dynamics were 
compared by calculating the Euclidean distance. 
EC50 values obtained from oxygen measurement showed no significant differences as compared 
to corresponding values from SRB- and LDH assays for all considered time points. Though, SRB 
showed the highest sensitivity of all three assays, while LDH assay was least sensitive. 
Comparison of EC50 dynamics from an extended panel of tested drugs revealed distinct 
differences in the EC50 profiles. Data analysis by means of hierarchical clustering revealed 
distinct grouping of drugs according to known toxic effects, for the majority of drugs. 
Considering EC50 dynamics of a drug can give information on the time dependant toxicity of a 
drug. This information can not be obtained from sole consideration of individual EC50 values at a 
certain time point. This approach might therefore be a valuable tool for the estimation of the 
potential mechanism of action and/or toxicity of a drug candidate.  
 
This chapter has been submitted as a manuscript in the Journal of Applied Toxicology. 
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Introduction 
The pharmacological assessment of the toxicity of a drug is mainly carried out using routine 
toxicity assays during preclinical drug development. Most of these assays are carried out upon 
exposure of cells to a compound for a certain period and the half effective concentration (EC50) is 
determined for the respective time period. However, determination of EC50 dynamics necessitates 
use and preparation of several cell culture plates in parallel (Beckers et al., 2009). In addition, 
due to the invasive nature of many commonly used assays such as MTT, XTT or WST-1, in 
which a reagent is added to the cells, reduction of these dyes by media components or by 
reducing groups of drugs (Hynes et al., 2003) cannot be excluded. The reagent may itself have an 
adverse effect which is not observed by commonly used assays.  
To overcome these drawbacks non-invasive immobilised fluorescent based sensors (Bambot et 
al., 1994; John et al., 2003) for the measurement of dissolved oxygen have been developed and 
were described as a convenient solution. Use of oxygen sensitive optodes in drug screening using 
mammalian cell culture has been demonstrated as a potential alternative to commonly used 
cytotoxicity assays (Beckers et al., 2009; Deshpande et al., 2005; Hynes et al., 2003; Wodnicka 
et al., 2000). Furthermore, determination of EC50 dynamics has been reported for several drugs 
and cell types (Beckers et al., 2009; Noor et al., 2009; Wolf et al., 2011).  
Although use of fluorescent dyes as a potential alternative to common cytotoxicity assays has 
been proposed, a direct comparison of EC50 dynamics obtained via oxygen measurement and 
other common assays has not been carried out yet. Besides, to our knowledge no study has 
performed a direct comparison of EC50 dynamic profiles within drugs of the same class and 
within different classes. Thus, it is not clear whether compounds from the same pharmacological 
class share similarities in their EC50 dynamics. We addressed these issues and compared time 
dependant EC50 values of amiodarone (antiarrhythmic), terfenadine (antihistamine), desipramin 
(antidepressant) and doxorubicin (antineoplastic) using a murine atrial cell line (HL-1 cells). We 
measured respiration/oxygen-consumption and compared the results with LDH and 
sulforhodamine B assay. The HL-1 cells were first described by Claycomb et al. (1998). HL-1 
cells have been extensively used for toxicological and pharmacological studies (Andersson et al., 
2010; Deng et al., 2009; Fox et al., 2005; Fritzsche et al., 2009; Strigun et al., 2011a) and are 
quite useful for studying concentration dependant toxic drugs effects as shown recently (Fritzsche 
et al., 2009; Strigun et al., 2011a).  
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Due to the different mechanism of toxicity of the mentioned drugs which have known toxic side 
effects, we assumed that these different toxic mechanisms are also reflected in the respective 
EC50 dynamics. 
 
Material and methods 
Cell Culture  
HL-1 cells (Claycomb et al., 1998) were kindly provided by Dr. Claycomb (Louisina State 
University) for research within the framework of EU-Invitroheart project (LSHB-CT-2007-
037636). The cells were maintained in Claycomb medium (Sigma Chemical, USA) supplemented 
with 2 mM glutamine (PAA Laboratories, Austria), 100 U/ml penicillin 100 µg/ml streptomycin 
(PenStrep stock solution: CC Pro, Germany), 100 µM norepinephrine (Sigma Chemical, USA) in 
30 mM L-ascorbic acid (Sigma Chemical, USA) and 10% FBS (JRH Biosciences, UK). Cells 
were passaged at confluency in a split ratio of 1:3. Culture flasks (75 cm2, Falcon, Germany) 
were pre-coated with a solution of 0.02% (wt./vol.) gelatine (AppliChem, Germany) containing 5 
µg/ml fibronectin (Sigma Chemical, USA). The cells were maintained at standard culture 
conditions (37°C, 5% CO2 and 95% relative humidity). 
 
Preparation of test solutions 
All drugs were purchased from Sigma Chemical USA with the highest purity available. Stock 
solutions of amiodarone (50 mM), verapamil (100 mM), daunorubicin (10 mM), terfandine (10 
mM), astemizol (10 mM), diclofenac (500 mM), haloperidol (10 mM) and desipramin (10 mM) 
were prepared in DMSO (Sigma Chemical, USA). A 10 mM stock solution of doxorubicin was 
prepared in cell culture grade water (PAN Biotech, Germany). For the cytotoxicity screening all 
stock solutions were serially diluted in supplemented Claycomb medium. The end DMSO 
concentration did not exceed 1% (v/v) in any of the final test solutions.   
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Measurement of dissolved oxygen 
HL-1 cells were trypsinized at confluency and counted three times via trypan blue exclusion in a 
hemocytometer. Cells were seeded in 24–well OxoDishes (PreSens) which were pre-coated with 
500 µl of a gelatine/fibronectine solution (see 2.1) for 24 h- Cells seeding density was 1.5 x 105 
cells in a total volume of 1 ml Claycomb medium (Sigma Chemical, USA) supplemented with 2 
mM glutamine (PAA Laboratories, Austria), 100 U/ml penicillin 100 µg/ml streptomycin 
(PenStrep stock solution: CC Pro, Germany), 100 µM norepinephrine (Sigma Chemical, USA) in 
30 mM L-ascorbic acid (Sigma Chemical, USA) and 10% FBS (JRH Biosciences, UK). After 24 
h preincubation, the supernatant was removed and the cells were washed twice with Claycomb 
medium without any supplements. Afterwards, 1 ml of fresh medium containing drugs at 
different concentration was added to the cells. Untreated controls, DMSO-controls and drugs 
treated cells were tested in triplicates.  To minimize evaporation, plates were covered with gas 
impermeable sticky foils. Cells were exposed to drugs for 48 h.  
 
Sulforhodamine B and Lactate dehydrogenase release (LDH ) assay 
Cytotoxicity of the tested drugs on HL-1 cardiomyocytes was assessed using lactate 
dehydrogenase release (LDH-release assay) and proliferation (SRB-proliferation assay). 1.5 x 105 
cells/well were seeded in four gelatin/fibronectin-coated (see 2.3) 24-well plates (Greiner, 
Germany) in 1 ml Claycomb medium (containing 2 mM glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, 100 µM norepinephrine in 30 mM L-ascorbic acid and 10% fetal bovine 
serum (FBS). After 24 hours (h) incubation, the supernatant was removed and the cells were 
washed twice with Claycomb medium. Fresh medium containing different concentrations of the 
drugs was added to the cells in triplicates. The cells were exposed to the drugs for 48 h. Finally, 
lactate dehydrogenase assay (Cytotoxicity Detection Kit (LDH), Roche Applied Science, 
Germany) was carried out according manufacturer's instructions. Sulforhodamine B (SRB) assay, 
a colorimetric protein quantification assay (Skehan et al., 1990) was carried out as recently 
described (Noor et al., 2009).  
Both assays were carried out after different exposure times (20 h, 30 h, 40 h, 48 h, referring to 
four plates). The SRB-assay was carried out as described recently (Strigun et al., 2011a). Lactate 
dehydrogenase assay (Cytotoxicity Detection Kit (LDH), Roche Applied Science, Germany) was 
carried out according kit instructions on supernatants obtained from SRB-assay. All conditions, 
untreated controls and different drug concentrations, were tested in triplicates. 
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Calculation of EC50-values  
For the respective time points, EC50 values were calculated with a four parameter sigmoidal 
concentration-response curve using Origin Pro Version 7.5G, exactly as described recently 
(Beckers et al., 2009; Noor et al., 2009). 
 
Statistical analysis 
The similarity of the EC50 dynamics as determined by oxygen measurement, LDH and SRB-
assay for amiodarone, desipramin, doxorubicin and terfenadin was tested by repeated-measures 
one-way ANOVA following Tukey´s posthoc test using Prism 5 V.5.04 (GraphPad Software, 
Inc., USA).  
For the determination of the Euclidean distance of EC50 dynamics of all drugs as determined by 
oxygen measurement, all EC50 values were normalized to the respective EC50 values obtained 
from 20 h time-point (100%). The dataset was then analysed by calculating the Euclidean 
distance between all tested drugs using XLSTAT 2010.3.06 (Addinsoft, Germany). 
 
Results 
Continuous oxygen measurement gives similar EC50 values and EC50 dynamics as compared to 
SRB and LDH assay 
The time course of EC50 values of amiodarone (class III antiarrhythmic), desipramin (tricyclic 
antidepressant), doxorubicin (cytostatic) and terfenadine (antihistamine) was determined by 
continuous measurement of dissolved oxygen measurement as well as SRB- and LDH-assay. 
In case of oxygen measurement, the amount of dissolved oxygen decreased from 70-80 % to 20-
30 % within 48 h incubation in medium containing untreated cells (Fig. 1 A-D). Medium controls 
remained steady at 80-90%. In case of cells treated with drugs a concentration dependant effect 
of each drug could be observed.  
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Figure 1: Time course of dissolved oxygen in culture medium containing HL-1 cells with different concentrations of 
(A) amiodarone (■: medium only; ▲: 100 µM; ∆: 33 µM; ●: 11 µM; ○: 3.7 µM; □: 0 µM); (B) desipramin (■: 
medium only; ▲: 100 µM; ∆: 50 µM; ●: 25 µM; ◊: 3.2 µM; □: 0 µM); (C) doxorubicin(■: medium only; ▲: 2.5 
µM; ∆: 0.625 µM; ●: 0.156 µM; ◊: 3.2 µM; □: 0 µM) and (D) terfenadine (■: medium only; ●: 12.5 µM; ○: 6.25 
µM; ●: 3.12 µM; ◊: 0.002 µM; □: 0 µM). Cells were seeded in 24 – well OxoDishes (PreSens) and allowed to 
equilibrate for 24 h. Afterwards medium was removed and fresh medium containing drugs at different concentrations 
was added to the cells. Dissolved oxygen in culture medium was then continuously measured for 48 h. S.D. was 
determined from triplicate measurement. 
 
Concentration-response curves were determined upon 20 h of exposure to the respective drugs. 
This initial time point allowed determination of a proper concentration dependant effect for each 
drug and assay. Subsequent considered time points for determination of concentration-response 
curves were 30 h, 40 h and 48h. Corresponding time courses were also determined by SRB- and 
LDH-assay. A direct comparison of concentration-response curves obtained by all three assays is 
shown using the example of doxorubicin (Fig. 2).  
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Figure 2: Concentration-response curves of doxorubicin screened on HL-1 cells by using (A) continuous oxygen 
measurement; (B) sulforhodamine B proliferation assay and (C) lactate dehydrogenase release assay. The 
concentration response was determined after 20 h (black symbols), 30 h (red symbols), 40 h (blue symbols) and 48 h 
(turquoise symbols) of exposure. Standard deviations were determined from triplicate measurement. 
 
As apparent, a time-dependant shift of concentration-response curves towards decreasing 
concentrations was observed for all considered drugs in the three assays (Fig. 2 and Fig. S1 in the 
appendix for chapter 2), pointing towards an increasing toxic effect. This is reflected by 
decreasing EC50 values (Tab. 1). The EC50 values obtained for all four drugs were quite similar 
for all three tested assays and all considered time points. 
The EC50 value of amiodarone obtained from oxygen measurement was 19 µM at 20 h and 
decreased to 15 µM after 48 h. In SRB- and LDH-assay the corresponding value decreased from 
18 µM (20 h) to 10 µM (48 h) and from 30 µM (20 h) to 12 µM (49h), respectively. EC50 values 
at each time point obtained from all three assays were not significantly different. 
The EC50 value of desipramin obtained by oxygen measurement decreased from 64 µM after 20 h 
to 33 µM after 48 h. Corresponding values obtained by SRB and LDH-assay decreased from 35 
µM (20 h) to 19 µM (48 h) and from 51 µM (20 h) to 30 µM (48 h), respectively (Tab. 1). The 
EC50 values obtained by oxygen measurement were significantly higher at each time point as 
compared with SRB-assay (p < 0.01), but not significantly different as compared with LDH-
assay. 
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Table 1: EC50 values of amiodarone, desipramin, doxorubicin and terfenadin tested on HL-1 cells for different 
exposure time points (20 h, 30 h, 40 h and 48 h). Cells were incubated in 24 – well OxoDishes and dissolved oxygen 
was continuously measured for 48. Corresponding EC50 values were determined by using sulforhodamine B and 
LDH-release assay. The brackets represent 95% confidence intervals. **: p < 0.01 (as compared with SRB assay) 
 
EC50 [µM] 
  
  
Amiodarone 
  
  
Desipramin 
  
  
Doxorubicin 
  
  
Terfenadin 
  
t [h] oxygen SRB LDH oxygen** SRB LDH oxygen SRB LDH oxygen SRB LDH 
20 19(17-21) 18(16-20) 30(28-31) 64(61-67) 35(33-38) 51(45-57) 3.5(3.3-3.6) 6.1(3.8-7.7) 13(4.5-17.6) 5.3 (5.0-5.6) 5.3(5.0-5.4) 7.5(7-7.9) 
30 18(17-19) 12(11-13) 16(15-18) 43(42-44) 25(23-27) 35(34-36) 2.1(2.2-3.3) 1.8(1.4-2.2) 6(5.1-7.1) 4.4 (4.2-4.6 4(3.8-4.2) 5.7(5.2-6.1) 
40 16(15-17) 9(8-10) 13(10-15) 35(34-36) 19(16-21) 30(27-33) 0.7(0.7-0.9) 0.77(0.62-0.88) 2.1(1.3-2.7) 4.3(4.1-4.5) 3.9(3.8-4.1) 4.5(4-4.9) 
48 15(14-16) 10(9-11) 12(10-14) 33(32-34) n.d. n.d. 0.5(0.4-0.6) 0.39(0.31-0.44) 1.7(1.3-1.9) 4.1(3.8-4.4) 3.7(3.5-3.8) 4.5(4.2-4.8) 
 
In case of doxorubicin, the EC50 value decreased from 3.5 µM at 20 h to 0.5 µM after 48 h in 
oxygen measurement. In SRB- and LDH-assay the values decreased from 6.1 µM (20 h) to 0.4 
µM (48 h) and from 12.7 µM (20 h) to 1.6 µM (48 h). No significant differences between EC50 
values at each time point could be determined. 
For terfenadine, the EC50 value obtained from oxygen measurement decreased from 5.3 µM (20 
h) to 4.1 µM (48 h). In case of SRB and LDH assay the values decreased from 5.2 µM (20 h) to 
3.7 µM (48 h) and from 7.5 µM (20 h) to 5.5 µM (48 h). EC50 values obtained from oxygen 
measurement were not significantly different from LDH- and SRB assay. 
 
Hierarchical clustering of EC50 dynamics obtained from oxygen measurement allows distinction 
of drugs according to their mechanisms of toxicity 
We screened five additional drugs (astemizol, haloperidol, daunorubicin, diclofenac and 
verapamil) using oxygen measurement to perform a more detailed analysis of time dependant 
EC50 profiles. Due to the differences of the actual EC50 values of each drug and time point, EC50 
values were normalized to the first determined EC50 at time point 20 h for better visual 
comparison of EC50 dynamics. The EC50 values for these drugs are given in Tab. S1 (Appendix 
for chapter 2). As apparent, the EC50 dynamics of all considered drugs were quite diverse (Fig. 
3A). While EC50 values of some drugs remained constant after 20 h, such as astemizol, a merely 
slight decrease by 10–20% was observed in case of amiodarone or verapamil. A rather high 
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change of the EC50 values was observed for daunorubicin and doxorubicin, where the EC50 
decreased by some 80% after 20 h. 
For better visualisation of similarities between EC50 dynamics of different drugs, hierarchical 
clustering was carried out on the data set by determination of the Euclidean distance (Fig. 3 B). 
This approach allowed the identification of three distinct drug groups with similarities in their 
EC50 dynamics.  
The first group, which was least related to the other two groups, consisted of daunorubicin and 
doxorubicin (both anthracyclines). This group revealed the lowest EC50 range, which was 
between 3.5 and 0.1 µM (Tab. S1, appendix for chapter 2). Compared to the other groups, a 
distinct decrease of EC50-values characterized this group. 
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Figure 3: (A) EC50 dynamics as percent of the respective EC50 values at 20 h of several drugs determined by 
continuous measurement of dissolved oxygen using 24–well OxoDishes. Drugs were tested on HL-1 cardiomyocytes 
for 48 h. The underlying EC50 values are given in Table S1 (Appendix for chapter 2); (B) Euclidean distance of drugs 
from tested groups calculated from EC50 dynamics (Tab. S1 and Fig. 3 A). 
 
The second group contained diclofenac (NSAID), desipramin (tricyclic antidepressant) and 
haloperidol (neuroleptic). Within this group haloperidol was closely related to desipramin. The 
actual EC50 values, which were between 33 µM and 596 µM, revealed that these drugs are least 
toxic among all tested drugs (Tab. S1, appendix for chapter 2). 
The third group contained amiodarone (class III antiarrythmic), verapamil (class IV 
antiarrhythmic), astemizol and terfenadine (both antihistamines). Compared to the second group, 
this group had a lower EC50 range (Tab. S1, appendix for chapter 2), which was between 4 µM 
and 44 µM. 
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Discussion 
The benefit of measurement systems which allow continuous measurement of metabolic 
parameters, such as respiration or acidification rate, was recently suggested as they avoid the 
need for multiplate seeding when determination of dynamic EC50 values is desired (Beckers et 
al., 2009; Wolf et al., 2011). A direct comparison of EC50 dynamics obtained from these 
approaches with corresponding dynamics obtained by commonly used cytotoxicity assays has not 
been carried out yet, least of all a comparison of EC50 dynamics between drugs with distinct 
pharmacological properties. 
We determined the EC50 dynamics of four drugs using continuous oxygen measurement and 
compared them with the dynamics obtained from commonly used cytotoxicity assays (SRB- and 
LDH-assay). In case of oxygen measurement concentration-response curves were determined 
from the underlying dissolved oxygen profiles (Fig. 1), similarly as recently described (Beckers 
et al., 2009; Wolf et al., 2011). Using oxygen measurement a proper concentration dependant 
effect could be determined after 20 h of drug exposure. The response span at earlier time points 
did not cover the whole viability range (0% - 100 %). Though, concentration response curves 
determined after 20 h allowed accurate calculation of EC50 values in case of oxygen 
measurement.  
Independent of the applied assay the concentration response curves showed a time dependant 
shift towards lower drug concentrations (Fig. 2), similar as reported recently for the same 
measurement setup for hepatic cells (Beckers et al., 2009). This shift is reflected by the time 
dependant decrease of EC50 values independent of the applied assay (Tab. 1). This decrease of 
EC50 values points towards a time dependant increase of toxicity depending on the drug and its 
mechanism of toxicity. The values obtained from all three approaches were similar for all 
considered time points which is represented by no significant differences of the time course of the 
corresponding EC50 values, thus justifying comparative studies of EC50 dynamics by using 
oxygen measurement and thereby eliminating the need for multiplate seeding. 
Subsequent respiration measurements on an extended drug panel showed that EC50 dynamics of 
the considered drugs were quite diverse (Fig. 3A). Hierarchical clustering on the respective EC50 
dynamics revealed a unique grouping of drugs (Fig. 3 B), which seemed to result from their 
known mechanism of action.  
Group 3 (Fig. 3 B) consisted of amiodarone, verapamil (both channel blockers), astemizol and 
terfandine (both antihistamines). This group was characterized by a relatively low decrease of 
Determination of EC50 dynamics 
 22
EC50 values (5%-22% within 24 h). It is well established that toxicity of astemizol, terfenadin and 
amiodarone is partially related to blockade of potassium and calcium channels (Taglialatela et al., 
1999; Yap and Camm, 1999, Waldhauser et al., 2006), while verapamil´s main indication is the 
blockade of L-type calcium channels. Though, we haven’t carried out mechanistic studies, it can 
be assumed that a toxic effect, which has partly been attributed to the interaction with ion 
channels, occurs relatively fast, as reflected by only decent decrease of the EC50 values. 
Group 2 (Fig. 3 B), which consists of both anthracyclines daunorubicin and doxorubicin formed a 
group with a distinct dissimilarity to all other drugs. As apparent from the underlying EC50 
dynamics (Fig. 3 A) a significant decrease of EC50 values was observed after 20 h of exposure for 
both drugs (80%-90% within 24 h). This significant increase of toxicity with time is reflected by 
the versatile acute and chronic toxicity of both drugs, which might become synergistic in the 
course of exposure. Toxicity of anthracycline has been studied extensively. Its hallmark is the 
formation of reactive oxygen species due to a mechanism known as redox cycling. Consequences 
of oxidative stress include formation of reactive oxygen species (Bachur et al., 1977; Sinha et al., 
1989) and consequently oxidative damage of DNA (Eliot et al., 1984; Feinstein et al., 1993). 
Besides, doxorubicin has been shown to deteriorate energy metabolism of cardiac cells both 
acutely and chronically (Tokarska-Schlattner et al. 2010), consequently leading to ATP depletion 
(Strigun et al., 2011c; Pointon et al., 2011). A significant decrease of EC50 values, as observed in 
our study, might therefore be related to time dependant cumulative effects. 
Group 1 (Fig. 3 B) contains the two psychoactive drugs, desipramin and haloperidol, as well as 
diclofenac. These drugs were least toxic as compared to all other drugs. Despite a higher 
similarity with the first group (amiodarone, verapamil, terfenadin and astemizol), these drugs also 
showed a significant decrease of EC50 values (40% - 60% within 24 h), pointing towards a time 
dependant increase of their toxicity. The in vitro toxicity of´these drugs has been described for 
several cell lines. While toxicity of desipramin potentially involves block of potassium channels, 
it was recently shown that diclofenac inhibits L-type calcium channels in ventricular myocytes. 
In spite of their channel blocking ability (Hong et al., 2010; Staudacher et al., 2011; Yarishkin et 
al., 2009) they formed an individual cluster apart from the group which contains amiodarone, 
verapamil, astemizol and terfenadin. The reason for this difference remains to be assessed but is 
probably related to cumulative toxic effects, similarly as observed for the anthracyclines, 
resulting in a delayed toxic effect. 
Determination of EC50 dynamics 
 23
We conclude that determination of a drug´s EC50 dynamic allows a rough estimation whether the 
toxicity of a drug is either immediate or delayed. Simple consideration of an EC50 value at a 
certain time point gives information on a drugs relative toxicity. However, measurement of the 
actual EC50 dynamics will include the dynamic information, which is otherwise mostly neglected 
due to the necessity of multi-plate seeding when using common cytotoxicity assays (such as 
SRB- or LDH-assay). The presented approach can contribute to the understanding of the potential 
mechanism of toxicity of an unknown drug. However, accurate estimation of the mechanism of 
toxicity based on its dynamic EC50 will necessitate an expanded set of training compounds with 
known toxicological and/or pharmacological properties. Work in this regard is underway in our 
laboratory.  
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Chapter 3 
Metabolic profiling using HPLC allows classification of drugs 
according to their mechanisms of action in HL-1 cardiomyocytes 
 
Abstract 
Along with hepatotoxicity, cardiotoxic side effects remain one of the major reasons for drug 
withdrawals and boxed warnings. Prediction methods for cardiotoxicity are insufficient. High 
content screening comprising of not only electrophysiological characterization but also cellular 
molecular alterations are expected to improve the cardiotoxicity prediction potential. 
Metabolomic approaches recently have become an important focus of research in 
pharmacological testing and prediction. In this study, the culture medium supernatants from HL-1 
cardiomyocytes after exposure to drugs from different classes (analgesics, antimetabolites, 
anthracyclines, antihistamines, channel blockers) were analyzed to determine specific metabolic 
footprints in response to the tested drugs. Since most drugs influence energy metabolism in 
cardiac cells, the metabolite “sub-profile” consisting of glucose, lactate, pyruvate and amino 
acids was considered. These metabolites were quantified using HPLC in samples after exposure 
of cells to test compounds of the respective drug groups. The studied drug concentrations were 
selected from concentration response curves for each drug. The metabolite profiles were 
randomly split into training/validation and test set; and then analysed using multivariate statistics 
(principal component analysis and discriminant analysis). Discriminant analysis resulted in 
clustering of drugs according to their modes of action. After cross validation and cross model 
validation, the underlying training data was able to predict 50%-80% of conditions to the correct 
classification group. We show that HPLC based characterisation of known cell culture medium 
components is sufficient to predict a drug’s potential classification according to its mode of 
action. 
 
This chapter has been published as: Strigun A, Wahrheit J, Beckers S, Heinzle E, Noor F, (2011). Metabolic 
profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 
cardiomyocytes. Toxicology and Applied Pharmacology 252: 183-191 
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Introduction 
Cardiac injury, a severe side effect of drugs, is of extreme concern to the pharmaceutical industry 
and drug regulatory agencies (Darpo, 2007). Despite stringent regulations and guidelines for the 
assessment of cardiac injury, several drugs have been withdrawn from the market due to 
cardiotoxic side effects (Gwathmey et al., 2009). Most traditional methods for preclinical 
assessment of cardiac side effects address electrophysiological aspects and involve determination 
of voltage-clamp analysis of ionic currents, action potential recordings in myocytes/tissues or 
measurement of QT-interval using whole animals (Sanguinetti and Mitcheson, 2005). Predictions 
on the basis of only electrophysiological screening have proved to be insufficient and at the same 
time may result in termination of lead compound development in preclinical assessment, even for 
compounds which may have been of beneficial value both to the patient and the pharmaceutical 
industry. In addition to electrophysiological evaluation, characterization of other cellular 
functional parameters such as substrate usage and metabolite trafficking may greatly improve the 
prediction potential of a test system. Over the years, extensive knowledge has been gained on 
cardiac substrate usage and metabolism; and its alterations in myocardial diseases (Ashrafian et 
al., 2007; Gertz et al., 1988; Mudge et al., 1976; Panchal et al., 2001; Randle et al., 1964; 
Stanley et al., 1997; Wisneski et al., 1985), e.g. in myocardial ischemia (Depre and Taegtmeyer, 
2000). There is growing evidence that changes in substrate metabolism lead to contractile 
dysfunction (Stanley et al., 2005). These changes therefore more or less reflect cardiac 
pathological conditions or a drug’s action/toxicity on the cardiac tissues (Ashrafian and 
Neubauer, 2009; Henney, 2009; Ho and Lieu, 2008; Nicholson and Wilson, 2003; Zhu et al., 
2008). 
Metabolomic approaches have been successfully applied in cardiovascular research, for  example, 
in profiling the metabolomic response of cardiac cells to induced ischemia (Sabatine et al., 2005) 
and human atrial fibrillation (Mayr et al., 2008b). Moreover, metabolic profiling has provided  
interesting insights on the response of microbial cells, mammalian cell cultures, other tissues or 
organs  to drugs (Allen et al., 2004; Tiziani et al., 2009) and their mechanisms of toxicity 
(Andreadou et al., 2009; Beger et al., 2010; Clarke and Haselden, 2008; Kaddurah-Daouk et al., 
2008; Keun, 2006; Robertson, 2005; Wei et al., 2009; West et al., 2010). Similarly, 
metabolomics may also be useful for mapping specific metabolic responses of cardiac cells in 
vivo and in vitro upon exposure to drugs from specific groups classified according to their modes 
of action. Mapping groups of drugs with known cardiotoxic outcome in humans in terms of the 
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metabolic response of cardiac cell or tissue type can be helpful in identifying whether new drug 
candidates share similar metabolic profiles and therefore bear a potential risk to share similar 
toxic properties. 
Assessment of drug induced toxicity using metabolomics requires cell or tissue models which 
closely reflect the in vivo system in humans. Immortalized cell lines respond in a different way 
than primary cells (Robertson, 2005). Human embryonic stem cell derived cell types, such as 
cardiomyocytes or hepatocytes have the potential to be applied as in vitro test models, since they 
have the required homogeneity and functionality to make them attractive for drug discovery 
(Jensen et al., 2009) as well as for human relevant toxicity assessment. Nevertheless, suitable cell 
lines of human or non-human origin still prove to be useful for preliminary screening and method 
optimisation since they are less costly and easier to handle.  
HL-1 cells have been shown to be quite useful for studying cardiac physiology (Claycomb et al., 
1998; White et al., 2004) since they express many genes typical for differentiated adult 
cardiomyocytes (Claycomb et al., 1998). HL-1 cardiomyocytes express several cardiac ion 
channels, such as L-and T-Type Ca2+ channels (Xia et al., 2004), ATP-sensitive K+ channels 
(Fox et al., 2005) and inward rectifier K+ channels (Goldoni et al., 2010). Besides, there is 
evidence that HL-1 cardiomyocytes possess intracellular calcium release channels (Kim et al., 
2010), that are assumed to play a role in Ca2+ signaling and in excitation-contraction coupling in 
cardiomyocytes  (Lipp et al., 2000). These properties make them attractive for assessing 
metabolic responses upon targeting these cells with drugs which have channel blocking 
properties. In addition these cells are useful to study mechanisms of anthracycline induced 
apoptosis (Kim et al., 2003) as well as in assessing damage of drugs on troponin T release 
(Andersson et al., 2010). Besides, presence of inducible nitric oxide synthase in these cells 
(Sanders et al., 2001) makes them attractive for studying drug induced disturbances of nitric 
oxide signalling pathways. Furthermore, cardiac adenosine receptors have been described in these 
cells, which are of high interest in studying effects of cardioprotective adenosine agonists on 
cardiomyocytes damage either induced by anthracyclines or due to hypoxia (Chaudary et al., 
2004; Keene et al., 2010). 
In this study, we investigated if selected drugs classified into groups; namely analgesics 
(acetaminophen, diclofenac), antimetabolites (methotrexate, 5-fluorouracil), anthracyclines 
(daunorubicin, doxorubicin), antihistamines (astemizol, terfenadin) and channel blockers 
(amiodarone, quinidine, verapamil); leave group specific profiles in culture supernatants of HL-1 
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cardiomyocytes. These drugs with the exception of acetaminophen have been associated with 
cardiac side effects. Diclofenac has been associated with cardiovascular risk (McGettigan and 
Henry, 2006; Waksman et al., 2007). A recent study indicated that diclofenac inhibits L-type 
calcium channel in cardiac cells, which was suggested as a potential reason for diclofenac 
associated risk of heart failure (Yarishkin et al., 2009). 5-fluoruracil is considered cardiotoxic 
(Senkus and Jassem, 2010), though the mechanism of is not well understood. Symptoms such as 
cardiac arrhythmias, congestive heart failure and sudden death due to 5-FU have been reported 
(Schimmel et al., 2004). Although methotrexate is not definitely considered cardiotoxic, 
supraventricular and ventricular arrhythmias were associated with this drug (Gasser et al., 1982; 
Kettunen et al., 1995). Terfenadin has been withdrawn from the market due to cardiotoxicity. It  
is cardiotoxic in overdose or when its first pass metabolism (by hepatic CYP3A4) is impaired, 
resulting in QT-prolongation (Armstrong and Cozza, 2003). Terfenadin induced cardiotoxicity 
may involve inhibition of the delayed rectifier potassium channel in cardiac tissue (Taglialatela et 
al., 1999; Yap and Camm, 1999). Astemizol also blocks potassium channels and prolongs the 
QT-interval (Yap and Camm, 1999). Cardiotoxicity has been extensively reviewed with the use 
of anthracyclines, daunorubicin and doxorubicin (Floyd et al., 2005; Schimmel et al., 2004; 
Simunek et al., 2009). Anthracyclines have been reported to cause cardiomyopathy, congestive 
heart failure and QT-prolongation. Potential arrhythmic effects of antiarrhythmic drugs are well 
known (Lazzara, 1993). QT- prolongation, in particular after amiodarone and quinidine therapy 
has been described repeatedly (Hii et al., 1992; McComb et al., 1980; Schrickel et al., 2003; 
Schrickel et al., 2006; White, 2007). 
In our study, unlike other recently reported studies using MS-based methods, we focused on 
HPLC quantification of metabolites which is accurate and precise (Hans et al., 2003; Niklas et 
al., 2009) based on selective derivatization of amino acids using ortho-pthaldehyde (OPA). We 
focused on common culture medium nutrients such as glucose, pyruvate and amino acids as well 
as lactate which is the most commonly secreted metabolite by cell lines. The presented data 
shows that this approach, combined with multivariate statistics (principal component analysis and 
discriminant analysis) is adequate for correct prediction of drug classification. It might prove 
useful in not only predicting a compound’s potential classification based on mode of action but 
may also help in the assessment of risk of cardiac injury in clinical applications based on 
classification. 
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Material and methods 
Cell Culture 
HL-1 cardiomyocytes were obtained from Dr. Claycomb (Louisiana State University) for 
research within the framework of EU-STREP (LSHB-CT-2007-037636) project 
“Invitroheart”(Claycomb et al., 1998). The cells were maintained in Claycomb medium (Sigma 
Chemical, USA) supplemented with 2 mM glutamine (PAA Laboratories, Austria), 100 U/ml 
penicillin, 100 µg/ml streptomycin (PenStrep stock solution: CC Pro, Germany), 100 µM 
norepinephrine (Sigma Chemical, USA) in 30 mM L-ascorbic acid (Sigma Chemical, USA) and 
10% foetal bovine serum (FBS, JRH Biosciences, UK). Cells were sub-cultured when confluent 
in a split ratio of 1:3. Culture flasks (75 cm2, Falcon, Germany) were pre-coated with a solution 
of 0.02% (w/v) gelatine (AppliChem, Germany) containing 5 µg/ml fibronectin (Sigma 
Chemical, USA). Beating HL-1 cardiomyocytes were maintained at standard cell culture 
conditions (37°C, 5% CO2 and 95% relative humidity). 
 
Preparation of test solutions 
All drugs were purchased from Sigma Chemical (USA) with the highest purity available. Stock 
solutions of terfenadine (10 mM), diclofenac (500 mM), verapamil (100 mM), methotrexate 
(100 mM), 5-fluorouracil (100 mM), quinidine (100 mM), daunorubicin (10 mM), amiodarone 
(50 mM) were prepared in dimethylsulfoxide (DMSO) also purchased from Sigma Chemical, 
USA. A doxorubicin stock solution (10 mM) was prepared in cell culture grade water (PAN 
Biotech, Germany). The stock solution of acetaminophen (30 mM) was directly prepared in 
supplemented Claycomb medium. For the cytotoxicity screening all stock solutions were serially 
diluted in supplemented Claycomb medium. The end DMSO concentration did not exceed 1% 
(v/v) in any of the final test solutions. Solvent controls using DMSO (DMSO controls) at 
concentrations identical to the corresponding test concentrations were also tested. The 
concentrations analyzed for metabolic footprinting are given in table 1. 
 
Determination of concentration response curves 
HL-1 cardiomyocytes were trypsinized at confluency and counted using trypan blue exclusion 
method in a hemocytometer. 1.5x105 cells/well were seeded in 24-well OxoDishes (PreSens, 
Germany) in a volume of 1 ml supplemented Claycomb medium per well. After 24 hours (h) 
incubation, the supernatant was removed and the cells were washed twice with Claycomb 
Metabolite profiling of HL-1 cardiomyocytes 
 29
medium without any supplements. Afterwards, fresh medium containing drugs at different 
concentrations was added to the cells. All conditions (untreated controls, DMSO controls, drugs) 
were tested in triplicates. For all drugs, cells were treated for 48h with the exception of 
antimetabolites, 5-fluorouracil (5-FU) and methotrexate, for which the exposure time was 96h. 
After the test period, cell culture supernatants were collected and spun down at 10000 x g for 5 
minutes (min) at 4°C to remove cell debris. The samples were stored at -20°C until further 
analysis of metabolic footprints. After medium removal each well was washed thrice with 1 ml 
non-supplemented Claycomb medium. Cells were fixed at 4°C for one hour by adding 250 µl 
TFA-solution (50% trifluoracetic acid (v/v) in water) into each well containing 1 ml of non-
supplemented Claycomb medium.  After fixation, the cells were washed carefully five times with 
deionized water. 250 µl of 0.4% sulforhodamine B (Sigma Chemical, USA) solution (w/v) in 
0.1% acetic acid (Sigma Chemical) (v/v) was added for staining cellular proteins for 30 minutes 
at room temperature on a plate shaker set at 200 rpm. The staining solution was removed and the 
wells were washed thrice with 0.1% acetic acid (v/v) to remove unbound dye. The stained cells 
were then dried for 30 minutes and the dye was extracted from the cells with 500 µl of 10 mM 
Tris base (Roth, Germany) solution (pH 10). Extraction was performed for 10 minutes on a 
microplate shaker set at 200 rpm. The absorption of the dye was measured in 96 well microtiter 
plates using a fluorescence reader (iEMS, Labsystems) at a wavelength of 540 nm against a 
reference wavelength of 660 nm.  
 
Sample preparation for metabolic footprint analysis 
The supernatant from each well was collected as described above. Serum proteins, such as 
albumin were removed by microfiltration using Microcon® Filter Devices (Millipore, Germany) 
with an exclusion size of 10kDa. Subsequently each filtrate was diluted 1:2 with α-aminobutyric 
acid solution (400 µM in deionized water) which was used as internal standard. 
 
Metabolic footprinting 
Quantification of glucose, lactate and pyruvate  
Glucose, lactate and pyruvate were quantified as described recently (Hans et al., 2003; Niklas et 
al., 2009). In short, quantification was carried out using HPLC (Kontron Instruments, Germany) 
with an Aminex HPX 87H ion exchange column (300 mm x 7.8 mm, Biorad, USA). The isocratic 
separation was carried out using 7 mM sulfuric acid as eluent and a flow rate of 0.8 ml/min at a 
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column temperature of 60°C. Injection volume was 20 µl. Lactate and pyruvate were detected by 
UV-detection (UV-detector: HPLC 535, Biotek, Germany) at a wavelength of 210 nm. Glucose 
was determined by measuring the refractive index (ERC-7515A, ERC Inc, Germany). Standard 
solutions of glucose, lactate and pyruvate (Sigma Chemical, USA) were used for identification 
and quantification of these metabolites, respectively. The standard concentration of glucose, 
lactate and pyruvate included 10mM, 5mM, 2.5mM, 1.25mM, 0.625mM, 0.312mM, 0.156mM 
and 0.078mM. Retention times of these metabolites are given in Table 2. 
 
Quantification of amino acids 
Amino acids were quantified as described earlier (Hans et al., 2003; Kromer et al., 2005; Niklas 
et al., 2009). In short, quantification was carried out using HPLC (Agilent 1100 series, Agilent 
technologies, Germany) with a C18 RP-column (Gemini® 5u C18 110A, 150 mm x 4.6 mm, 
Phenomenex, Germany) at 40°C. A gradient separation was carried out (Eluent 1 : 40 mM 
Na2HPO4, pH 7.8; Eluent 2: methanol, acetonitrile, water 45:45:10 (v/v)) with a flow rate of 1 
ml/min. Primary amino acids were derivatized by pre-column derivatisation using ortho-
pthaldehyde (OPA) (Agilent, Germany) (excitation wavelength: 330 nm; emission wavelength: 
450 nm). Proline, a secondary amino acid, was derivatized using 9-fluorenylmethyl-chloroform 
(FMOC) (Agilent, Germany) (excitation wavelength: 266 nm, emission wavelength: 305 nm). 
Amino acids were obtained from Sigma Chemical, USA. Standard solutions of amino acids were 
used for identification and quantification of these metabolites, respectively. The standard 
concentrations of amino acids included 1000µM, 500µM, 250µM, 125µM, 62.5µM, 31.25µM, 
15.6µM and 7.8µM, respectively. Retention times of all amino acids are given in Table. 2. 
 
Data handling and statistical analysis 
The changes in the metabolite concentrations (glucose, lactate and amino acids) upon exposure to 
the drugs were compared with the respective untreated controls using student’s t-test. The 
changes were considered significant at p<0.05. 
The concentrations of each metabolite in the respective supernatants were normalized to the 
individual untreated controls (% of control) of each experiment. Principal component analysis 
(PCA) and discriminant analysis (DA) were carried out using XLSTAT 2010.3.06 (Addinsoft, 
Germany). For discriminant analysis, all conditions were assigned to specific classification, 
which represents the group labels. These are: 1) untreated controls 2) DMSO controls (cells 
Metabolite profiling of HL-1 cardiomyocytes 
 31
treated with concentrations of DMSO identical to those which were used in case of drugs) 3) 
channel blockers (amiodarone, quinidine & verapamil) 4) antihistamines (astemizol & 
terfenadine) 5) anthracyclines (daunorubicin & doxorubicin) 6) analgesics (acetaminophen & 
diclofenac) and 7) antimetabolites (5-fluorouracil & methotrexate). Cross model validation was 
carried out similar to a recently reported approach (Westerhuis et al., 2008). Briefly, the data 
matrix, which consisted of 152 rows and 18 columns, was split into a test set (76 rows) and a 
second training/validation set (76 rows). From the training/validation set, which was used to 
determine discriminant models of drug groups, 35 observations were randomly selected and cross 
validation was carried out. This procedure was repeated until all conditions of the whole data set 
were part of the test set at least once. Thus, a total number of 76 prediction models were created. 
In no case, conditions from the test set were used to create a prediction model. The accuracy of 
each prediction model was assessed by determination of the percentage of correctly predicted 
groups in conditions from the test set. 95% confidence intervals were calculated with XLSTAT. 
In order to determine whether correct classification of conditions in the test set is random, a 
permutation test was carried out. Hereby, assignments of group labels in the training/validation 
set were permuted in a random way. Prediction quality was determined by comparing the 
accuracy of both permuted and non-permuted prediction models. 
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Results 
Concentration response curves  
A complete set of concentration response curves of the tested drugs is shown in Fig. 1. Each 
experiment was carried out with its individual untreated control. As apparent, the effective 
concentrations for different drugs were quite diverse, ranging from the nanomolar range in case 
of anthracyclines and antimetabolites to the upper micromolar range in case of analgesics. Along 
with anthracyclines and antimetabolites, the antihistamines (astemizol and terfenadine) were 
quite toxic, since the effective concentration range was in the lower micromolar range. The 
concentration response curves of both compounds were almost identical. Channel blockers 
amiodarone, quinidine and verapamil gave similar sigmoidal curves with similar shapes. 
However, they showed a shift in concentration response range. The effective concentration 
ranges for both analgesics (acetaminophen and diclofenac) were quite different, while 
corresponding curves for anthracyclines (daunorubicin and doxorubicin) were almost identical. 
Based on these concentration response results, drug concentrations were selected (Table 1) at 
specific points of the concentration response curve (ranging from 40%-100% of relative 
proliferation) for further HPLC quantification of metabolites in the supernatants. 
 
Figure 1: Concentration response curves of selected drugs A. Analgesics: acetaminophen (●) & diclofenac (○) B. 
Antihistamines: astemizol (●) & terfenadine (○) C. Channel blockers: amiodarone (●), quinidine (○) & verapamil (■) 
D. Anthracyclines/antimetabolites: methotrexate (●), 5-fluorouracil (○), doxorubicin (■) & daunorubicin (□). The 
drugs were tested on HL-1 cardiomyocytes for 48 h (except antimetabolites which were tested for 96 h) using 
sulforhodamine B proliferation assay. Error bars indicate + S.D. (n = 3). 
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Table 1: Drug concentrations considered for footprint analysis on culture supernatants of HL-1 cardiomyocytes after 
48h of drug exposure (except for 5-fluorouracil and methotrexate for which the exposure time was 96h).  
 
Drug class Concentrations analysed for metabolic profiling [µM] 
Analgesics 
Acetaminophen 
Diclofenac 
 
940 
80 
 
470 
40 
 
235 
 
117 
 
Antihistamines 
Astemizol 
Terfenadine 
 
1 
3.2 
 
0.1 
1.6 
 
0.01 
0.8 
 
0.001 
 
0.0001 
Channel blockers 
Amiodarone 
Quinidine 
Verapamil 
 
4 
50 
12.5 
 
1.2 
0.5 
2.5 
 
0.4 
 
0.5 
  
Anthracyclines 
Daunorubicin 
Doxorubicin 
 
0.04 
0.04 
 
0.012 
0.01 
 
0.004 
0.0025 
 
0.001 
 
Antimetabolites 
5-Fluorouracil 
Methotrexate 
 
0.01 
0.01 
 
0.001 
0.001 
 
 
 
 
 
 
Since most drugs were dissolved in DMSO, the corresponding DMSO controls were also included in metabolic 
footprint analysis in addition to the untreated controls from each experiment. 
 
Metabolic footprinting (consumption and production of metabolites)  
Uptake and production of all considered metabolites (glucose, lactate, pyruvate and 19 amino 
acids) in untreated HL-1 cardiomyocytes is shown in Table 2. Average changes in glucose and 
lactate concentration within 48 h incubation were -5591 ± 651 µM and 9596 ± 1184 µM 
respectively. Among amino acids, glutamine and alanine showed the highest changes in 
concentrations (-411 ± 24 µM and 190 ± 17 µM) followed by branched chain amino acids 
(BCAA) leucine, isoleucine and valine (-118 ± 8 µM, -104 ± 8 µM and -70 ± 9 µM).  Net 
concentration changes for the remaining amino acids ranged from 10 to 70 µM. Concentration 
changes for asparagine (-6 ± 3 µM), aspartic acid (0 ± 4 µM) and glycine (8 ± 6 µM) were 
negligible. 
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Table 2: Retention time of metabolites and changes in extracellular metabolite concentrations in untreated HL-1 
cardiomyocytes within 48h incubation. Quantification of metabolites was carried out according to methods part. 
Concentrations of metabolites were measured in cell culture supernatants using HPLC at t = 48h and t = 0h (medium 
without cells). Standard deviations were calculated from four replicates. Negative and positive values refer to uptake 
and production respectively. 
 
Metabolite ∆ [µM] ± S.D Retention time [min] 
Lactate 9596 1184 9.8 
Glucose -5591 651 7.0 
Glutamine -411 24 15.2 
Alanine 190 17 21.7 
Leucine -118 8 39.7 
Isoleucine -104 8 37.5 
Valine -70 9 32.0 
Lysine -53 3 41.9 
Pyruvate -47 10 7.4 
Serine 46 7 13.1 
Proline -38 10 45.6 
Glutamic acid 34 10 7.0 
Arginine -31 3 19.4 
Tyrosine -30 5 26.0 
Phenylalanine -24 4 36.8 
Methionine -23 1 32.8 
Threonine -18 11 17.6 
Histidine -12 2 15.9 
Tryptophan -9 2 35.7 
Glycine 8 6 17.0 
Asparagine -6 3 12.2 
Aspartic acid 0 4 4.6 
 
The metabolite uptake and production was quantified and analyzed for the drug treated cells as 
well. A detailed overview of the data is given in supplementary material (Appendix for Chapter 
3, Table S1). Figure 2 shows changes in glucose and lactate concentrations induced by the 
highest analysed drug concentrations (Table 1) as percent of untreated controls. Since most of the 
drugs were dissolved in DMSO, the corresponding DMSO controls were analyzed for any 
changes due to the solvent (Fig. 2 A). No significant changes in glucose uptake and lactate 
production were observed for DMSO concentrations of 0.012 % or lower. Therefore, DMSO 
controls for drug concentrations containing less than 0.0012% of DMSO were not analyzed. 
Significant variations in glucose uptake and lactate production could be observed for most of the 
tested drugs, except for 5-fluorouracil (0.01 µM) and methotrexate (0.01 µM) (Fig. 2 H and I). 
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The highest impact on glucose uptake and lactate production was observed for channel blockers 
(amiodarone and verapamil) and analgesics (acetaminophen and diclofenac). Acetaminophen 
(940 µM) reduced glucose uptake as well as lactate production by 50% (Fig. 2 B). For this drug 
DMSO was not used as solvent. Amiodarone (4 µM) decreased relative uptake and production of 
glucose and lactate respectively by 35% (Fig. 2 C), while the corresponding DMSO control 
(0.04% v/v) resulted in a reduction of 11% for glucose uptake and 10% for lactate production 
(Fig. 2 A). In case of astemizol (1 µM), glucose uptake and lactate production was reduced by 
20% and 25%, respectively (Fig. 2 D). Unlike doxorubicin (0.04 µM) which had no significant 
effect on both metabolites (Fig. 2 G), daunorubicin (0.04 µM) reduced glucose uptake and lactate 
production (Fig. 2 E) most significantly by 75% and 70%, respectively. In case of daunorubicin, 
the influence of DSMO was neglected as the DMSO concentration was below 0.0012%. 
Diclofenac (80 µM) reduced glucose uptake and lactate production by 60% and 55% respectively 
(Fig. 2 F), and was significantly different from untreated control and DMSO control, which 
contained 0.012 % (v/v) DMSO (Fig. 2 A). A slight increase in glucose uptake and lactate 
production was observed in response to channel blocker quinidine (8% and 12% respectively) 
(Fig. 2 J), which was however not significantly different from DMSO (0.012%) control. 
Terfenadine (3.2 µM) reduced glucose uptake by 35% and lactate production by 50%, as 
compared to untreated controls (Fig. 2 K). However, because of the larger error in glucose uptake 
measurement only reduced lactate production was significantly different from the corresponding 
DMSO control, which contained 0.04% (v/v) (Fig. 2 A). Verapamil (12.5 µM) decreased relative 
concentrations of glucose and lactate by about 50%, respectively (Fig. 2 L), while in 
corresponding DMSO (0.012%) controls no significant changes in glucose and lactate 
concentrations, as compared to the untreated controls, were observed. Amino acids which showed 
the highest uptake and production in untreated cells (glutamine, alanine, branched chain amino 
acids) were significantly affected by several of the tested drugs at the highest analysed 
concentration. A detailed overview of changes in measured amino acids in the presence of drugs 
is given in the supplementary material (Appendix for Chapter 3; Tab. S1 and S1.1). 
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Figure 2: Drug induced changes in uptake/production of glucose and lactate in HL-1 cells as percent of untreated 
controls. HL-1 cells were incubated with the respective drugs for 48 h or 96h (in case of 5-fluorouracil and 
methotrexate). A) DMSO controls B) Acetaminophen (940 µM) C) Amiodarone (4 µM) D) Astemizol (1 µM) E) 
Daunorubicin (0.04 µM) F) Diclofenac (80 µM) G) Doxorubicin (0.04 µM) H) 5-Fluorouracil (0.01 µM) I) 
Methotrexate (0.01 µM) J) Quinidine (50 µM) K) Terfenadine (3.2 µM) L) Verapamil (12.5 µM). Metabolites were 
quantified using HPLC and the metabolite concentration at t = 48h and t = 0h (negative control; medium without 
cells) was calculated. Standard deviations from triplicate measurements are indicated as error bars. 
 
Principal component and discriminant analysis 
Using principal component analysis (PCA) the data set was analyzed for better visual inspection 
of differences in metabolite uptake and production (Fig. 3). The amino acids namely aspartate, 
asparagine, proline and tryptophan were not included in statistical analysis, since their uptake 
showed relatively high experiment to experiment variations in untreated cells. 
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Figure 3: PCA score plot of the first two principal components (F1 and F2, 59.5% of the total variance in the data 
set). Metabolic profiling was carried out on supernatants from HL-1 cardiomycoytes upon exposure to drugs. Selected 
analyzed drugs from several classes (analgesics, channel blockers, antihistamines, anthracyclines, antimetabolites) are 
depicted; Amiodarone (pink squares), astemizol (green squares), acetaminophen (red squares), untreated controls 
(grey squares), daunorubicin (blue triangles), doxorubicin (blue squares), diclofenac (red triangles), DMSO (orange 
squares), 5-fluorouracil (black squares), methotrexate (black triangles), terfenadine (green triangles), quinidine (pink 
circles), verapamil (pink triangles). Untreated controls and DMSO controls are shown within 95% confidence 
ellipses.  
 
In the score plot (Fig. 3), an approximate clustering of drugs from certain classes i.e. those with a 
similar mechanism of action is seen for the majority of the replicates for anthracyclines namely 
daunorubicin and doxorubicin (upper left quadrant), channel blockers namely amiodarone and 
verapamil (lower right quadrant), as well as most observations of analgesics (acetaminophen and 
diclofenac) (lower left quadrant). However, antihistamines (astemizol and terfendadine) were not 
located in a single quadrant but clearly grouped for the individual drugs. As apparent from 
loading coefficients (Fig. 4), the separation of drugs along the first component was mainly 
attributed to amino acids, especially those which are catabolised in TCA-cycle e.g. 
phenylalanine, branched chain amino acids (leucine, isoleucine, valine), glutamate (Fig. 4 A), 
while separation along the second component was mainly due to changes of glucose uptake and 
metabolites which are connected to intermediates from glycolysis (alanine, pyruvate, serine, 
lactate) (Fig. 4 B). 
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Figure 4: PCA-loading coefficients of 18 metabolites (glucose, lactate, pyruvate and 15 amino acids) from A) PC 
axis F1 and B) PC axis F2, obtained from the analysis shown in Figure. 3. 
 
Discriminant analysis (DA) was carried out to further assess the clustering of the drugs. As 
depicted in figure 5, at least four distinct clusters were obtained. The first cluster includes the 
antihistamines, astemizol and terfenadine (Fig. 5, green symbols) while the second cluster 
includes analgesics, acetaminophen and diclofenac (Fig. 5, red symbols). The third cluster 
includes both anthracyclines daunorubicin and doxorubicin (Fig. 5, blue symbols), while the last 
cluster includes untreated controls, DMSO-controls, channel blockers and antimetabolites. 
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Figure 5: Discriminant analysis score plot of axis 1 and 2 (75% of the variance). Metabolic profiling was carried out 
on supernatants from HL-1 cardiomycoytes upon exposure to drugs from several classes (analgesics, channel blocker, 
antihistamines, anthracyclines, antimetabolites) represented by; Amiodarone (pink squares), astemizol (green 
squares), acetaminophen (red squares), untreated controls (grey squares), daunorubicin (blue triangles), doxorubicin 
(blue squares), diclofenac (red triangles), DMSO (orange squares), 5-fluorouracil (black squares), methotrexate (black 
triangles), terfenadine (green triangles), quinidine (pink circles), verapamil (pink triangles). The score plot is based on 
a prediction model which was created by using all 152 observations. Full symbols: training set; Empty symbols: cross 
validation data set. 
 
Accuracy of prediction of classification/grouping  
We used discriminant analysis to see if it allows specific drug classification of conditions in a test 
data set based on prior determination and cross validation of discriminant models. The whole 
data set was split into training/validation data and test data. A total of 76 discriminant models 
was established (see methods), each with its own accuracy. Prediction of test data by using all 18 
considered metabolites as variables in the training data was most reliable for the majority of the 
drugs in the test data (Fig. 6). 
In the case of predictions, which are based on “non-permuted” assignments of groups in the 
training/validation data (Fig. 6, white bars), average accuracy of classification in the test data set 
is quite reliable in case of untreated controls (82% ± 9), anthracyclines (78% ± 11) and 
antihistamines (76% ± 10). Accuracy of classification was 54% ± 11 for antimetabolites, 
62% ± 12 for DMSO, 59% ± 8 for analgesics, 50% ± 9 for channel blockers. 
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Figure 6: Discriminant analysis of extracellular metabolic footprints in HL-1 cardiomyocytes upon exposure to drugs 
from several classes/groups. The footprint data set (152 rows, 18 columns) was split into test data (76 rows) and a 
second set, which again was randomly split into training and validation data for cross validation. The average percent 
of correctly predicted classes/groups for each condition in the test data set and 95% confidence intervals were 
calculated from 76 evaluations i.e. discriminant functions. White bars indicate predictions which are based on models 
with correct assignment of group labels in the training/validation data set. Grey bars show predictions which are based 
on random i.e. permuted assignments of group labels to conditions in the training/validation data set.   
 
Accuracy of classification was significantly better as compared with the corresponding 
predictions based on models in which classifications were randomly assigned (permuted) in the 
training/validation data set. Here, the accuracy of correctly predicted drug classes was 13% ± 10 
(anthracyclines), 18% ± 11 (antihistamines), 10% ± 9 (antimetabolites), 38% ± 23 (untreated 
controls), 7% ± 11 (DMSO controls), 18% ± 10 (channel blockers) and 10% ± 9 (analgesics).  
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Discussion 
Since cardiac injury has been associated with alterations in substrate usage in cardiomyocytes 
(Stanley et al., 2005), we assumed that the “sub-profile” of considered metabolites is unique for 
individual drug groups thereby allowing clustering of drugs according to their modes of action 
and for prediction of drug classification using supervised pattern recognition approach. Unlike 
recent metabolomic studies in which MS-based methods were used to monitor a whole spectrum 
of peaks of either known or unknown metabolites upon exposure of cells or tissues to toxic drugs 
(Allen et al., 2003; Allen et al., 2004; Dunn et al., 2009; Henriques et al., 2007; Kim et al., 2010) 
we focused on HPLC measurement of known metabolites in common cell culture medium i.e. 
glucose, pyruvate and amino acids. Lactate secreted by cells was also taken into consideration. 
These metabolites not only serve anabolic functions (i.e. biomass synthesis) but to a high extent 
catabolic functions as well (oxidation in TCA-cycle). Uptake and secretion of metabolites 
relevant to glycolytic pathway (glucose, lactate, pyruvate, glycine and serine) as well as TCA-
cycle (glutamine, BCAA, lysine, arginine etc.) showed both significant and non-significant 
changes induced by certain drugs. Changes in glucose uptake and lactate production represented 
the highest changes among the measured metabolites. Despite alterations in glucose uptake and 
lactate production in case of some drugs, the lactate/glucose ratio, which was 1.8 ± 0.2 in 
untreated cells, was not significantly disturbed for any of the considered drugs concentrations. 
The observed lactate/glucose ratio in HL-1 cells is in accordance with recent observations 
(Monge et al., 2009). It was argued that HL-1 cells share properties of cancer cells with a 
relatively high anaerobic glycolysis. The highest decrease in glucose uptake and lactate 
production was observed in case of channel blockers, analgesics and antihistamines. Since no 
significant alterations in lactate/glucose ratios were observed it can be assumed that the extent of 
glucose-derived pyruvate, which enters TCA-cycle where it is oxidized to CO2, was not disturbed 
at least by some of the tested drugs. However, additional tracer experiments using 13C-labelled 
glucose might reveal actual alterations of glucose entering TCA-cycle upon treatment with the 
respective drug with higher accuracy. The actual decrease in glucose uptake observed in this 
study could be to some extent explained by reduced energy demand. Since HL-1 cells are 
spontaneously beating in culture, exposure to drugs which act on ion channels disturb excitation-
contraction coupling in these cells, leading to decreased contraction and thereby reduced energy 
demand.  
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The changes in the metabolite concentrations were analyzed using PCA. PC1 and PC2 accounted 
for 60 % of the total variance observed in the data set. As depicted, several observations on 
supernatants from cells treated with drugs are plotted outside the 95% confidence ellipses of both 
untreated controls and DMSO treated cells (Fig. 3). There is a clear separation of treated cells 
from the untreated controls. An approximate clustering of individual drug classes, as indicated by 
different colours, could be observed in the corresponding PCA-scores plot (Fig. 3). Based on 
these results, the relevancy of each metabolite in the separation/formation was assessed by 
determination of the loading coefficients. Loading coefficients of the first two principal 
components (Fig. 4 A and B) revealed that separation of observations along the first two axis 
distinguishes between metabolites connected to glycolytic and TCA-cycle pathways. Separation 
of observations along principal component 1 was mainly attributed to metabolites which undergo 
degradation in TCA-cycle reactions, such as phenylalanine, branched chain amino acids (leucine, 
isoleucine, valine), tyrosine, glutamine and glutamic acid etc. On the other hand, separation along 
principal component 2 was mainly due to metabolites connected to the glycolytic pathway 
(glucose, lactate, alanine, glycine & serine).  
Clustering could be improved by a supervised approach i.e. by assigning each drug to a specific 
drug group followed by discriminant analysis. Untreated controls and DMSO-controls were also 
treated as individual groups. Score plot of axis 1 and 2 (75% of the variance in the data) shows 
that some clusters could be obtained which refer to distinct drug classes (Fig. 5). Four clusters 
could be obtained by this supervised approach which included anthracyclines (daunorubicin & 
doxorubicin), antihistamines (astemizol & terfenadine) and analgesics (acetaminophen & 
diclofenac). The fourth cluster contained channel blockers, untreated controls, DMSO-controls 
and antimetabolites.  
Average prediction quality was determined by applying cross model validation of both non-
permuted and permuted group assignments, as described recently (Westerhuis et al., 2008). 
Indeed the prediction of classes in this study worked quite well, which is reflected by high 
sensitivities of the calculated prediction models in the non-permuted prediction models. As 
predictions based on permuted class assignment should not be able to classify very well  
(Westerhuis et al., 2008) (based on the assumption that no differences between the classes exist) 
an average of 14.3 % correctly predicted conditions was expected for each class, considering that 
the whole data set was split into seven distinct classes. Indeed, average accuracy observed in this 
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approach was 7%-38% for the majority of the classes. It can therefore be concluded that 
prediction accuracy is clearly not random but due to specific and unique metabolic profiles.  
HPLC quantification of such metabolites was recently applied to study drug induced changes in 
extracellular fluxes (Niklas et al., 2009) at subtoxic concentrations in a hepatic cell line. It was 
found that drug induced changes in metabolite uptake and production is linked to altered fluxes in 
central energy metabolism. The observed changes in metabolite uptake and production may 
therefore also be linked to changes in substrate usage i.e. to central metabolism and in turn 
probably effects fluxes through certain catabolic pathways for example in TCA-cycle reactions.  
Despite the fact that we measured many different metabolites, measuring the relative uptake of 
fatty acids, a rich provider of ATP in cardiac cells, might increase the predictive power since it 
might give supportive insights in the extent of drug induced changes in energy metabolism. The 
approach used in the presented study allowed classification of drugs according to their modes of 
action. This can be very useful in the assessment of not only a new drug candidate’s potential 
pharmacological properties according to group labels but also to assess its toxicity potential 
depending on the cell system used. 
However, since HL-1 cells represent an immortalised atrial murine cell line, with some cardiac 
phenotype, its relevance in predicting potential cardiotoxic side effects in humans is limited. By 
using cell types which more closely reflect human tissue i.e. human embryonic stem cell derived 
cardiomyocytes, improvement in human specific and relevant prediction is expected. Moreover, 
using a similar profiling approach, even the risk of unknown compounds/new pharmaceuticals 
for cardiac side effects might be reliably assessed when applying pattern recognition techniques 
on the basis of clinically observed side effects, such as QT-prolongation or cardiac arrest. 
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Chapter 4 
Metabolic flux analysis gives an insight on verapamil induced 
changes in central metabolism of HL-1 cells 
Abstract 
Verapamil has been shown to inhibit glucose transport in several cell types. However, the 
consequences of this inhibition on central metabolism are not well known. In this study we 
focused on verapamil induced changes in metabolic fluxes in a murine atrial cell line (HL-1 
cells). These cells were adapted to serum free conditions and incubated with 4 µM verapamil and 
[U-13C5] glutamine. Specific extracellular metabolite uptake/production rates together with mass 
isotopomer fractions in alanine and glutamate were implemented into a metabolic network model 
to calculate metabolic flux distributions in the central metabolism. Verapamil decreased specific 
glucose consumption rate and glycolytic activity by 60%. Although the HL-1 cells show Warburg 
effect with high lactate production, verapamil treated cells completely stopped lactate production 
after 24 hours while maintaining growth comparable to the untreated cells. Calculated fluxes in 
TCA cycle reactions as well as NADH/FADH2 production rates were similar in both treated and 
untreated cells. This was confirmed by measurement of cell respiration. Reduction of lactate 
production seems to be the consequence of decreased glucose uptake due to verapamil. In case of 
tumors, this may have two fold effects; firstly depriving cancer cells of substrate for anaerobic 
glycolysis on which their growth is dependent; secondly changing pH of the tumor environment, 
as lactate secretion keeps the pH acidic and facilitates tumor growth. The results shown in this 
study may partly explain recent observations in which verapamil has been proposed to be a 
potential anticancer agent. Moreover, in biotechnological production using cell lines, verapamil 
may be used to reduce glucose uptake and lactate secretion thereby increasing protein production 
without introduction of genetic modifications and application of more complicated fed-batch 
processes.  
 
 
 
 
This chapter has been published as: Strigun A, Noor F, Pironti A, Niklas J, Yang TH, Heinzle E (2011). 
Metabolic flux analysis gives an insight on verapamil induced changes in central metabolism of HL-1 cells. 
Journal of Biotechnology 155: 299-307. 
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Introduction 
Verapamil belongs to the class of calcium channel blockers (CCBs) and is clinically used for the 
treatment of hypertension (Kaplan, 1989) and angina pectoris (Brogden and Benfield, 1996). In 
addition to calcium channel antagonism, verapamil has been reported to exert other physiological 
effects such as inhibition of glucose uptake in several cell types (skeletal muscle cells (Cartee, 
1992), neuronal cells (Ardizzone et al., 2002) and adipocytes (Bechtel et al., 2008))  via several 
mechanisms. Many of the glucose uptake studies in diverse cell lines point towards a direct effect 
of verapamil on glucose transporters (Ardizzone et al., 2002; Cartee et al., 1992; Louters et al., 
2010). Verapamil’s ability to inhibit glucose uptake makes it attractive in applications other than 
its intended use as calcium channel antagonist. For example, inhibition of glucose uptake is one 
of the potential targets in cancer therapy (Gatenby and Gillies, 2007). While none of the studies 
considering verapamil ability to inhibit glucose uptake were carried out in the context of cancer 
therapy, there is growing evidence that verapamil has an anticancer effect itself (Zhang et al., 
2009) as well as a synergistic effect on other anticancer agents (Tsuruo et al., 1981; Zhang et al., 
2007). It was shown that verapamil reversibly inhibits cell proliferation of many tumor cell lines 
independent of calcium channel block (Schmidt et al., 1988).  
In addition, inhibition of glucose uptake may be exploited in biotechnological applications. In 
biotechnological production of biopharmaceuticals cell lines are used due to their ability to carry 
out posttranslational modifications. These cell lines are usually immortalized and show high 
glycolytic activity producing much lactate as by-product. Various approaches (such as genetic 
modifications or fed batch cultivations) are used to reduce substrate (glucose) uptake and by-
product production to improve protein production. On smaller scales, a simple method to do this 
is desirable. Using a compound which inhibits glucose uptake such as verapamil in low non-toxic 
concentrations improving the efficiency of growth and thereby production could be very useful. 
It is therefore of great importance to study physiological effects of glucose uptake inhibitors on 
metabolism especially with regard to substrate needs of cancer cells and cell lines. Taking 
verapamil as reference compound, in this study we used HL-1 cells to study its effects on central 
metabolism. HL-1 cells have been extensively characterized (Claycomb et al., 1998; Eimre et al., 
2008; Monge et al., 2009; Sartiani et al., 2002; White et al., 2004; Xia et al., 2004) and were 
used in pharmacological (Deng et al., 2009; Fox et al., 2005) as well as toxicological studies 
(Andersson et al., 2010; Fritzsche et al., 2009). Glucose uptake studies on HL-1 cells in the 
presence of pharmacological compounds were carried out recently and it was found that HL-1 
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cells have relevant glucose transport isoforms (GLUT1 and GLUT4) (Shuralyova et al., 2004), 
which also play a significant role in many cancer types. Moreover, the fact that HL-1 cells show 
high glycolytic activity (Monge et al., 2009), a characteristic of many cancer cells and 
commercially available cell lines, makes them attractive for glucose uptake studies.  
Metabolic flux analysis has been used for the analysis of mammalian metabolism mainly in the 
areas of cell culture technology as reviewed recently (Niklas et al., 2010). Other applications 
include the physiological characterization of animal cell lines, such as hybridomas (Bonarius et 
al., 2001), CHO-cells (Goudar et al., 2010), human production cell lines (Henry et al., 2010, 
Niklas et al., 2011), hepatocytes (Maier et al., 2009), kidney cells (Sidorenko et al., 2008), the 
analysis of effects of drugs (Niklas et al., 2009) and the physiological characterization of the 
whole murine myocardium (Vo and Palsson, 2006). In the present study we investigated the 
effect of verapamil on the glucose uptake and applied 13C metabolic flux analysis on HL-1 cells 
upon treatment with verapamil to estimate the influence of decreased glucose uptake induced by 
verapamil on intracellular fluxes in central metabolic pathways namely glycolysis and TCA 
cycle. The results of this study are discussed in the context of verapamil’s potential application in 
the field of cancer therapy and biotechnology. 
 
Material and Methods 
Cell Culture 
HL-1 cells were kindly provided by Dr. Claycomb (Louisiana State University) for research 
within the framework of EU STREP-project “Invitroheart”. The cells were maintained in 
Claycomb medium (Sigma Chemical, USA) supplemented with 2 mM glutamine (PAA 
Laboratories, Austria), 100 U/ml penicillin, 100 µg/ml streptomycin (PenStrep stock solution, C. 
C. Pro GmbH, Oberdorla, Germany), 100 µM norepinephrine (Sigma Chemical, USA) in 30 mM 
L-ascorbic acid (Sigma Chemical, USA) and 10% fetal bovine serum (FBS) (JRH Biosciences, 
UK). Cells were sub-cultured at confluency in a split ratio of 1:3. Culture flasks (75 cm2, Falcon, 
Germany) were pre-coated with a solution of 0.02% (w/v) gelatin (AppliChem, Germany) 
containing 5 µg/ml fibronectin (Sigma Chemical, USA). Beating cells were maintained at 
standard cell culture conditions (37°C, 5% CO2 and 95% relative humidity) in a cell culture 
incubator (Memmert GmbH, Schwabach, Germany). 
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Adaptation of HL-1 cells to serum free medium 
For metabolic flux analysis serum free culture conditions are desired, therefore, a modified 
composition of previously reported serum free medium for hESC cardiomyocytes (Xu et al., 
2006) was used. Carnitine, creatine and taurine were purchased from Sigma Aldrich. Stock 
solutions of taurine (100 mM), carnitine (100 mM), creatine (50 mM) were prepared in cell 
culture grade water (Invitrogen, Paisley, UK). Each solution was sterile filtered with a 0.2 µm 
filter (Millipore, Billerica, USA). 2 mM taurine, 2 mM carnitine, 1 mM creatine, 0.1 mM 
norepinephrine, PenStrep and 2 mM glutamine were added to the basal Claycomb media 
(referred as CCT-medium henceforth). The HL-1 cells were gradually adapted to CCT-medium 
in four weeks. The standard supplemented Claycomb medium was step by step replaced with 
CCT-medium during the time of adaptation. The cells were passaged three times during this 
period. 
 
Dose response curve for verapamil using cell proliferation assay 
HL-1 cells adapted to serum free conditions were trypsinized at confluency and counted using 
trypan blue exclusion method in a hemocytometer. 3.0 × 104 cells/well were seeded in 96-well 
plates in a total volume of 200 µl of CCT medium. After 24 hours (h) equilibration, the medium 
was removed. Fresh medium containing verapamil in five different concentrations (0.21 µM, 1.04 
µM, 5.2 µM, 26.2 µM, 131 µM) in triplicates was added. Cells were incubated with verapamil at 
37°C for 96 h in the incubator. A concentration response curve was plotted using the 
Sulforhodamine B assay according to a previously described method (Skehan et al., 1990). 
 
Experimental setup for studies on verapamil induced changes in metabolite uptake and 
production rates 
1.5 × 105 HL-1 cells adapted to serum free medium were seeded per well in 24-well plates which 
were already coated with a gelatin/fibronectin solution for 24 h (five plates in total were seeded). 
The total medium volume per well was 500 µl. After 24 h equilibration the medium was removed 
and the cells were carefully washed twice with 500 µl of pre-warmed (37 °C) Claycomb medium 
without supplements. Afterwards, 500 µl fresh medium with and without 4 µM verapamil was 
added to the cells in triplicates, respectively. This medium contained 2 mM [U-13C5] glutamine 
(99 %) (Cambridge Isotope Laboratories, USA). Cell free medium served as blank. Plates were 
incubated under standard cell culture conditions (37 °C, 95 % relative humidity, 5 % CO2) in the 
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incubator. Every 24 hours, one plate was taken out of the incubator, the supernatant was collected 
and the cells were fixed for protein quantification using sulforhodamine B (SRB) assay as 
explained above. Cell number was estimated using the standard population curve obtained with 
different cell numbers of HL-1 cells (data not shown).  
 
Sample preparation for HPLC measurements 
Each of the collected supernatants was individually diluted (1:2) with α-amino-butyric acid 
solution (400 µM in deionized water) which was used as internal standard.  
 
Quantification of glucose, lactate and pyruvate  
Quantification was carried out using HPLC (Kontron Instruments, Germany) with an Aminex 
HPX 87H ion exchange column (300x7.8mm, Biorad, USA). The isocratic separation was carried 
out using 7 mM sulfuric acid as eluent and a flow rate of 0.8 ml/min at a column temperature of 
60°C. Injection volume was 20 µl. Lactate and pyruvate were detected by UV-detection (UV-
detector: HPLC 535, Biotek, Germany) at a wavelength of 210 nm. Glucose was determined by 
measuring the refractive index (ERC-7515A, ERC Inc., Germany). Standard solutions of glucose, 
lactate and pyruvate (Sigma Chemical, USA) were used for identification and quantification. 
 
Quantification of amino acids 
Amino acids were quantified as described earlier (Hans et al., 2003; Kromer et al., 2005). 
Briefly, quantification was carried out using HPLC (Agilent 1100 series, Agilent technologies, 
Germany) with a C18 RP-column (Gemini® 5u C18 110A, 150 x 4.6 mm, Phenomenex, 
Germany) at 40 °C. A gradient separation was carried out (Eluent 1: 40 mM Na2HPO4, pH 7.8; 
Eluent 2: methanol, acetonitrile, water 45:45:10 (v/v)) with a flow rate of 1 ml/min. Primary 
amino acids were derivatized by pre-column derivatization using ortho-phthalaldehyde (OPA) 
(Agilent, Germany) (excitation wavelength: 330 nm; emission wavelength: 450 nm). Proline, a 
secondary amino acid, was derivatized using 9-fluorenylmethylchloroformate (FMOC) (Agilent, 
Germany) (excitation wavelength: 266 nm, emission wavelength: 305 nm).  
Since glutamine is not stable at standard cell culture conditions (37°C) for longer time periods, its 
degradation was taken into account. Glutamine degradation was found to be a first order process 
having a rate constant (kG) of 0.0148 µM h-1 in the applied medium. The measured glutamine 
data was corrected for degradation using the following equation: 
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G Gln
d[Gln] (k [Gln] r )
dt
= − × +
        (1) 
Where rGln is the actual glutamine uptake rate. 
 
Sample preparation for mass isotopomer measurement 
100 µl of collected supernatants were frozen in individual glass vials at -70 °C and lyophilized 
overnight. 50 µl of dimethylformamide (Sigma Aldrich, Germany) containing 0.1% pyridine 
(Sigma Aldrich, Germany) (v/v) was added to the dried supernatants. For derivatization 50 µl of 
N-methyl-N-tert-butyldimethylsilyl-trifluoroacetamide (MBDSTFA, Macherey-Nagel, Germany) 
were added and each sample was incubated for 1 h at 80°C. The derivatized samples were 
centrifuged at 6000 rpm and the supernatant (60 µl) was transferred into glass vials with micro-
inlays for GC/MS analysis.  
 
Mass isotopomer measurement using GC/MS 
Measurement of mass isotopomers was carried out using gas chromatography (HP 6890 Hewlett 
Packard, USA) equipped with a HP-5 MS column (5 % phenyl-methyl-siloxane-
diphenylpolysiloxane, 30 m x 0.25 mm x 0.25 µm, Agilent, Germany) and coupled with a 
quadrupole mass spectrometer (MS 5973, Agilent, Germany). The injection volume was 1 µl. 
The separation was carried out with a flow rate of 1.1 ml/min (carrier gas: helium). The 
temperature gradient was as follows: 135°C for 7 minutes, temperature increase 10°C/min until 
160°C, 7°C/min until 170°C, 10°C/min until 325°C which is held for 2.5 minutes. Ionization was 
carried out by electron impact at 70 eV.  
Metabolites such as alanine and glutamate were silylated using MBDSTFA as previously 
described (Yang et al., 2009). From the mass spectra of MBDSTFA derivatives, carbon mass 
isotopomer distributions were computed using the method described earlier (Yang et al., 2009). 
The metabolic fluxes were computed from carbon mass isotopomer distributions obtained from 
the mass spectrometric labeling analysis of fragment ions of alanine and glutamate-derivatives, 
for which monoisotopic peaks were detected at m/z 261 and 432, respectively. Mean mass 
isotopomer distributions for the phase considered for metabolic flux analysis were calculated 
according to the following equation: 
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( ) ncorr
j 0
[m i]
m i
[m j]
=
+
+ =
+∑
  n = nc + 1, i = 0…n      (2)  
(m+i)corr represents the corrected mass isotopomer fraction (%) which was used for calculation of 
fluxes. [m+i] gives the concentration of each measured mass isotopomer, nc is the numbers of 
carbon atoms in the metabolite.  
 
Calculation of growth rate and specific uptake/production rates of metabolites 
Growth rate of HL-1 cells in serum free medium was calculated by using the following equation 
and plotting ln(N) against time (t); 
( ) ( )0ln N t ln N= µ +           
µ represents the growth rate [h-1]. N is the cell number at a defined time point and N0 is the initial 
cell number at t=0.  
Yield coefficients (Yi) for each metabolite were calculated by the equation given below: 
i
i
dMY
dN
=            (4) 
where N represents the cell number and Mi concentration of metabolite i.  
Specific consumption and production rates for measured metabolites (v) were calculated from the 
growth rate µ and the respective yield coefficients Yi using the equation below: 
m,i iv Y µ= ×            (5) 
13C flux analysis 
A carbon atom transition network model of the central metabolism was set up (Appendix for 
chapter 4, Tab. S1) and applied for 13C metabolic flux analysis. Substrate metabolites which were 
only taken up for anabolic demand were excluded from the model since their carbon atoms were 
not entering central metabolic pathways. The model consisted of 41 reactions. 16 reactions were 
measured from extracellular uptake and production fluxes, while 25 reactions were intracellular 
rates of which 11 were defined as reversible. Anabolic fluxes were estimated from the growth 
rate and biomass composition which was taken from (Niklas et al., 2009). Flux estimation was 
carried out using MATLAB 2008b (The Mathworks) using the elementary metabolite unit 
concept (Antoniewicz et al., 2007) with a recently described method (Yang et al., 2008). 
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In the applied stationary metabolic flux analysis approach, metabolic and isotopic steady state 
conditions are a prerequisite. To determine whether the pseudo steady state assumption is 
justified, metabolite and isotopomer concentrations at different time points of the cultivations 
were plotted against the corresponding number of cells, as described recently (Deshpande et al., 
2009).  
 
Respiration measurement  
HL-1 cells were seeded with a density of 3 × 105 cells/well in 24-well OxoDishes (PreSens, 
Germany). Cell free medium served control. After 24 h equilibration, fresh medium with and 
without 4 µM verapamil was added to the cells in triplicates. Dissolved oxygen was continuously 
measured for 48 h as recently described (Beckers et al., 2009). Afterwards cell number in each 
well was quantified by using SRB assay. 
Specific oxygen consumption rate (qO2) was estimated using the liquid phase balance equation as 
follows: 
[ ] [ ]( ) ⋅ = ⋅ − − 2 sat 2L 2 2d O qO Xk a O Odt V         (6) 
[O2sat] is the dissolved oxygen concentration at saturation in culture medium taken (6.23 mg/L; 
from (Oeggerli et al., 1995) while [O2] represents the actual dissolved oxygen concentration, X 
the number of cells per well and V the liquid volume per well. Equation (6) was integrated using 
MATLAB and statistical errors were estimated using Monte Carlo simulation (Further details are 
provided in the Appendix for chapter 4, Text S1, Figure S1 and S2). 
 
Statistical analysis 
Extra- and intracellular fluxes in cells treated with 4 µM verapamil were compared with the 
respective untreated controls using student’s t-test. The changes were considered significant at p 
< 0.05. 
 
Results 
Maintenance of HL-1 cells in serum free medium  
The HL-1 cells were successfully adapted to serum free Claycomb media. The cells were beating 
for more than six month after the complete removal of FBS. 
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Cytotoxicity of verapamil 
Figure 1 shows the concentration response curve of verapamil obtained using sulforhodamine B 
assay for proliferation. The concentration range in which the relative cell number ranged from 
100 to 20% of the control was between 5 µM and 130 µM. Based on the concentration response 
curve, a verapamil concentration of 4 µM was chosen (95 % relative proliferation after 96 h of 
treatment) for further studies on specific uptake/production rates for glucose, lactate, pyruvate 
and amino acids. 
 
R
e
la
ti
v
e
 c
e
ll
 n
u
m
b
e
r
[%
 o
f 
c
o
n
tr
o
l]
 
 
Figure 1: Effect of verapamil on proliferation of HL-1 cells adapted to serum free (CCT)-medium. Cells were 
seeded in 96-well plates and after 24 h equilibration; fresh medium with different concentrations of verapamil was 
added to the cells. Cells were fixed 96 h after exposure to verapamil and relative cell number was determined by 
sulforhodamine B staining. Standard deviations were determined from triplicate measurements. The arrow indicates 
the concentration (4 µM) which was used for subsequent flux analysis studies. 
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Proliferation and metabolite profiles in HL-1 cells upon verapamil treatment  
Figure 2A shows the growth profiles of HL-1 cells in serum free medium with and without 4 µM 
verapamil. Cell number increased from 1.5 × 105 cells/well to 8.0 × 105 (untreated control) and 
7.4 × 105 cells/well (verapamil) after 96h of incubation at standard incubation conditions. 
Although there was no significant change in the proliferation of HL-1 cells, exposure to 
verapamil (4µM) resulted in complete arrest of microscopically observed beating. 
The concentration of glucose in the medium decreased from 22.5 mM to 12.7 mM in case of 
untreated control in 96 h (Fig. 2B) showing high consumption of glucose. Whereas, in the 
presence of verapamil, glucose consumption by the cells was much lower. The concentration of 
glucose in the medium of treated cells was 17 mM after 96 h incubation (Fig 2B). As glucose 
was consumed from the medium, the concentration of lactate continuously increased to 10 mM 
in untreated control cells after 96 h. In the presence of verapamil an initial production of lactate 
(2.5 mM) was observed within the first 24 h of incubation. After 96 h of incubation lactate 
concentration slightly decreased to 2.2 mM. Therefore, lactate was slightly consumed at 96 h of 
treatment with verapamil. Pyruvate concentration continuously decreased from 60 µM to 2 µM 
(untreated control) and 3 µM (verapamil treated cells) within the initial 48 h of incubation. 
Afterwards pyruvate concentration increased to 66 µM (untreated control) and 11 µM 
(verapamil) until 96 h of incubation (Fig. 2C). Alanine concentration continuously increased 
from 320 µM (the initial concentration in the medium) to 922 µM in untreated control and to 
912 µM in verapamil treated HL-1 cells (Fig 2D). No significant difference in glutamine 
consumption between untreated and treated HL-1 cells was observed (Fig. 2D). Glutamine 
concentration decreased from initially 2 mM to 1 µM (control) and 12 µM (treated cells). The 
profiles of all metabolites versus time are shown in the Appendix for chapter 4 (Figure S3). 
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Figure 2:  A) Growth of untreated control (closed symbols) and treated (4 µM verapamil) HL-1 cells (open 
symbols). B) Concentration of glucose (squares) and lactate (triangles) in culture medium with (open symbols) and 
without (closed symbols) verapamil. C) Changes of concentration of pyruvate in untreated controls (closed symbols) 
and in cells treated with 4 µM verapamil (open symbols) D) Changes of concentration of glutamine (squares) and 
alanine (circles) in culture medium with (open symbols) and without (closed symbols) verapamil. Standard 
deviations were calculated from triplicates measurements.  
 
Influence of verapamil on uptake and production rates of metabolites 
Accumulation/depletion of metabolites versus cell number (Appendix for chapter 4, Fig. S4) 
showed a linear relationship, as apparent from correlation coefficients which were > 0.9 for most 
of the considered metabolites (Appendix for chapter 4, Tab. S2). Based on the yields, average 
specific rates of metabolite uptake and production were calculated as shown in table 1. Glucose 
uptake rate was around 135 % higher in control cells as compared to the treated cells (Tab.1). 
Specific lactate production rate was 213 fmol cell-1 h-1 in untreated HL-1 cells, whereas after 
initial production of lactate in the first 24 h, a slight uptake of lactate (11 fmol cell-1 h-1) was 
observed in HL-1 cells treated with verapamil. Lactate yield on glucose was 1.0 
mollactate/molglucose in untreated control and -0.12 mollactate/molglucose in treated HL-1 cells. 
Pyruvate was produced by untreated HL-1 cells (0.8 fmol cell-1 h-1) but was significantly 
consumed by treated cells (0.54 fmol cell-1 h-1, p < 0.01). Glutamine, alanine and branched chain  
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amino acids (isoleucine, leucine and valine) showed the highest uptake rates among all amino 
acids. With the exception of glycine, no significant differences of specific rates in controls and 
treated HL-1 cells were observed. Glycine production rate was 0.7 fmol cell-1 h-1 in untreated 
and 0.04 fmol cell-1 h-1 in treated HL-1 cells (p < 0.01). 
 
Table 1: Specific uptake and production rates of metabolites in untreated control and treated HL-1 cells (4 µM 
verapamil). Specific rates were calculated from specific growth rate and biomass yield. The biomass yield was 
constant for most of considered metabolites within 24 and 96 h of incubation (see Appendix for Chapter 4, Fig. S4 
for biomass yield plots and Tab. S2 for correlation coefficients). Average rates were calculated from 24-96 h of 
incubation (see methods). Standard deviations (s.d.) were calculated from triplicate measurement. Rates were 
considered significantly different when p < 0.05, as calculated from two-tailed t-test. n.s.: not significant 
 
 Specific rate [fmol cell-1 h-1] 
Metabolite control ± s.d. 4 µM 
verapamil ± s. d. p 
GLC -221.2 34.9 -94.3 15.8 < 0.01 
LAC 213.5 48.0 -11.2 8.3 < 0.01 
PYR 0.8 0.3 -0.5 0.3 < 0.01 
ALA 13.8 2.0 14.3 0.7 n.s. 
ARG -2.5 0.4 -2.9 0.2 n.s. 
ASN -1.6 0.4 -1.8 0.2 n.s. 
ASP -0.5 0.7 -0.2 0.2 n.s. 
GLU 2.7 1.0 2.9 0.3 n.s. 
GLN -31.3 4.6 -33.1 1.9 n.s. 
GLY 0.7 0.3 0.04 0.2 < 0.01 
HIS -1.0 0.2 -1.2 0.4 n.s. 
ILE -8.6 1.5 -9.0 0.6 n.s. 
LEU -5.9 1.1 -6.4 1.0 n.s. 
LYS -3.6 1.0 -5.0 0.6 n.s. 
MET -2.0 0.3 -2.1 0.4 n.s. 
PHE -1.7 0.3 -2.0 0.4 n.s. 
PRO -7.6 6.5 -2.0 4.5 n.s. 
SER 3.4 0.6 2.9 0.2 n.s. 
THR -2.6 1.0 -2.9 0.6 n.s. 
TYR -2.1 0.3 -2.1 0.7 n.s. 
VAL -5.6 1.4 -5.6 0.7 n.s. 
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Influence of verapamil on intracellular fluxes 
A time dependent increase of 13C mass isotopomer fractions in alanine and glutamate derived 
from [U-13C5] glutamine was observed in both treated and untreated HL-1 cells (Appendix for 
Chapter 4, Tab. S3 and S4). Figures 3 and 4 show the alanine and glutamate mass isotopomer 
concentrations plotted against the respective cell numbers at each time point of the cultivation. 
The slope of each plot represents the yield of the respective mass isotopomers. A linear 
relationship of alanine and glutamate mass isotopomer concentrations versus cell number is 
given in both untreated and verapamil treated cells (4 µM) as apparent from correlation 
coefficients > 0.9 (Appendix for Chapter 4, Tab. S5 and S6). 
 
 
Figure 3: Concentrations of alanine 13C-mass isotopomers (unlabelled alanine (m+0), single labelled alanine (m+1), 
double labelled alanine (m+2) and fully labelled alanine (m+3)) versus cell number of untreated controls (closed 
symbols) and in cells treated with 4 µM verapamil (open symbols). Mass isotopomer concentrations were calculated 
by multiplication of alanine concentrations with corresponding mass distributions. The slope of each plot represents 
the yield coefficient (Yi) which was used for the calculation of the steady state mass distribution that was used as 
input data for estimation of intracellular fluxes in HL-1 cells. Enrichment of 13C in alanine was derived from [U-
13C5] glutamine. The correlation coefficients for each mass isotopomer yield are shown in Tab. S5 (Appendix for 
Chapter 4). Error bars represent standard deviations determined from triplicate measurements.  
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Figure 4: Concentrations of glutamate 13C-mass isotopomers (unlabelled glutamate (m+0), single labelled glutamate 
(m+1), double labelled glutamate (m+2) and triple labelled glutamate (m+3), four fold labelled glutamate (m+4) and 
fully labelled glutamate (m+5)) versus cell number of untreated controls (closed symbols) and in HL-1 cells treated 
with 4 µM verapamil (open symbols). The slope of each plot represents the yield coefficient (Yi) which was used for 
calculation of the steady state mass distribution that was used as input data for estimation of intracellular fluxes in 
HL-1 cells. Enrichment of 13C in glutamate was derived from [U-13C5] glutamine. The correlation coefficients for 
each mass isotopomer yield are shown in Tab. S6 (Appendix for Chapter 4). Error bars represent standard deviations 
determined from triplicate measurements.  
 
Intracellular fluxes were estimated by using extracellular fluxes and labeling patterns of alanine 
and glutamate in a metabolic network model (Appendix for Chapter 4, Tab. S1). The fit between 
measured data and simulated data gives an estimate of the accuracy of the flux calculation. 
Figure S5 (Appendix for Chapter 4) shows the regression plots of simulated versus measured 
mass isotopomer distributions and extracellular fluxes from both untreated and treated cells. A 
good match of simulated and measured extracellular fluxes was found as most of the flux and 
mass distribution ranges were located on the angle bisector of the plot. The distribution of 
calculated intracellular steady state fluxes (containing reactions from glycolysis, TCA-cycle, 
amino acid metabolism and anaplerosis) is graphically depicted in Figure 5. The line widths are 
normalized to glucose uptake in untreated cells. The underlying flux values are given in Table  
S7 (Appendix for chapter 4). Flux rates through reactions of glycolysis (G6PF6P, F6PGAP, 
GAP3PG and 3PGPYR) were significantly decreased by about 60 % (P<0.01). Oxidative 
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decarboxylation of pyruvate to acetyl-CoA was decreased by 17 % and TCA-cycle fluxes by 17-
20 % in cells treated with verapamil. These changes, however, were not statistically significant 
(95 % confidence). Alterations of fluxes through reactions in amino acid metabolism were not 
significant for the majority of reactions. However, intracellular deamination of glutamine to 
glutamate was significantly increased by 27 % (p < 0.05). Though not significant, the flux of 
glutamate to α-ketoglutarate (AKG) was increased by 22 %. 
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Figure 5: Impact of channel blocker verapamil (4 µM) on reactions from glycolysis, TCA cycle and glutamine 
catabolism. Intracellular fluxes in HL-1 cells were calculated from extracellular rates and 13C mass isotopomer 
distribution in alanine and glutamate. The relative change of intracellular fluxes through individual reactions was 
normalised to glucose uptake rate in untreated control. 
 
Influence of verapamil on respiration  
Respiration of HL-1 cells, i.e. the consumption of O2 was calculated from metabolic flux 
analysis, i.e. the surplus NADH/FADH2 formation rate. The calculated specific oxygen uptake  
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rate was decreased by 16 % in treated cells (untreated cells: 750 fmol cell-1 h-1, treated cells: 630 
fmol cell-1 h-1, Appendix for chapter 4, Tab. S7). However, this change was not significant. 
Measured specific oxygen uptake rates as determined from continuous measurement of 
dissolved oxygen uptake rates accounted for 582 fmol cell-1 h-1 in untreated cells and 560 fmol 
cell-1 h-1 in treated cells (Tab. 2), corresponding to a decrease of about 4 % upon treatment with 
Verapamil (Appendix for Chapter 4, Fig. S1 and S2).  
 
Table 2: Estimation of specific oxygen uptake rate, qO2, using optical measurement of dissolved oxygen in 24-well 
plates and simultaneous estimation of kLa in untreated control and treated HL-1 cells (4 µM verapamil). Details of 
measurement results and estimation of parameters are provided in the Appendix for Chapter 4 (Text S1, Fig S1 and 
S2).  
 Untreated control 4 µM verapamil Assumed experimental 
error in oxygen measurement 
kLa [h-1] 
0.24 ± 0.01 0.25 ± 0.01 5% 
0.18 ± 0.02 0.16 ± 0.05 10% 
qO2  
[fmol cell-1 h-1] 
582 ± 27 560 ± 17 5% 
402 ± 45 368 ± 109 10% 
 
The differences between values determined via metabolic flux analysis and direct respiration 
measurement may be caused by some systematic deviations originating most likely from 
incomplete mixing in the static 24-well plates (Weiss et al., 2002). Most importantly a similar 
trend between control and verapamil treated cells was observed.  
 
Discussion 
Independent of the calcium channel blocking effect, verapamil has been shown to exert other 
physiological effects such as on the glucose uptake. Various studies have shown a potential 
effect of verapamil on glucose transporters such as GLUT1 and GLUT4. Using HL-1 cells, we 
investigated the influence of verapamil on specific uptake and production rates of a whole 
spectrum of metabolites and nutrients, such as lactate, pyruvate and amino acids in addition to 
glucose in serum free conditions. 13C labeled glutamine was used to obtain an insight into the 
central metabolism. Based on specific uptake rates and 13C enrichment in alanine and glutamate, 
we estimated the effect of verapamil on TCA cycle activity. 
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Untreated control cells consumed glucose and produced lactate, resulting in a lactate/glucose 
ratio of 1 mollactate/molglucose. A recent study on HL-1 cells maintained in serum containing 
medium, reported a lactate/glucose ratio of 1.8 (Monge et al., 2009) suggesting conversion of 
almost all glucose into lactate. This study suggested that HL-1 cells share properties with cancer 
cells and other immortalized cell lines, which often show Warburg effect, i.e. high anaerobic 
glycolysis. Secreted lactate may also serve to keep the tumor environment acidic which is 
commonly needed for tumor growth. We conducted our study in serum free conditions and our 
results indicate that the HL-1 cells adapted to serum free conditions seem to shuttle glucose 
carbon to a higher extent into the TCA cycle, as apparent from the lower lactate/glucose yield.  
A significant decrease of specific glucose uptake rate in HL-1 cells was observed upon 
verapamil treatment. In addition, lactate production completely stopped after 24 h and a slight 
consumption of initially produced lactate was observed afterwards. The decrease in glucose 
uptake is probably partly caused by less energy demand due to arrest of myocyte beating i.e. the 
working state of the cardiomyocytes upon verapamil treatment. However, the fact that lactate 
was not produced in case of verapamil treated cells but even slightly consumed is a strong 
evidence that reduced glucose uptake is not solely due to reduced energy demand.  A direct 
effect of verapamil on glucose uptake results in significantly reduced glycolytic flux. Recent 
studies suggest a direct effect of  verapamil on glucose transporters (Ardizzone et al., 2002; 
Cartee et al., 1992; Louters et al., 2010). Since HL-1 cells posses glucose transporters GLUT1 
and GLUT4 (Shuralyova et al., 2004) it can be assumed that the decreased glycolysis and halted 
lactate production are consequences of verapamil’s effect on glucose uptake. Besides the 
reduction of lactate production, pyruvate is consumed in treated cells but not in untreated cells 
whereas glycine production was significantly decreased. As secreted pyruvate is probably linked 
to intracellular pyruvate pools and secreted glycine most probably derives from glycolytic 
intermediate 3-phosphoglycerate, it can be assumed that verapamil treated HL-1 cells try to 
make efficient use of available glucose. The complete halt of lactate production, which itself 
requires reduction of 1 mole of pyruvate on the expense of 1 mole NADH facilitates the 
maintenance of NADH production rate. In addition, slight uptake of lactate may yield additional 
NADH in verapamil treated cells.  
These changes allow the cells to maintain TCA cycle activity, cell respiration (figure 2 and table 
2) and cell growth almost comparable to untreated cells. However, despite a more efficient use 
of available glucose carbon in verapamil treated cells, the extent of carbon derived from glucose  
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entering TCA cycle doesn’t seem sufficient to maintain TCA cycle activity at a similar level as 
in untreated cells, as calculated from a non-significant decrease in TCA cycle rates. This might 
explain the increased rate of deamination of glutamine to glutamate as well as the slight increase 
of transamination/deamination of glutamate to α-ketoglutarate. This increased flux contributes to 
anaplerosis in the TCA cycle. 
Verapamil’s property to decrease glucose uptake and consequently glycolysis may be exploited 
in the fields of cancer therapy and biotechnology. It was recently suggested that verapamil has 
an anticancer effect itself (Zhang et al., 2009) and also enhances the effect of other anticancer 
agents. Despite the fact that most studies regarding verapamil’s antiproliferative effect were 
performed in vitro, which does not reflect tumor environment, verapamil induced reduction of 
glucose uptake and thereby glycolytic activity may contribute to decreased tumor growth. The 
interruption of tumor glycolytic metabolism is a potential strategy in cancer therapy (Gatenby 
and Gillies, 2007). In addition, lack of acidic environment may abolish selective advantage of 
tumor cells, as tumor invasion seems to favor H+ environment (Gillies and Gatenby, 2007).  As 
apparent from our study, growth of untreated controls and verapamil treated cells was similar. 
We therefore assume that hypoxic conditions prevalent in tumor tissue, would favor verapamil’s 
antiproliferative effect in vivo. Further experiments e.g. under hypoxic conditions would lead to 
a better insight since it can be expected that the HL-1 cells would not be able to maintain growth 
as was observed in our study. 
Besides the field of cancer therapy verapamil (or compounds with similar properties i.e. 
phenylalkylamines) may have potential application from biotechnological point of view whereby 
cell lines are desired to efficiently use the substrate and produce minimum lactate as by product. 
Several strategies have been developed to reduce lactate formation in cell lines. It has been 
shown that lactate formation can be highly reduced in CHO cells by substitution of glucose by 
either fructose or galactose (Altamirano et al., 2000). In addition, disruption of LDH-genes can 
significantly decrease lactate formation despite high glucose concentrations in the culture 
medium, while at the same time increasing both viable cell number and antibody production 
(Chen et al., 2001). It was recently shown that down regulation of LDH-A gene via siRNA also 
allows significant reduction of lactate production (Kim and Lee, 2007). In addition, efficient use 
of glucose as substrate in mammalian cell culture can be achieved by fed-batch cultivation using 
low glucose concentrations (~0.5 mM) as described for several cell lines (Gambhir et al., 1999; 
Maranga and Goochee, 2006; Zhou et al., 1995). We assume that addition of verapamil or 
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similarly acting compounds, to culture medium may serve as a potential alternative to the above 
mentioned approaches or an additional supplement for production efficiency. This is especially 
true in case of lab-scale production of proteins where the application of fed-batch cultivation 
would usually be considered too costly and where, therefore, batch cultivation of cells is 
preferentially applied necessitating rather high glucose concentrations. Reduction of glucose 
uptake by a compound and thereby elimination of lactate formation while maintaining cell 
growth and protein secretion at a high level might be very useful in such cases. Instead of 
optimizing cell lines by genetic modifications, simple addition of verapamil in non-toxic 
concentrations may result in lower glucose uptake rate and higher efficiency i.e. less production 
of lactate. Further experiments using verapamil and other glucose uptake inhibitors/modulators 
with cell lines used for biotechnological purposes are underway in our laboratory.  
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Chapter 5 
Doxorubicin results in increased oxidative metabolism in HL-1 
cardiomyocytes as shown by metabolic flux analysis 
 
Abstract 
Doxorubicin (DXR), an anticancer drug, is limited in its use due to severe cardiotoxic effects. 
These effects are partly caused by disturbed myocardial energy metabolism. We analyzed the 
effects of therapeutically relevant but non-toxic DXR concentrations for their effects on 
metabolic fluxes, cell respiration and intracellular ATP. 13C isotope labeling studies using [U-
13C6]glucose, [1,2-13C2]glucose and [U-13C5]glutamine were carried out on HL-1 cardiomyocytes 
exposed to 0.01 µM and 0.02 µM DXR and compared with the untreated control. Metabolic 
fluxes were calculated by integrating production and uptake rates of extracellular metabolites 
(glucose, lactate, pyruvate, amino acids) as well as 13C-labeling in secreted lactate derived from 
the respective 13C-labeled substrates into a metabolic network model. The investigated DXR 
concentrations (0.01 µM and 0.02 µM) had no effect on cell viability and beating of the HL-1 
cardiomyocytes. Glycolytic fluxes were significantly reduced in treated cells at tested DXR 
concentrations. Oxidative metabolism was significantly increased (higher glucose oxidation, 
oxidative decarboxylation, TCA-cycle rates and respiration) suggesting a more efficient use of 
glucose carbon. These changes were accompanied by decrease of intracellular ATP. We conclude 
that DXR in nanomolar range significantly changes central carbon metabolism in HL-1 
cardiomyocytes which results in a higher coupling of glycolysis and TCA-cycle. The myocytes 
probably try to compensate for decreased intracellular ATP which in turn may be the result of a 
loss of NADH electrons via either formation of reactive oxygen species or electron shunting.  
 
 
 
 
 
 
 
This chapter has been published as: Strigun, A., Wahrheit, J., Niklas, J., Heinzle, E., Noor, F. (2011). 
Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C-metabolic flux 
analysis. Toxicological Sciences, doi: 10.1093/toxsci/kfr298 
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Introduction  
Doxorubicin (DXR), an anthracycline antibiotic, is used in first line therapy of many human 
cancers. However, severe cardiotoxic side effects limit its clinical use (Simunek et al., 2009). 
Multiple mechanisms of DXR toxicity in vivo and in vitro have been described (Gewirtz, 1999; 
Tokarska-Schlattner et al., 2006). These include formation of reactive oxygen species (Bachur et 
al., 1977; Sinha et al., 1989), disturbances in nitric oxide pathway resulting in protein nitration 
(Fogli et al., 2004), oxidative damage of DNA (Bates and Winterbourn, 1982; Eliot et al., 1984; 
Feinstein et al., 1993), lipid peroxidation (Gewirtz, 1999) and apoptosis (Ling et al., 1993; 
Skladanowski and Konopa, 1993). 
Yet, it is more and more evident that alterations in myocardial energy metabolism, especially due 
to mitochondrial dysfunction (Berthiaume and Wallace, 2007a), play an important role in the 
onset of DXR induced cardiac toxicity. DXR related acute and chronic cardiotoxicity has been 
associated with impaired cardiac high-energy phosphate metabolism. The compromising effect of 
DXR on cardiac energy metabolism is reflected by loss of mitochondrial ATP (Pointon et al., 
2010 ; Vidal et al., 1996). Cardiac substrate usage for the  generation of the ATP and its 
alterations in myocardial diseases  has been extensively studied (Ashrafian et al., 2007; Gertz et 
al.; 1988; Mudge et al., 1976; Panchal et al., 2001; Randle et al., 1964; Stanley et al., 1997; 
Wisneski et al., 1985). It is well accepted that ATP is mainly generated from fatty acid oxidation 
in the healthy heart (Stanley et al., 2005). Several studies have shown that DXR alters fatty acid 
and glucose metabolism in the myocardium (Abdel-aleem et al., 1997; Bordoni et al., 1999; 
Carvalho et al., 2010; Wakasugi et al., 1993). However, the effects of DXR on main energy 
generating pathways besides TCA cycle, such as glycolysis are contradictory. Recent in vivo and 
in vitro studies demonstrated increased mRNA of several glycolytic enzymes (Berthiaume and 
Wallace, 2007b) as well as increased glycolytic activity which is correlated to a decrease in the 
fatty acid oxidation (Carvalho et al., 2010). In addition, it was recently demonstrated that DXR 
results in an up-regulation of mRNA from TCA-cycle relevant enzymes in perfused rat heart 
(Tokarska-Schlattner et al., 2010). Contradictorily, decreased levels of TCA-cycle relevant 
mRNA has been described in another model (Berthiaume and Wallace, 2007b). Such conflicting 
data in this regard is most probably related to differences in the applied biological model and 
experimental setup. Moreover, these differences in observations regarding alterations in 
metabolic pathways may be partly due to either acute or chronic effects of DXR. 
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To our knowledge, holistic fluxome studies on DXR induced effects on central energy 
metabolism integrating reactions, such as glycolysis, TCA-cycle and amino acid degradation, 
have not been carried out at clinically relevant concentrations on myocardial cells. This can be 
very challenging with commonly used endpoint methods since therapeutic concentrations should 
not cause acute myocyte dysfunction or cytotoxicity. The plasma kinetics of DRX shows an 
initial half-life of ~8 minutes followed by a terminal half-life of about 30 hours (Greene et al., 
1983). The major exposure occurs during the terminal phase where drug concentrations are 
generally less than 10-7 M. Following a 15 min infusion of DXR, the plasma concentration 
rapidly declines from 5 to 0.1 µM within one hour and steadily declines until ~30 hours. Total 
plasma concentration ranges from 20nM to 2µM of which only 20-25 % is freely available i.e. 
the amount not bound to serum albumin. We assumed that DXR even at nanomolar 
concentrations exerts an effect on the central metabolism. To assess such effects sensitive 
methods and cutting edge technology is required. Using 13C metabolic flux analysis we analyzed 
the effect of DXR on the central metabolism in an in vitro model (HL-1 cardiomyocytes). The 
used methodology includes the measurement of a whole set of metabolite uptake and production 
rates as well as the measurement of 13C enrichment in metabolites derived from 13C labeled 
substrates. These data are implemented into a metabolic network model which allows the 
estimation of intracellular fluxes over metabolic pathways. This method has been successfully 
used to study the energy metabolism of mammalian cells in vitro (Forbes et al., 2006; Goudar et 
al., 2010; Maier et al., 2009; Metallo et al., 2009; Niklas et al. 2011; Strigun et al., 2011b) and 
that of the whole myocardium, as shown earlier (Vo and Palsson, 2006). However, this method 
has not been yet applied to analyze the effect of DXR on cardiac metabolism. The advantage of 
13C based fluxomic studies over transcriptomic or proteomic approaches is that activities of ATP-
relevant pathways can be more reliably determined. Most importantly, specific rates of certain 
reactions cannot always be directly derived from changes of corresponding genes or proteins, due 
to the complex regulations of enzyme activities. We investigated the suitability of this method for 
the description of actual in vivo activities of metabolic pathways.  
We furthermore complemented flux determinations with the measurement of cell respiration and 
intracellular ATP. The HL-1 cardiomyocytes is a murine cardiac cell line (Claycomb et al., 1998; 
White et al., 2004) which retains a differentiated morphology (Sartiani et al., 2002, White et al., 
2004, Fukuda et al., 2005, Clarke et al., 2006). These cells have been used in the study of glucose 
and fatty acid metabolism (Palanivel et al., 2006, Alfarano et al., 2008) in addition to studying 
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DXR induced effects (Andersson et al., 2010; Budde et al., 2011). We used a dose response 
curve from an LDH release assay to determine the DXR concentrations which were not cytotoxic 
and did not inhibit myocyte beating. These concentrations have been reported to be clinically 
relevant corresponding to serum concentrations in patients undergoing DXR treatment (Greene et 
al., 1983). These are also significantly lower than the DXR concentrations at which cardiac 
Troponin T release, an indicator for cardiac damage, has been recently reported in the HL-1 
cardiomyocytes (Andersson et al., 2010). The results of the present study are discussed in the 
context of current knowledge regarding DXR induced alterations of cardiac energy metabolism. 
 
Material and Methods 
Cell Culture 
HL-1 cardiomyocytes (Claycomb et al., 1998; White et al., 2004) were kindly provided by Dr. 
Claycomb (Louisiana State University) for research within the framework of EU STREP-project 
“Invitroheart”. The cells were maintained in Claycomb medium (Sigma Chemical, USA) which 
was supplemented with 2 mM glutamine (PAA Laboratories, Austria), 100 U/ml penicillin, 100 
µg/ml streptomycin (PenStrep stock solution, C. C. Pro GmbH, Oberdorla, Germany), 100 µM 
norepinephrine (Sigma Chemical, USA) in 30 mM L-ascorbic acid (Sigma Chemical, USA) and 
10% fetal bovine serum (FBS) (JRH Biosciences, UK). At confluency the cells were passaged in 
a split ratio of 1:3. Cells were cultivated in culture flasks (75 cm2, Falcon, Germany) which were 
pre-coated with a solution of 0.02% (w/v) gelatin (AppliChem, Germany) containing 5 µg/ml 
fibronectin (Sigma Chemical, USA). The cells were maintained at standard cell culture 
conditions (37 °C, 5% CO2 and 95% relative humidity) in a cell culture incubator (Memmert 
GmbH, Schwabach, Germany). 
 
LDH assay 
A doxorubicin-HCl (DXR) (Sigma Chemical, USA) stock solution (10 mM) was prepared in cell 
culture grade water (PAN Biotech, Germany). Cytotoxicity of DXR on HL-1 cardiomyocytes 
was assessed using lactate dehydrogenase release (LDH-release assay). 5 × 104 cells/well were 
seeded in gelatin/fibronectin-coated (see 2.1) 96-well plates (Greiner, Germany) in 200 µl 
Claycomb medium (containing 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 
100 µM norepinephrine in 30 mM L-ascorbic acid and 10% FBS). After 24 hours (h) incubation, 
the supernatant was removed and the cells were washed once with Claycomb medium. Fresh 
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supplemented Claycomb medium containing DXR at different concentrations (20 µM, 10 µM, 
2.5 µM, 0.6 µM, 0.16 µM and 0.004 µM) was added to the cells in triplicates. The cells were 
incubated with DXR for 48 h. Finally, lactate dehydrogenase assay (Cytotoxicity Detection Kit 
(LDH), Roche Applied Science, Germany) was carried out according to manufacturer's 
instructions.  
 
Experimental setup for labeling studies on HL-1 cardiomyocytes 
A stock solution of 1 mM DXR in cell culture grade water (PAN Biotech, Germany) was diluted 
in supplemented Claycomb medium (see 2.2) to obtain 0.02 µM or 0.01 µM DXR final 
concentrations. For each test (0.02 µM, 0.01 µM or untreated control without DXR) four separate 
media containing different combinations of labeled glucose and glutamine substrates (enrichment 
99%) (Cambridge Isotope Laboratories, USA) were prepared as follows; medium 1: 5 mM [U-
13C6] glucose and 2 mM naturally labeled glutamine, medium 2: 5 mM [1,2-13C2] glucose and 2 
mM naturally labeled glutamine, medium 3: 5 mM naturally labeled glucose and 2 mM [U-13C5] 
glutamine, medium 4: 5 mM naturally labeled glucose and 2 mM naturally labeled glutamine. 
Since the commercially available Claycomb medium already contains 20 mM glucose, the final 
glucose concentration in the media was 25 mM. In this way 12 different media in total were 
prepared (four media for controls, four for each 0.01 µM and 0.02 µM DXR, respectively). 
1.5 × 105 HL-1 cardiomyocytes in a volume of 1 ml were seeded per well in 24-well plates pre-
coated with a gelatine/fibronectin solution (see 2.1) using Claycomb medium (25 mM naturally 
labeled glucose, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µM 
norepinephrine in 30 mM L-ascorbic acid and 10 % FBS). After 24 h equilibration the medium 
was removed and the cells were carefully washed twice with pre-warmed (37 °C) Claycomb 
medium without supplements. The 12 different media containing 0.02 µM, 0.01 µM or no DXR 
and differently labeled glucose and glutamine substrates were added to the respective wells. Cell 
free medium served as blank. For each test condition (0.02 µM DXR, 0.01 µM DXR, untreated 
control, cell free medium control) four replicates per 24-well plate were prepared. Replicate 1 
contained medium 1, replicate 2 contained medium 2, replicate 3 contained medium 3 and 
replicate 4 contained medium 4. Four 24-well plates were prepared in this way. 
 
The plates were incubated under standard cell culture conditions (37 °C, 95 % relative humidity, 
5 % CO2) in the incubator. After 2, 10, 24 and 34 h of incubation one plate was removed from the 
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incubator and the respective supernatants were collected and stored at - 20 °C until further 
analysis. The cells of each plate were fixed and a protein quantification assay (SRB assay) was 
performed as described previously (Noor et al., 2009). Cell number was estimated using a 
calibration curve obtained with different cell numbers of HL-1 cardiomyocytes. 
 
Sample preparation for HPLC analysis 
Serum proteins, such as albumin were removed from the samples by microfiltration using 
Microcon® Filter Devices (Millipore, Germany) with an exclusion size of 10 kDa. Subsequently 
each filtrate was diluted 1:2 with α-aminobutyric acid solution (400 µM in deionized water) 
which was used as an internal standard for amino acid quantification. 
 
Quantification of extracellular glucose, lactate, pyruvate, amino acids and total fatty acids 
Quantification of glucose, lactate and amino acids was carried out exactly as described recently 
(Strigun et al., 2011b). Quantification of total free fatty acids was performed using a NEFA kit 
(Wako Chemicals, Germany) for the determination of non-esterified fatty acids. 300 µl of each 
culture supernatant was lyophilized and reconstituted in 30 µl cell culture grade water. Total free 
fatty acids in these samples were quantified according to the manufacturer’s instructions. Briefly, 
100 µl of the prepared reaction solution were mixed with 10 µl of the sample. After incubation 
for 10 minutes at room temperature (RT) the absorbance of the formed dye was measured at 550 
nm using an iEMS reader (Labsystems, Finland). To exclude any influence of DXR on the 
measurement, reconstituted medium without cells was used. An oleic acid standard solution 
(Wako Chemicals, Germany) was used for calibration. 
 
Mass isotopomer measurement using GC/MS 
Measurement of mass isotopomers was carried out using gas chromatography (HP 6890 Hewlett 
Packard, USA) equipped with a HP-5 MS column (5 % phenyl-methyl-
siloxanediphenylpolysiloxane, 30 m x 0.25 mm x 0.25 µm, Agilent, Germany) and coupled with 
a quadrupole mass spectrometer (MS 5973, Agilent, Germany). Sample preparation, 
measurement of mass distributions of lactate and calculation of mean mass isotopomer 
distributions was carried out using a recently reported procedure (Strigun et al., 2011b). 
13C flux analysis 
Effect of doxorubicin on metabolic fluxes in HL-1 cells 
 69
A carbon atom transition network of the central metabolism was set up for 13C metabolic flux 
analysis (Appendix of chapter 5, Tab. S6). The model consisted of 63 reactions of which 14 
reactions represent extracellular uptake and production rates whereas 49 reactions were 
intracellular rates including 16 reversible reactions. Anabolic fluxes were estimated from the 
growth rate and biomass composition. Biomass composition was taken from literature (Niklas et 
al., 2009). The estimation of fluxes was carried out with MATLAB 2008b (The Mathworks, 
USA) using the elementary metabolite unit concept (Antoniewicz et al., 2007) applying a 
recently described method (Yang et al., 2008). 
 
Respiration measurement 
1.5 × 105 HL-1 cardiomyocytes per well were seeded in 24-well OxoDishes (PreSens, Germany) 
pre-coated with gelatine/fibronectine solution (see 2.1). Cell free medium served as control. After 
24 h equilibration, fresh Claycomb medium (25 mM naturally labeled glucose, 2 mM naturally 
labeled glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µM norepinephrine in 30 
mM L-ascorbic acid and 10 % FBS) containing 0.01 and 0.02 µM DXR was added to the 
respective wells. Untreated control was also included. The percentage of dissolved oxygen was 
measured continuously for 34 h using a recently described method (Beckers et al., 2009). 
Specific oxygen consumption rate (qO2) [fmol cell-1 h-1] was estimated by fitting the time course 
of dissolved oxygen using equation (eq. 1).  
 
[ ] [ ]( ) ⋅ = ⋅ − − 2 sat 2L 2 2d O qO Xk a O Odt V
        (1) 
[O2sat] represents the dissolved oxygen concentration at saturation in culture medium i.e. 
6.23 mg/L as previously reported (Oeggerli et al., 1995), while [O2] represents the actual 
dissolved oxygen concentration, X the number of cells per well and V the liquid volume per well. 
Curve fitting and estimation of the parameter qO2 was carried out using Berkely Madonna 
V.8.3.14 (Berkeley Madonna Inc., USA). For each condition (control, 0.01 µM DXR and 0.02 
µM DXR) qO2 was estimated thrice referring to each of the triplicate measurements. 
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Measurement of intracellular ATP  
For determination of intracellular ATP HL-1 cardiomyocytes were seeded in two 96-well plates 
in a total volume of 100 µl/well of Claycomb medium (containing 25 mM naturally labeled 
glucose, 2 mM naturally labeled glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 
µM norepinephrine in 30 mM L-ascorbic acid and 10 % FBS) in triplicates. After 24 h 
equilibration, the medium was replaced by 100 µl of the above supplemented Claycomb medium 
containing 0.01 µM and 0.02 µM DXR was added to the cardiomyocytes. An untreated control 
was also included. Intracellular ATP was determined after 2 and 34 h of incubation using ATPlite 
1Step assay (PerkinElmer, USA). 100 µl of lysis solution containing substrate was added to the 
cells. After 10 minutes incubation at RT luminescence was measured using a LumiCount plate 
reader (Wallac 1420 Multilabel counter Victor3, PerkinElmer, USA). A standard curve with 
known ATP concentrations was used to estimate the ATP-concentration in samples. In parallel an 
SRB assay (see 2.3) was carried out for the estimation of cell number. 
 
Statistical analysis 
All data, except respiration measurement, were compared using one-way ANOVA following 
Dunnett’s posthoc analysis. Significance of altered cellular respiration was determined via two 
different methods. The time courses of dissolved oxygen in culture medium of all three 
conditions (control, 0.01 µM DXR, 0.02 µM DXR) was compared by repeated-measures two way 
ANOVA analysis following Bonferroni posthoc test. Secondly, all qO2 (3 for each condition, (see 
2.8)), were compared by one-way ANOVA following Dunnett’s posthoc analysis. One-way and 
two way ANOVA as well as posthoc tests were carried out using Prism 5 V.5.04 (GraphPad 
Software, Inc., USA). Statistical significance is reported at p < 0.05. 
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Results 
Cytotoxicity of doxorubicin 
Concentration dependent release of LDH was observed (Figure 1) after exposure to DXR for 48 
h. DXR concentrations lower than 0.16 µM did not show a significant release of LDH as 
compared with the control. However, 0.6 µM and higher DXR concentrations led to 
approximately 1.5 to 1.9 fold higher release of LDH (p < 0.001). Based on these results two DXR 
concentrations in an assumed sub-toxic range (0.01 µM and 0.02 µM DXR) were considered for 
the analysis of DXR-induced metabolic changes in HL-1 cardiomyocytes. 
 
Figure 1: Concentration dependent release of LDH in DXR treated HL-1 cardiomyocytes determined in an LDH 
assay. Cells were exposed to DXR for 48 h. Values are given as fold increase of LDH release from the untreated 
control. Error bars indicate standard deviations (n=3). Statistical significance was determined using one-way 
ANOVA following Dunnett’s posthoc test. n.s.: not significant; ***: p < 0.001.  
 
Cultivation profile and specific uptake/production rates of metabolites in HL-1 cardiomyocytes 
upon doxorubicin treatment 
Figure 2 A shows the growth profiles of HL-1 cardiomyocytes exposed to 0.01 µM or 0.02 µM 
DXR and the untreated control. Microscopically observed beating frequency in both DXR treated 
cells and controls were similar throughout the whole experiment. Cell number increased from 
1.5  105 cells per well seeding density to 3.61  105 for untreated control, 3.92  105 upon  
Effect of doxorubicin on metabolic fluxes in HL-1 cells 
 72
treatment with 0.01 µM DXR and 3.77  105 with 0.02 µM DXR after 24 hours pre-incubation 
followed by 34 h drug exposure. Although cell growth seemed slightly increased in DXR treated 
cells the actual cell number at each time point was not significantly different from the control 
cells as shown by the SRB assay (figure 2A). 
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Figure 2: Cell number (A), glucose (B), lactate (C), glutamine (D) and oleic acid (E) concentrations versus time in 
culture medium of untreated HL-1 cardiomyocytes (■) and cells treated with 0.01 µM (□) and 0.02 µM (∆) DXR. 
Error bars indicate standard deviations (n=4). Statistical significance was determined using one-way ANOVA 
following Dunnett’s posthoc test. The cell number was estimated using an SRB assay. 
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Extracellular concentrations of glucose, lactate, glutamine, the 20 proteinogenic amino acids and 
total free fatty acids were similar in both controls and treated cells throughout DXR exposure 
(Figure 2 B, C, D, E and Figure S1 in the Appendix of Chapter 5). The time course of glucose, 
lactate, glutamine and oleic acid are depicted in figure 2 B-E. Despite slight differences of 
metabolite concentrations at each time point, these alterations were not statistically significant. 
Specific uptake or production rates of all metabolites were calculated from cell growth (Fig. 2 A) 
as well as metabolite concentrations and are given in Tab. S1 (Appendix of Chapter 5). Glucose, 
lactate and glutamine showed the highest specific uptake/production rates independent of DXR 
exposure. A trend towards decreased glucose uptake was observed in DXR treated cells (300 
fmol cell-1 h-1 in untreated control; 288 fmol cell-1 h-1 with 0.01 µM DXR; 262 fmol cell-1 h-1 with 
0.02 µM DXR). A similar trend was observed for lactate production which was also slightly 
decreased in treated cells (642 fmol cell-1 h-1 in untreated control; 604 fmol cell-1 h-1 with 0.01 
µM DXR; 603 fmol cell-1 h-1 with 0.02 µM DXR). Glutamine consumption was similar in 
controls and treated cells (46 fmol cell-1 h-1 in untreated control; 45 fmol cell-1 h-1 with 0.01 µM 
DXR; 38 fmol cell-1 h-1 with 0.02 µM DXR). For the majority of all other metabolites slight 
alterations due to DXR exposure were observed. Especially, pyruvate, arginine, lysine, leucine 
and isoleucine were consumed in slightly lower amounts as compared to the control. The uptake 
of oleic acid was relatively low in both treated and untreated cells and accounted on average for 
merely 0.1 % and 0.7 % of glucose and glutamine uptake, respectively. However, a statistically 
non-significant slight increase of uptake was observed in treated cardiomyocytes (0.16 fmol cell-1 
h-1 in controls; 0.29 fmol cell-1 h-1 with 0.01 µM DXR; 0.25 fmol cell-1 h-1 with 0.02 µM DXR).  
 
Influence of clinically relevant concentrations of doxorubicin on metabolic flux distribution 
An enrichment of 13C in lactate derived from differently 13C labeled substrates (see material and 
methods, 2.3) was observed (Appendix of Chapter 5, Tab. S2-4). Intracellular fluxes were 
estimated by implementing extracellular uptake/production rates and the labeling pattern of 
secreted lactate into a metabolic network model (Appendix of Chapter 5, Tab. S6). In figure 3 
simulated lactate mass isotopomer distributions are plotted against respective measured mass 
isotopomer distribution data for the three test conditions. Simulated mass isotopomer distribution, 
in this regard, refers to computed values of lactate mass isotopomer distributions, i.e. they 
represent the output with which lactate labeling theoretically can be expected from the used 
metabolic network model (Appendix of Chapter 5, Tab. S6) at a given set of measured metabolite 
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uptake and production rates. Thus, a good fit in a linear regression between measured and 
simulated mass distribution indicates that the used metabolic network model is suitable for the 
applied data and secondly, that the computed intracellular fluxes give a robust description of the 
actual flux distribution in the HL-1 cardiomyocytes. 
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Figure 3: Calculated (simulated) lactate mass isotopomer distributions compared to experimentally measured lactate 
mass isotopomer distributions in untreated HL-1 cardiomyocytes (A) and in HL-1 cardiomyocytes treated with 0.01 
µM (B) and 0.02 µM (C) DXR showing good correlation. The graphs inserts represent an enlargement of lower mass 
isotopomer distributions. 
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A very good correlation was found as shown by a linear relationship of measured and calculated 
lactate mass distributions for treated cells and untreated control (linear correlation coefficients R2 
= 1.00). The calculated distribution of intracellular steady state fluxes is depicted in figure 4. The 
network includes reactions from glycolysis, pentose-phosphate-pathway, TCA-cycle, anaplerosis 
and amino acid metabolism. The underlying flux values are given in the appendix of Chapter 5. 
(Table S5). The calculated intracellular flux distribution revealed significant changes in the 
metabolism of HL-1 cardiomyocytes upon DXR treatment at the tested concentrations. 
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Figure 4: Metabolic flux distribution in untreated HL-1 cardiomyocytes and in cells treated with 0.01 µM and 0.02 
µM DXR. Both DXR concentrations showed no significant effect on LDH release (figure 1). Cells were incubated 
for 34 h with 5 mM [U-13C6]glucose, 5 mM [1,2-13C6]glucose, 5 mM unlabeled glucose and 2 mM [U-13C5]glutamine 
in four parallel experimental setups. Cell number, metabolite concentrations and 13C enrichment in secreted lactate 
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were measured at specific time intervals. Metabolic fluxes were calculated by implementation of uptake and 
production rates of glucose, lactate, pyruvate and amino acids and the enrichment of 13C in lactate into a metabolic 
network model (Tab. S6, Appendix of chapter 5). All rates are given as fmol cell-1 h-1. The denotations v1-v35 
represent simplified identifiers of the respective fluxes/reactions (see Appendix of Chapter 5 Tab. S5). Statistical 
significance was determined using one-way ANOVA following Dunnett’s posthoc test. Most of the fluxes in DXR 
treated cells were significantly different from untreated controls (p < 0.05). Red and green boxes refer to 
significantly decreased and increased fluxes as compared to controls (p < 0.05). A detailed overview of the 
significance of individual fluxes is given in table S5 (Appendix of chapter 5). 
 
Glycolytic flux (v1 – v4) was dose dependently decreased in DXR treated cells to 96% (0.01 µM 
DXR; p < 0.001) and 87% (0.02 µM DXR; p < 0.001) of the control. Lactate production (v21) 
was reduced by 17% (0.01 µM DXR; p < 0.001) and by 30% (0.02 µM DXR; p < 0.01). Alanine 
production (v18) was increased by 24% in HL-1 cardiomyocytess treated with 0.02 µM DXR (p 
< 0.01).  
However, connectivity between glycolysis and TCA-cycle was enhanced in DXR treated 
cardiomyocytes. Pyruvate transport into mitochondria (v5) was increased to 197% and 239% of 
control in cardiomyocytes exposed to 0.01 µM or 0.02 µM DXR, respectively (p < 0.01). 
Cytosolic flux from pyruvate to oxaloacetate (v16) was activated upon drug exposure and caused 
a nearly four-fold increase (p < 0.01) of oxaloacetate import into mitochondria via malate-shuttle 
(v24; p < 0.001) in treated cardiomyocytes. Activity of mitochondrial malic enzyme (v15) 
producing mitochondrial pyruvate was low in control but increased in cells treated with DXR (p 
< 0.01). Import of pyruvate into mitochondria was therefore increased via both direct pyruvate 
transport (v5) and anaplerotic reactions (v15, v16, v24). TCA-cycle fluxes (v11-v14) were 
significantly increased by 54-72% (p < 0.001) in treated cardiomyocytes compared to the 
untreated control. TCA-cycle was mainly sustained by oxidative decarboxylation of pyruvate into 
acetyl-CoA (v6) indicating increased glucose oxidation, and glutaminolysis (v27). Upon DXR 
treatment oxidative decarboxylation (v6) was significantly increased to 234% (0.01 µM DXR, 
p < 0.001) or 243% (0.02 µM DXR, p < 0.05) so that carbons deriving from pyruvate accounted 
for more than 85% of TCA fluxes compared to only 60% in untreated control. Glutaminolysis 
(v28) was significantly increased by 74-86% (0.01 µM DXR, p < 0.01; 0.02 µM DXR, p < 0.05). 
However, glutamine-derived carbons contributed to the same extent (~ 20%) to the TCA cycle 
fluxes in treated cardiomyocytes and untreated control. 
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Whereas the specific rates of the anaplerotic reactions, the TCA-cycle fluxes, the major input 
fluxes into TCA cycle, oxidative decarboxylation and glutaminolysis were increased upon DXR 
exposure, consumption of other amino acids feeding into TCA-cycle such as lysine (v35), 
arginine (v34), branched chain amino acids (v31-v33) and aspartate (v25) was significantly 
decreased in treated cells (p < 0.05). For valine, isoleucine, arginine and aspartate a dose-
dependent effect of DXR was observed. Export of citrate via citrate-shuttle to produce cytosolic 
acetyl-CoA and oxaloacetate (v26) was slightly increased by 7% (0.01 µM DXR; p < 0.01) and 
12% (0.02 µM DXR; p < 0.001) as compared to the untreated control. 
 
Influence of DXR on cellular respiration 
Figure 5 A shows the dissolved oxygen for untreated control and cardiomyocytes treated with 
0.01 µM and 0.02 µM DXR in the cultivation media. Dissolved oxygen in the media of both 
treated and untreated cardiomyocytes decreased due to consumption of oxygen by the cells. 
Dissolved oxygen in culture medium decreased from 0.19 mM to 0.096 mM (untreated control), 
0.089 mM (0.01 µM DXR) and 0.085 mM (0.02 µM DXR). The time course of dissolved oxygen 
was significantly different after 24 h exposure in case of cardiomyocytes treated with 0.02 µM 
DXR (p < 0.05), but not for cardiomyocytes treated with 0.01 µM DXR. Figure 5 B shows the 
corresponding specific oxygen uptake rates (qO2), which were derived from the profiles of 
dissolved oxygen as well as cell growth. The specific oxygen uptake rates were 66.5fmol cell-1 h-1 
(untreated control), 78.5 fmol cell-1 h-1 (0.01 µM DXR; p < 0.05) and 100 fmol cell-1 h-1 (0.02 µM 
DXR; p < 0.001).  
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Figure 5: Influence of DXR on respiration in HL-1 cardiomyocytes. A) Course of dissolved oxygen in culture 
medium without cells ( ), untreated control ( ), cells treated with 0.01 µM DXR ( ) and 0.02 µM DXR ( ). 
Statistical significance was determined using repeated measures two-way ANOVA following Bonferroni posthoc 
test. B) Specific oxygen uptake rate in untreated cells (white bars), cells treated with 0.01 µM DXR (light grey bars) 
and cells treated with 0.02 µM DXR (dark grey bars). Significance was determined using one-way ANOVA 
following Dunnett’s posthoc test. Measurements were carried out in triplicates. Significance is indicated at *: p < 
0.05; *** p < 0.001.  
 
Influence of DXR on intracellular ATP concentration  
The influence of DXR on intracellular ATP concentration in whole cells extracts was measured at 
2 h and 34 h after DXR exposure (Figure 6). After 2 h of incubation, ATP concentration was 16.2 
pmol cell-1 in untreated cells. In cells treated with 0.01 µM and 0.02 µM DXR, ATP 
concentrations was non-significantly decreased to 15.1 pmol cell-1 and 15.2 pmol cell-1 
respectively. After 34 h ATP concentration was 13.7 pmol cell-1 in untreated cells. No significant 
change of ATP concentration was observed in case of cells treated with 0.01 µM DXR (13 pmol 
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cell-1; p > 0.05). However, in case of cells treated with 0.02 µM a significant decrease of ATP 
concentration (11.2 pmol cell-1; p < 0.05) was observed. The cell number was estimated using an 
SRB assay. 
 
Figure 6: ATP-content (A) in untreated cells (white bars), cells treated with 0.01 µM DXR (light grey bars) and 0.02 
µM DXR (dark grey bars) in HL-1 cardiomyocytes. ATP-concentration was determined using ATPlite assay. Cell 
number was estimated by sulforhodamine B staining. Error bars indicate standard deviations (n=4). Statistical 
significance was determined using one-way ANOVA following Dunnett’s posthoc test (*: p < 0.05). 
 
Discussion 
In the present study we analyzed the effects of DXR on central energy metabolism in HL-1 
cardiomyocytes. The DXR concentrations investigated were clearly not toxic in the LDH-release 
assay. Furthermore, it was recently shown that these concentrations do not result in significant 
Troponin T release (Andersson et al., 2010). By using 13C-metabolic flux analysis we found that 
DXR-concentrations as low as 0.01 and 0.02 µM significantly affect glycolysis, TCA-cycle and 
amino acid catabolism in vitro in HL-1 cardiomyocytes. 
Glycolytic rates in DXR treated cardiomyocytes decreased in a dose dependent manner. Down-
regulation of phosphofructokinase at the transcriptional level upon DXR treatment was 
previously described in neonatal rat cardiomyocytes (Jeyaseelan et al., 1997) and could partly 
explain decreased glycolytic rates. However, in the work of Jeyaseelan et al. DXR was applied at 
a concentration of 1 µM which approximately represents the peak plasma concentration shortly 
after a bolus administration in cancer patients which declines relatively fast (within 1 h) to the 
lower nanomolar level (Greene et al., 1983). DXR has a biphasic pharmacokinetic profile with 
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exposure of tissues without substantial clearance to extracellular free drug concentrations that are 
identical to plasma free drug exposure. Nowadays, in vivo, DXR is administered by intravenous 
infusion and the plasma concentration is much lower than 1 µM. Most in vitro studies on DXR 
are carried out using high concentrations and do not necessarily reflect the situation in vivo. It is 
therefore important to investigate effects of DXR in the nanomolar range. Recent in vivo and in 
vitro transcriptomic studies at clinically relevant concentrations have demonstrated an 
upregulation of mRNA of several genes in the glycolytic pathway (Berthiaume and Wallace, 
2007b; Tokarska-Schlattner et al., 2010), which, at a first view, contradicts the observation of 
decreased glycolytic fluxes in our study. The level of the corresponding mRNA probably directly 
correlates with increased enzyme but not necessarily with enzymatic activity. While the 
upregulation of glycolytic genes in the work Berthiaume et al. and Tokarska-Schlattner et al. was 
in good agreement, corresponding data on TCA-cycle relevant mRNA from these two studies 
was conflicting. Contradictory data regarding DXR induced alterations in the fluxome or 
transcriptome might be related to different biological models or experimental setups. In addition, 
it has to be considered that DXR exerts diverse effects on energy metabolism both acutely and 
chronically. The transcriptomic in vivo study of Berthiaume et al. was carried out on isolated rat 
hearts upon 5 week chronic subcutaneous DXR treatment, whereby the heart weight was 
significantly decreased and the rats were in a poor health (Berthiaume and Wallace, 2007b). In 
the work of Tokarska-Schlattner et al. rat hearts were perfused with 2 µM DXR for 2 h and the 
hearts showed mild cardiac dysfunction. This concentration highly exceeded the concentrations 
used in our study and the exposure to this relatively high concentration was longer than the 
observed peak plasma concentration in patients undergoing DXR treatment. Cardiac dysfunction 
independent of DXR exposure, contributes to increased glycolysis and glucose oxidation in vivo 
as shown previously (Lei et al., 2004; Osorio et al., 2002, review: Stanley, 2005). As such, care 
should be taken in the interpretation of results and cardiac damage should be taken into account. 
In our study there was no change in cell viability (LDH and SRB assays) and myocyte 
contraction/beating. Therefore, the changes in glycolytic fluxes in our study are due to DXR and 
not due to decreased cardiomyocyte viability and dysfunction.  
In our study, the decreased glycolytic activity was accompanied by an increased oxidative 
decarboxylation (Pyruvate  Acetyl-CoA) i.e. a higher flux of cytosolic pyruvate into 
mitochondria to form acetyl-CoA, which points towards an increase of glucose oxidation in DXR 
treated cells. Remarkably, the increased oxidative phosphorylation was facilitated by cytosolic 
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pyruvate entering the mitochondrion via two entry routes; firstly via direct entry into the 
mitochondrion through pyruvate transporter and secondly via cytosolic and mitochondrial malic 
enzyme. The anaplerotic entry of pyruvate into mitochondria via malic enzyme might make up 
for a saturated direct transport via mitochondrial pyruvate transporters and thus facilitate supply 
of TCA-cycle with sufficient carbon. An increased contribution of glucose carbon to 
mitochondrial acetyl-CoA upon DXR treatment was recently shown in a rat in vivo model 
(Carvalho et al., 2010), which is in accordance with increased flux of pyruvate into mitochondrial 
acetyl-CoA, as observed in our study. In the study of Carvalho et al. it was shown that the 
increased contribution of glucose to acetyl-CoA is related to a decreased contribution of long 
chain fatty acids to acetyl-CoA. Decreased fatty acid oxidation has been generally linked to 
DXR-related cardiac toxicity (Abdel-aleem et al., 1997; Bordoni et al., 1999; Hong et al., 2002; 
Iliskovic et al., 1998). However, the uptake of fatty acids in HL-1 cardiomyocytes was relatively 
low for both untreated controls and DXR treated cells as compared to the glucose uptake (~0.1 
%). Comparison of results should be considered with care as most studies on altered fatty acid 
uptake were carried out either on in vivo models or the applied DXR concentrations (Abdel-
aleem et al., 1997) highly exceeded the concentrations tested in our study. Nevertheless, it must 
be noted that the low uptake of fatty acids in HL-1 cardiomyocytes can be partly attributed to the 
low concentration of fatty acids in the used culture medium. Generally, glucose is the most 
abundant energy source in most cell culture media. The glucose concentration in the used culture 
medium was 25 mM. In contrast, the total fatty acid concentration in supplemented Claycomb 
medium mainly derived from 10% FBS, was only ~ 9 µM, which is in the same range as recently 
reported for culture medium containing 10% FBS (Andersson et al., 2008). In addition, cells 
cultured in vitro mainly use glucose to generate ATP (Marroquin et al., 2007). However, the fact 
that fatty acid uptake was relatively low in both DXR-treated and untreated cardiomyocytes 
points to the fact that the higher contribution of glucose to acetyl CoA as observed in our 
considered in vitro model is most probably not related to altered fatty acid uptake. 
The consequence of increased oxidative decarboxylation of mitochondrial pyruvate to form 
acetyl-CoA was significantly increased rates of TCA-cycle reactions in DXR treated 
cardiomyocytes. This increased oxidative metabolism was in accordance with an increased cell 
respiration. An up-regulation of TCA-cycle related genes upon DXR treatment was recently 
reported in perfused rat heart (Tokarska-Schlattner et al., 2010) and might explain the increased 
TCA-cycle rates in our study, despite significant differences in the experimental setup. In 
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addition, a recent study (Pointon et al., 2010) using a murine in vivo model showed increased 
activity of citrate synthase after acute DXR exposure which further supports the observation in 
our study. Though, several other studies on DXR induced alterations of respiration demonstrated 
decreased respiration (Bugger et al., 2010; Nicolay and de Kruijff, 1987; Tao et al., 2006). 
However, these studies were either carried out with much higher concentrations directly on whole 
cells (Tao et al., 2006) or on isolated mitochondria, which have been shown to be different in 
their regulatory properties from mitochondria in the cell (Kuznetsov et al., 2008; Picard et al., 
2010). Those reported effects, if occurring in vivo, might represent acute effects of DXR toxicity, 
e.g. when the concentration of DXR is relatively high in plasma within the initial hour of DXR 
application (Greene et al., 1983). 
The increase of TCA-cycle activity might be related to an early compensatory mechanism to the 
onset of functional defects as recently suggested (Tokarska-Schlattner et al., 2010). Functional 
defects in conjunction with apoptotic events could include loss or depletion of high energy 
phosphates. Short term exposure (2 h) of cells to 0.01 µM and 0.02 µM DXR had no significant 
effect on cellular ATP concentration in our study. However, at 34 h, ATP concentration 
decreased at both concentrations of DXR, but only significantly at 0.02 µM DXR. Recently 
decrease of ATP in murine in vivo model upon acute DXR exposure has been described (Pointon 
et al., 2010). It can be assumed that increased TCA-cycle activity as well as respiration is a direct 
consequence of decreased levels of ATP. By increasing TCA-cycle activity the cells try to 
compensate for a decrease of intracellular ATP. However, we observed that increase of oxidative 
metabolism does not seem sufficient to completely compensate for ATP-decrease/depletion. 
Besides depletion of ATP due to potential apoptotic events, reduction of DXR itself by 
mitochondrial NADH dehydrogenase by complex I in the respiratory chain might partially 
contribute to increased TCA-cycle activity. It is well established that DXR acts as an electron 
acceptor in reactions involving P450 reductase and NADH dehydrogenase (Doroshow, 1983; 
Goodman and Hochstein, 1977; Graham et al., 1987). Addition of electrons to the DXR quinone 
group yields the semiquinone which after interaction with oxygen produces superoxides and 
other reactive oxygen species in vitro (Bates and Winterbourn, 1982; Doroshow, 1983; Sinha et 
al., 1989) or results in electron shunting, more likely to occur in vivo as recently suggested 
(Pointon et al., 2010). Pointon et al. argued that production of reactive oxygen species is more 
likely to occur in vitro than in vivo due to higher oxygen tension in most in vitro models. Electron 
shunting in case of DXR may involve electron transfer on DXR by complex I to form the 
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semiquinone and subsequent electron transfer downstream complex I, eventually to cytochrome 
C, thereby skipping electron transfer through complex II and III (Pointon et al., 2010). Both 
scenarios would result in an uncoupling of electron transfer and building up of an H+ gradient in 
the inner mitochondrial membrane and consequently decreased ATP concentration.  
In brief, we show for the first time the effect of therapeutically relevant concentrations on the 
whole central metabolism including glycolysis, TCA-cycle and amino acid degradation in a 
cardiac cell model by means of 13C metabolic flux analysis. Although 13C flux studies have been 
carried out for the assessment of DXR´s effect on the metabolism, the estimation of the flux 
distribution in cardiac cells upon DXR treatment via integration of a whole set of extracellular 
rates and 13C labelling information into a metabolic network model has not been yet reported to 
our knowledge, least of all at concentrations as low as 0.01 µM. Most importantly, these 
concentrations had no significant effect on cell growth, beating frequency and cell morphology. 
Nevertheless, these tested therapeutically relevant concentrations result in an increased oxidative 
metabolism in HL-1 cardiomyocytes, i.e. a higher efficiency of glucose usage in TCA-cycle. This 
effect in HL-1 cardiomyocytes is most probably, not related to alterations in fatty acid uptake 
since it was negligible and was not significantly altered by DXR. In fact, changes in metabolic 
fluxes seem to occur due to decrease of intracellular ATP. The present work therefore 
complements and partly confirms recent in vivo data. Our results significantly contribute to the 
understanding of DXR induced cardiotoxicity which is more and more highlighted in the context 
of changes in energy metabolism. Further work including in depth studies of the role of reactive 
oxygen species in changes of metabolic fluxes would complement the observations in our study. 
In addition, it would be very interesting to apply 13C metabolic flux analysis to human relevant 
system such as cardiomyocytes derived from human embryonic stem cells having both atrial and 
ventricular phenotypes which would more closely reflect the in vivo situation. This will greatly 
advance the understanding of mechanism of toxicity of DXR at the metabolic pathways level. 
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Chapter 6 
Characterisation of the central metabolism in cardiomyocytes 
derived from human embryonic stem cells in response to 
Doxorubicin 
Abstract 
Doxorubicin (DXR) is a potent anticancer drug with severe cardiotoxic side effects, which are 
related to changes in the cardiac substrate spectrum, as shown in several animal in vitro models. 
However, animal models have a low validity in man. Therefore, human embryonic stem cell 
derived cardiomyocytes (hESC-CM) represent an ideal cardiac in vitro model for studying DXR 
induced cardiotoxicity. The purpose of this study was the metabolic characterization of untreated 
hESC-CM and of hESC-CM treated with a clinically relevant concentration of DXR by using 13C 
metabolic flux analysis. 
hESC-CM were incubated with and without 0.078 µM DXR for 66 h. Uptake and production 
rates of glucose, lactate, pyruvate and amino acids from hESC-CM culture medium were 
determined using HPLC. The enrichment of 13C in secreted lactate derived from feeding with [U-
13C6]glucose was measured by GC/MS. Using metabolite rates, 13C-labelling information in 
lactate and by presuming steady state conditions, intracellular fluxes were estimated in both 
untreated and DXR treated hESC CM. 
Untreated hESC CM showed high activity of anaerobic glycolysis, which was reflected by a high 
lactate/glucose ratio (1.57) while fluxes in oxidative reactions were comparably low. Low TCA 
cycle activity was facilitated by high lactate and pyruvate production, but also by amino acid 
production i.e. by carbon loss from TCA-cycle. DXR treated cells showed reduced glycolytic 
fluxes and reduced lactate production. Though, the lactate/glucose ratio was increased (1.71). 
However, despite a higher lactate/glucose ratio, oxidative metabolism was significantly 
increased, which was facilitated by increased degradation of amino acids into TCA-cycle 
intermediates. These data partly agree with recent transcriptomic approaches. However, due to 
the high anaerobic glycolysis in the used hESC-CM, modifications in the cardiac differentiation 
protocol or design of adequate hESC-CM culture media should be considered for future studies. 
This chapter is in preparation for submission in Toxicology and Applied Pharmacology. 
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Introduction 
Doxorubicin (DXR) is used as a potent anticancer drug. However, severe cardiotoxic side effects 
observed in cancer patients undergoing DXR treatment limit its clinical use (Simunek et al., 
2009). DXR-toxicity is related to formation of reactive oxygen species (Bachur et al., 1977; 
Sinha et al. 1989), disturbances in nitric oxide pathway resulting in protein nitration (Fogli et al., 
2004), oxidative damage of DNA (Bates and Winterbourn, 1982; Eliot et al., 1984; Feinstein et 
al., 1993), lipid peroxidation (Gewirtz, 1999) and apoptosis (Ling et al., 1993; Skladanowski and 
Konopa, 1993). 
However, DXR induced cardiac toxicity also seems related to impaired cardiac energy 
metabolism, potentially leading to ATP-depletion. In the healthy myocardium ATP is mostly 
generated from oxidative metabolism (Stanley et al., 2005). It was shown that DXR alters fatty 
acid and glucose metabolism in the myocardium (Abdel-aleem et al., 1997; Bordoni et al., 1999; 
Carvalho et al., 2010; Wakasugi et al., 1993). Recent transcriptomic approaches have shown 
alterations in the transcript levels of genes relevant in main catabolic pathways, such as 
glycolysis and TCA-cycle. It was recently shown that DXR results in increased transcripts of 
genes relevant in glycolysis (Berthiaume and Wallace, 2007b; Tokarska-Schlattner et al., 2010). 
Though, results on TCA-cycle genes were contradictory. Such differences might be the result of 
differences in the biological models.  
We have recently studied the effect of clinically relevant DXR concentrations on central 
metabolism of murine atrial HL-1 cardiomyocytes (Strigun et al., 2011c). DXR resulted in an 
increased oxidative metabolism (increased TCA-cycle activity and respiration), probably as an 
attempt to compensate for a decreased intracellular ATP-concentration.  
Despite the usefulness of HL-1 cells as a cardiac model system, the major drawback is their 
murine origin. Human embryonic stem cell derived cardiomyocytes (hESC-CM) have been 
suggested as an alternative for cardiac cell lines (Steel et al., 2009). Primary cells from the human 
heart would be an alternative, but their availability is limited for obvious reasons. The use of 
hESC-CM probably circumvents the problem of species to species differences. 
In terms of contractile characteristics hESC-CM have been shown to be similar to adult 
ventricular cells (Harding et al., 2007). Though, it has been suggested that the maturation process 
of hESC-CM is not complete, since the Ca2+- handling properties in the excitation-contraction 
process do not seem to reflect the adult human myocardium  (Binah et al., 2007; Dolnikov et al., 
2006). Mature cardiomyocytes rely on intracellular sarcoplasmic Ca2+ - stores for contraction, 
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while hESC-CM seem to rely on external calcium (Dolnikov et al., 2006), most probably due to 
underdeveloped sarcoplasmic reticulum (Binah et al., 2007; Satin et al., 2008; Sedan et al., 
2008). However, a recent gene expression study has shown that hESC-CM clusters show similar 
expression patterns, compared to human cardiac tissue (Asp et al., 2010). Ion channels, 
characteristic for the human myocardium, such as sodium channel SCN5A, the L-type calcium 
channel CACNA1C, the voltage-gated potassium channels KCNA4 and KCNH2 (hERG) have 
been found in hESC-CM (Sartiani et al., 2007; Satin et al., 2008). The availability of relevant ion 
channels as well as the ability for spontaneous contraction makes them attractive for preclinical 
drug testing based on electrophysiological measurement, as shown recently (Braam et al., 2010; 
He et al., 2003; Reppel et al., 2005; Satin et al., 2004). 
Besides electrophysiological studies, hESC-CM can potentially be used to study drug-induced 
changes of cardiac energy metabolism and substrate usage. Although hESC-CM represent an 
attractive cardiac model system for metabolic, particularly metabolomis or fluxomic studies, a 
rather in depth quantification of central metabolism, i.e. in glycolysis, TCA-cycle or amino acid 
catabolism has not been carried out yet, least of all in the presence of drugs with known 
cardiotoxic properties, such as DXR.  
The purpose of this study was the metabolic characterisation of untreated hESC-CM and DXR 
treated hESC-CM by means of 13C metabolic flux analysis. The application of 13C metabolic flux 
analysis has been shown to be useful for the determination of the effect of cardioactive drugs on 
HL-1 cardiomyocytes (Strigun et al., 2011b; Strigun et al., 2011c). The applicability of this 
method has been demonstrated in a recent study, which reported the flux distribution in the 
perfused mouse heart (Vo et al., 2006). The results of the present study are compared with 
current knowledge of DXR induced effects on cardiac energy metabolism.  
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Material and methods 
hESC-CM cell culture  
The hESC-CMs were obtained from Cellartis (Sweden), within the framework of EU-STREP 
(LSHB-CT-2007-037636) project “Invitroheart”. The cells were delivered as adherent monolayer 
cultures and showed a beating phenotype. The cells were maintained in an optimized culture 
medium, referred to as hESC-CM medium in following chapters (The interested reader is asked 
to contact Cellartis for further information on the composition of the hESC-CM medium).  
 
Determination of DXR cytotoxicity 
A doxorubicin-HCl (DXR) (Sigma Chemical, USA) stock solution (10 mM) was prepared in cell 
culture grade water (PAN Biotech, Germany). 3 × 104 cells/well were maintained in 200 µl 
medium containing 20% FBS. After ~72 hours (h) incubation, the supernatant was removed and 
the cells were washed once with fresh medium. Subsequently, medium containing DXR at 
different concentrations (1.25 µM, 0.62 µM, 0.32 µM, 0.16 µM, 0.078 µM and untreated 
controls) was added to the cells in duplicates. Medium without cells served as medium control. 
For reduction of evaporation, the wells were covered with gas impermeable adhesive foils 
(Greiner, Germany). Subsequently, the cells were incubated for 66 h. Afterwards, the medium 
was removed and the cells were washed twice with 100 µl of pre-warmed (37°C) PBS. Cells 
were then lysated in 100 µl Cellytic M Cell Lysis reagent (Sigma Aldrich, USA) according to the 
manufacturer’s instructions. Total protein was determined with a detergent-compatible protein 
assay (Bio-Rad, Hercules, CA). 
 
Experimental setup for labeling studies on hESC CM 
3 × 104 cells/well were maintained in 200 µl hESC-CM medium following 72 h incubation. 
Subsequently, the medium was removed and the cells were washed twice with 200 µl of pre-
warmed (37°C) PBS to remove contaminating lactate from the preincubation.  
Instead of 25 mM naturally labeled glucose this medium contained 25 mM fully 13C-labelled 
glucose ([U-13C6] glucose] (enrichment 99%) (Cambridge Isotope Laboratories, USA)). The 
plates were incubated under standard cell culture conditions (37 °C, 95 % relative humidity, 5 % 
CO2) in the incubator for 66 h. Afterwards, the supernatants were removed and stored at -20°C 
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until further analysis. The cells were washed once with 100 µl of pre-warmed (37°C) PBS and 
the total cell protein was quantified by using a protein assay (Bio-Rad, Hercules, CA). 
 
Sample preparation for HPLC analysis and metabolite quantification 
Serum proteins, such as albumin were removed from the supernatants by microfiltration using 
Microcon® Filter Devices (Millipore, Germany) with an exclusion size of 10 kDa. Subsequently 
each filtrate was diluted 1:2 with α-aminobutyric acid solution (400 µM in deionized water) 
which was used as an internal standard for amino acid quantification. Quantification of glucose, 
lactate, pyruvate and amino acids was carried out exactly as described recently (Strigun et al., 
2011b). 
 
Mass isotopomer measurement using GC/MS 
Measurement of mass isotopomers was carried out using gas chromatography (HP 6890 Hewlett 
Packard, USA) equipped with a HP-5 MS column (5 % phenyl-methyl-
siloxanediphenylpolysiloxane, 30 m x 0.25 mm x 0.25 µm, Agilent, Germany) and coupled with 
a quadrupole mass spectrometer (MS 5973, Agilent, Germany). Sample preparation, 
measurement of mass distributions of lactate and calculation of mean mass isotopomer 
distributions was carried out using a recently reported procedure (Strigun et al., 2011b). 
 
13C flux analysis 
A carbon atom transition network of the central metabolism was set up for 13C metabolic flux 
analysis for both untreated hESC-CM and DXR treated hESC-CM. (Appendix of chapter 6, Tab. 
S1 and Tab. S2). The estimation of fluxes was carried out with MATLAB 2008b (The 
Mathworks, USA) using the elementary metabolite unit concept (Antoniewicz et al., 2007) 
applying a recently described method (Yang et al., 2008). 
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Statistical analysis 
Extra- and intracellular fluxes in HL-1 cardiomyocytes treated with 0.01 µM and 0.02 µM DXR 
were compared with the respective untreated controls using student’s t-test. The changes were 
considered significant at p < 0.05. 
 
Results  
Toxicity of Doxorubicin on hESC-derived cardiomyocytes  
DXR application on spontaneously beating hESC-CM resulted in a dose-dependant decrease of 
total cell protein after 66 h of exposure (Fig. 1). 0.078 µM and 0.16 µM DXR had no significant 
effect on cell protein compared to controls. 0.32µM, 0.62 µM and 1.25 µM DXR reduced total 
cell protein by 37%, 57% and 63%, respectively. The EC50 value obtained from protein 
determination after 66 h of DXR exposure was 0.22 µM (0.11 µM – 0.44 µM). A concentration 
of 0.078 µM was considered for subsequent studies of metabolism in hESC-CM in response to 
DXR, since it resulted in no significant alteration of cellular protein and was clearly below the 
EC50 value. At this concentration, the cells showed a beating phenotype comparably to untreated 
cells, as determined microscopically. 
 
 
Figure 1: Effect of DXR on total cell protein of human embryonic stem cell derived cardiomyocytes after 66 h 
incubation. Total cell protein in each well was determined by Bradford assay. Measurements were carried out in 
duplicate measurement. The dotted line indicates 50% of viability as compared with untreated controls. 
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Metabolic response of hESC-CM to DXR treatment 
Glucose, lactate and pyruvate 
Figure 2A shows the effect of DXR on specific rates of glucose uptake as well as lactate and 
pyruvate production. Glucose was net consumed by both untreated and treated cells. Though, in 
treated cells glucose uptake was reduced by 28% (control: 53 µmol g-1 h-1; DXR: 38 µmol g-1 h-1; 
p < 0.01). Lactate production was by 22% lower in treated cells (control: 84 µmol g-1 h-1; DXR: 
65 µmol g-1 h-1). However, this change was not significant. Lactate/glucose yields were quite 
high in both treated and untreated cells. This ratio was 1.57 in untreated cells and 1.71 in treated 
cells. 
Pyruvate was produced at both conditions, however, production was by 28% lower in treated 
cells (control: 15 µmol g-1 h-1; DXR: 11 µmol g-1 h-1; p < 0.05). 
 
Amino acids 
DXR treatment had diverse effects on amino acid consumption and production (Fig. 2 B). 
Amongst the amino acids, alanine, glutamine, glutamate, glycine, proline and arginine were net 
produced in untreated cells, while leucine and aspartate were net consumed from the culture 
medium. Most significant effects due to DXR were observed for alanine, glutamine, glycine, 
tyrosine, arginine, histidine, phenylalanine, lysine and leucine.  
Alanine production was highly reduced in DXR treated cells (control: 5.7 µmol g-1 h-1; DXR: 3.1 
µmol g-1 h-1; p < 0.001). Glutamine was produced by untreated cells (3.9 µmol g-1 h-1) but 
consumed by DXR treated cells (1.2 µmol g-1 h-1, p < 0.001). Production of glutamate and proline 
was not significantly different. Glycine was produced by controls (1.5 µmol g-1 h-1) but consumed 
by treated cells (1.5 µmol g-1 h-1; p < 0.001). While no significant uptake of isoleucine could be 
determined, uptake of leucine was significantly higher in DXR treated cells (control: 1.75 µmol 
g-1 h-1; DXR: 4.2 µmol g-1 h-1; p < 0.05). Similarly, uptake of aspartate and trypophane was 
higher in DXR treated cells (Aspartate; control: 0.64 µmol g-1 h-1; DXR: 1.3 µmol g-1 h-1; p < 
0.05; Tryptophane; control: 0.1 µmol g-1 h-1 DXR: 0.43 µmol g-1 h-1). No significant uptake of 
lysine and phenylalanine could be determined. However, uptake of these amino acids was 
significantly increased in treated cells (p < 0.001, respectively) 
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Figure 2: Metabolite uptake and production rates in untreated hESC-CM (white bars) and in hESC-CM treated with 
0.078 µM DXR (black bars). (A) Effect of DXR on glucose, lactate and pyruvate rates, (B) Effect of DXR on amino 
acid rates. Negative and positive values refer to uptake and production, respectively. Rates were calculated from 
metabolite depletion/enrichment in culture medium and total protein amount after 66 h incubation. Measurements 
were carried out in duplicates. 
 
Intracellular fluxes 
For the estimation of the influence of DXR on intracellular fluxes in hESC-CM, cells were fed 
with universally 13C labelled glucose ([U-13C6]glucose) without DXR and with 0.078 µM DXR. 
The mass isotopomer distribution of lactate was measured upon 66 h of incubation using GC/MS. 
As apparent from Fig. 3 an enrichment of lactate containing single (m+1), double (m+2) and fully 
labelled lactate (m+3) could be observed. Though, independent of DXR treatment, the fraction of 
fully labelled lactate was highly exceeding both, single and double labelled lactate. 
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Figure 3: 13C mass isotopomer distribution in lactate secreted by hESC-CM after 66 h incubation with fully 13C-
labelled glucose ([U-13C6]glucose) in controls (white bars) and in cells exposed to 0.078 µM DXR (black bars). All 
values were determined from duplicate measurement. The carbon skeleton of lactate consists of three carbon atoms, 
which gives four mass isotopomers (m0-m3). m0: unlabelled lactate; m1: single labelled lactate; m2: double labelled 
lactate; m3: fully/triple labelled lactate. 
 
The mass distribution in secreted lactate together with the extracellular yields of glucose, lactate 
and amino acids were used for calculation of intracellular fluxes in untreated hESC-CM and in 
DXR treated hESC-CM using the metabolic network shown in table S1 and table S2 (Appendix 
of chapter 6). 
Figure 4 shows the net intracellular fluxes in treated and untreated cells. Changes of fluxes were 
determined in all considered pathways (glycolysis, TCA-cycle, amino acid degradation). 
Glycolytic fluxes (G6P3PG, 3PGPYR) were decreased by 28% in treated cells (p < 0.001). 
Oxidative decarboxylation (PYRAcCoA) was relatively small in both treated and untreated 
cells and no significant difference could be determined. TCA-cycle fluxes in untreated cells were 
relatively small and merely accounted for 8%-17% of glycolytic fluxes. In DXR treated cells the 
flux of oxaloacetate and acetyl-CoA to form citrate in the TCA-cycle was significantly increased 
by 200% (p < 0.05). This increase was facilitated by a significant increase of lysine and leucine 
degradation to acetyl-CoA (p < 0.05), but also by reduced secretion of pyruvate. The fluxes in 
subsequent TCA-cycle reactions (CITAKG; AKGSUC; SUCOAA) were similarly 
increased (p < 0.05). Unlike controls, TCA-cycle fluxes in DXR treated cells accounted for 40%-
13C-MFA in human embryonic stem cell derived cardiomyocytes 
 94
80% of glycolytic fluxes. Apart from leucine and lysine, the relatively high uptake and 
catabolism of other amino acids also contributed to the higher TCA–cycle activity in DXR 
treated cells. The flux of phenylalanine and tyrosine into succinate was highly increased by 105% 
and 83%, respectively (p < 0.05). Though, the most significant change was determined around 
TCA-cycle intermediate α-ketoglutarate. While a net flux of α-ketoglutarate towards glutamate 
was determined in untreated cells, which contributed to carbon loss in the TCA-cycle, this flux 
was reversed in treated cells (p < 0.05), pointing towards increased anaplerosis of the TCA-cycle 
in case of treated cells. In addition, metabolism of arginine, histidine, glutamine and proline, 
which are catabolised to glutamate, also showed significant changes. Interestingly, a net flux of 
glutamate to glutamine was observed in untreated cells. This flux was reversed in DXR-treated 
cells (p < 0.001).  
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Figure 5: Effect of DXR (0.078 µM) on main catabolic pathways of human embryonic stem cell derived 
cardiomyocytes. hESCM were incubated with and without DXR in the presence of fully 13C labelled glucose ([U-
13C6]glucose) for 66 h. Metabolite uptake and production in hESC-CM culture medium as well as 13C enrichment in 
secreted lactate were then measured by HPLC and GC/MS. The data was then implemented into a simplified 
metabolic model containing main reactions from glycolysis, TCA-cycle and amino acid catabolism for calculation of 
fluxes. All rates are given in µmol g-1protein h-1. 
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Discussion 
The presented work shows the effect of DXR on the metabolism of cardiomyocytes derived from 
human embryonic stem cells (hESC-CM). Similar to our recent work using a murine cardiac cell 
line (HL-1 cells) the considered DXR concentration for metabolic studies was clearly below the 
EC50 value, which was approximately between 0.11 µM – 0.44 µM after 66 h of exposure. The 
lowest concentration of 0.078 µM DXR had no significant effect on the amount of cell protein 
after 66 h exposure and was used for further analysis of the effect of DXR on hESC-CM 
metabolism. As in our recent study regarding metabolic effect of DXR in HL-1 cells, this 
concentration was also in the range of clinical relevancy (Greene et al., 1983). 
The rather high lactate/glucose ratio in untreated cells (1.57) as well as 13C metabolic flux 
analysis suggest a high anaerobic metabolism in untreated cells. This is substantiated by a high 
extracellular enrichment of fully/triple labelled lactate, which is directly derived from the fully 
labelled glucose and which approximately accounted for ~80% of total produced lactate. The 
high anaerobic metabolism in untreated cells was accompanied by a quite low TCA-cycle 
activity, though loss of carbon via secretion of pyruvate as well as net synthesis and secretion of 
amino acids derived from TCA-cycle intermediates contributed its low activity. The observed 
“Warburg-like effect” in untreated cells was rather surprising, given that the healthy myocardium 
generates the vast majority of its ATP by oxidative metabolism (Stanley et al., 2005). Generally, 
anaerobic glycolysis seems to be sufficient for embryonic stem cell homeostasis (Chung et al., 
2007). However, engagement of oxidative metabolism seems to be a prerequisite for the 
differentiation of stem cells into a functional cardiac phenotype (Chung et al., 2007). Dissolved 
oxygen concentration in our experimental setup was sufficient to exclude hypoxia as a potential 
reason for the high anaerobic glycolysis (dissolved oxygen > 50% air saturation, data not shown). 
However, the observed anaerobic glycolysis still allowed a contracting phenotype.  
The presented data suggests that the used hESC-CM somehow share similarities with pluripotent 
stem cells on the metabolic level. While similarities of hESC-CM with human cardiac tissue on 
the transcriptomic level was recently demonstrated (Asp et al., 2010), other recent studies on 
hESC-CM have suggested that these cells differ from adult human myocardium regarding the 
Ca2+-handling in excitation-contraction coupling (Binah et al., 2007; Dolnikov et al., 2006), most 
probably due to an immature sarcoplasmic reticulum capacity (Binah et al., 2007). 
hESC-CM treated with DXR showed a decreased glycolytic flux. A similar effect could also be 
observed in a recent study using HL-1 cardiomyoctes (Strigun et al., 2011c). The reason for the 
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observed decrease of glycolytic flux remains to be determined, but may involve DXR induced 
alterations of relevant mRNA levels of glycolytic genes. In fact, it has been shown that DXR 
alters mRNA levels of glycolytic genes in animal cardiac in vivo models (Berthiaume and 
Wallace, 2007b; Tokarska-Schlattner et al., 2010).  
Despite a decreased glucose uptake and lactate production in DXR treated cells, the average 
amount of mole lactate per mole glucose was slightly higher (lactate/glucose ratio: 1.71). This 
points towards a decreased oxidation of glucose carbon in the TCA-cycle. Nevertheless, the flux 
of pyruvate to acetyl-CoA (oxidative decarboxylation) was similar at both conditions. Thus, the 
higher lactate/glucose ratio was mainly facilitated by a significant increase of the TCA-cycle 
activity as well as a high cataplerotic flux from either malate or oxaloacetate to cytosolic 
pyruvate. A higher cataplerotic flux to pyruvate might circumvent depletion of cytosolic pyruvate 
pools, as a result of decreased glucose uptake. This would also explain the slightly decreased 
secretion of alanine and pyruvate, which additionally prevents a depletion of intracellular 
pyruvate. The maintenance of intracellular pyruvate pools might allow the cells to still rely on 
anaerobic glycolysis, since this energy-pathway needs pyruvate for NADH-oxidation to form 
lactate. The higher TCA-cycle activity in DXR treated cells is mainly due to an increased 
catabolism of amino acids into relevant intermediates, such as leucine and lysine flux to acetyl-
CoA but also α-ketoglutarate and succinate. Most importantly, glutamine was secreted by 
untreated cells, while DXR treated cells showed a net uptake of glutamine, which therefore 
contributed to an increased TCA-cycle activity. Thus, DXR treated cells revealed a significant 
shift towards oxidative metabolism independent of glucose carbon. However, an increased TCA-
cycle flux might also prevent DXR-induced depletion of intracellular ATP, as suggested recently 
(Strigun et al., 2011c; Tokarska-Schlattner et al., 2010).  
In summary, this work shows for the first time the influence of a clinically relevant concentration 
of DXR on the metabolism of hESC-CM. However, the clinical relevancy of the observed effect 
is questioned by the fact that both untreated and DXR-treated hESC-CM highly rely on anaerobic 
glycolysis. Preferably, the used hESC-CM should mimic adult myocardial cells in terms of their 
energy metabolism, especially when considering that the healthy myocardium mainly relies on 
oxidative metabolism. However, by using medium design strategies the metabolism of the hESC-
CM potentially could be altered to a state which more reflects the metabolism of the adult human 
cardiomyocyte. In the used hESC-CM medium, glucose was the dominating substrate and its 
concentration highly exceeded the concentration of other metabolites (e.g. amino acids). The 
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relatively high concentration of glucose, which was 25 mM (standard glucose concentration in 
commercially available DMEM medium), might partly contribute to the observed high anaerobic 
glycolysis. In fact, this glucose concentration exceeds the blood glucose concentration in healthy, 
non-diabetic adults (4.0–5.9 mM)(Ceriello et al., 2008) Thus, future studies on hESC-CM energy 
metabolism should take into account an adequate glucose concentration. Besides, fatty acids and 
lipids are the main energy source in the human myocardium and it has been shown that the 
average fatty acid concentration in human plasma is in the lower mM range (Kuriki et al., 2006). 
However, culture medium which contains 10%-20% FBS (as was used for this study) merely 
contains fatty acids in the lower µM range (as shown in Chapter 5 and in (Andersson et al., 
2008)). Thus, when applying metabolic studies on hESC-CM, a higher concentration of fatty 
acids should be considered. An optimal ratio between fatty acids and glucose, which mimics the 
ratio in human plasma, might result in a substrate usage which more reflects the cardiac in vivo 
situation in man and thus, gives more reliable results, when the assessment of the effect of drugs 
on cardiac energy metabolism is desired.  
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Chapter 7 
Concluding remarks 
 
It is assumed that alterations in cardiac energy metabolism either due to disease or drugs result in 
cardiac dysfunction (Stanley et al., 2005). While several studies report alterations of metabolism 
in the diseased heart (Ashrafian et al., 2007; Gertz et al., 1988; Mudge et al., 1976; Panchal et 
al., 2001; Randle et al., 1964; Stanley et al., 1997; Wisneski et al., 1985), holistic descriptions of 
the cardiac energy metabolism in response to cardioactive/toxic drugs are rare. 
The presented work describes the assessment of the effects of drugs with known clinical cardiac 
toxicity on two cardiac in vitro model systems, namely HL-1 cardiomyocytes and human 
embryonic stem cell derived cardiomyocytes (hESC-CM) by using metabolic profiling 
(metabolomics) and 13C-metabolic flux analysis. In addition, respiration measurement was used 
for cell viability measurements. The combination of all three methodologies allowed the 
assessment of the effect of cardiotoxic drugs on the metabolism of the two model cell types. 
However, the focus was clearly set on HL-1 cells due to their ready availability. Unlike hESC-
CM the source of HL-1 cells is not limited. Due to the limited availability of hESC-CM not all 
studies could be carried out on these cells in such detail as for HL-1 cells.  
Parts of the thesis were published as three scientific papers (Strigun et al., 2011a; Strigun et al., 
2011b; Strigun et al., 2011c). Two manuscripts are in preparation for submission. 
 
Cytotoxicity screening of cardioactive drugs on murine HL-1 cardiomyocytes 
In the first part of this study the effect of cardioactive drugs on the respiration in HL-1 
cardiomyocytes was determined by using oxygen-sensitive fluorescent sensors (Optodes). These 
optodes have been described as a convenient alternative to common cytotoxicity assays (e.g. 
WST-1, MTT, Alamar Blue) when the determination of EC50 dynamics of drugs is desired 
(Beckers et al. 2009; Noor et al., 2009; Wolf et al., 2011). However, a direct comparison of EC50 
dynamics of drugs with similar or different mechanism of action or toxicity has not been reported 
yet. The first part of the thesis shows for the first time EC50 dynamics of several 
cardioactive/toxic drugs. Significant differences in the EC50-dynamic profiles could be 
determined, which partly dependend on the mechanism of action or toxicity of the drugs. The 
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distinct differences in the dynamic profiles suggest that preclinical in vitro studies on drug 
toxicity (independant of the cell model) should include measurement of EC50 dynamics, since 
such profiles potentially allow conclusions whether the toxic effect of a drug occurs directly or 
with a certain delay. The presented results suggest that the determination of EC50 dynamics gives 
information on the mechanism of toxicity of a drug or chemical. 
 
Metabolic profiling of HL-1 cardiomyocytes in response to cardiotoxic drugs 
In the second part of this study HPLC-based metabolomics was used to assess whether drugs 
create specific profiles in the extracellular metabolome of HL-1 cells. The metabolome was 
measured at drug concentrations which were not cytotoxic. This methodology included the 
measurement of culture medium metabolites after a specific time of exposure and the subsequent 
data evaluation using common statistical multivariate procedures e.g. principal component 
analysis. This study shows that a targeted metabolomics approach, in which the considered sub-
profile merely consists of nutrients available in most common cell culture media (glucose, 
pyruvate, amino acids), is sufficient to classify drugs according to their known mechanism of 
action. The presented results suggest that this approach also provides indications on the 
mechanism of toxicity of a new drug compound. 
 
13C metabolic flux analysis in HL-1 cells upon exposure to Doxorubicin and 
Verapamil 
The first drug which was considered in the flux analysis approach was the calcium channel 
blocker verapamil. Although clinical cardiotoxic reports on this drug are rare and mainly involve 
overdoses, this drug was quite interesting for flux studies for several reasons. First, metabolic 
profiling revealed a unique effect of verapamil on glucose and lactate metabolism and second, 
fluxomic studies clarified the consequences of this effect on the central metabolism. 13C flux 
analysis on HL-1 with and without verapamil was successfully carried out and gave a holistic 
description of the effect of verapamil on central metabolism. At the applied conditions, 
verapamil resulted in a highly decreased glucose uptake which was accompined by a halt of 
lactate production. This effect allowed the cells to maintain the TCA-cycle- as well as 
respiratory activity and thereby maintenance of cell growth similar to untreated cells. Thus, the 
verapamil-induced decrease of glucose uptake resulted in an efficient use of available glucose 
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carbon. This is especially of importance when considering that HL-1 cells highly rely on 
anaerobic glycolysis under normal conditions (i.e. high lactate production). These results were 
published (Strigun et al., 2011a) and have been discussed extensively there. However, although 
verapamil highly influenced glucose and lactate metabolism of HL-1 cardiomyocytes, a direct 
correlation to clinically observed toxicity of verapamil could not be made. Although, several 
recent reports showed an inhibiting influence of verapamil on glucose uptake in several cell 
types, these studies were not carried out in the context of cardiotoxicity related research. Thus, in 
the published work, the effects of verapamil on HL-1 metabolism were not discussed in the 
context of cardiotoxic research, but in the context of cancer research and of potential 
biotechnological applications. Inhibition of glucose uptake along with the observed effects on 
lactate metabolism might contribute to verapamils potential usefulness as an anticancer drug 
which has been recently proposed (Zhang et al., 2009). Second, verapamil induced inhibition of 
glucose uptake and the observed halt of lactate production might be exploited in the field of 
bioproduction of therapeutical proteins using mammalian cell lines, which often show high 
lactate production i.e. inefficient use of glucose. Further work is necessary on relevant cell lines 
to assess this potential.  
Like verapamil, doxorubicin highly influenced the extracellular metabolome of HL-1 
cardiomyocytes at sub-toxic concentrations. The fact that doxorubicin shows high cardiotoxicity 
in cancer patients undergoing DXR treatment and the assumption that doxorubicin highly 
influences cardiac energy metabolism (Tokarska-Schlattner et al., 2006) additionally motivated 
an extended fluxomic characterisation by means of 13C-metabolic flux analysis. The most 
important finding of this study was that doxorubicin significantly increases activity of the TCA-
cycle as well as respiration, apparently to prevent doxorubicin induced depletion of ATP in HL-
cells. Unlike most recent studies, the analysis was carried out at clinically relevant concentrations 
that are considered non-toxic. This was facilitated by the high sensitivity of the GC/MS-based 
flux analysis approach. The results of this study were recently published (Strigun et al., 2011c) 
and have been extensively discussed in the context of current knowledge regarding doxorubicin 
cardiotoxicity. The presented results give additional weight to the assumption that doxorubicin 
deteriorates cardiac energy metabolism. If occurring in vivo in patients undergoing doxorubicin 
treatment, depletion of cardiac ATP might be exacerbated by other reported metabolic effects, 
such as doxorubicin-induced decrease of fatty acid oxidation.  
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13C metabolic flux analysis in human embryonic stem cell derived cardiomyo-
cytes upon exposure to Doxorubicin 
Reliable in vitro cardiotoxicity testing necessitates cardiac models which closely mimic human 
cardiac tissue. Human embryonic stem cell derived cardiomyocytes have been suggested as a 
convenient alternative to isolated primary cells from either human or animal origin. 
Since the healthy human heart covers the majority of its ATP demand by oxidative metabolism, 
in vitro cardiac cell models should also share this metabolic phenotype. This is especially of 
importance when the reliable in vitro determination of drug induced changes in cardiac energy 
metabolism is desired.  
In this work the central energy metabolism of hESC-CM and its alteration due to the anticancer 
drug doxorubicin was studied by using 13C metabolic flux analysis.  
Untreated cells seemed to cover the majority of their ATP-demand by anaerobic glycolysis i.e. 
the flux of glucose carbon into the TCA-cycle was relatively low. The TCA-cycle was mainly 
fuelled by catabolism of amino acids. This result suggests further optimisation of the cardiac 
differentiation process, or alternatively, a proper design of adequate cultivation media. 
However, treatment of the cells with doxorubicin showed significant alterations of the 
intracellular metabolism, similar to HL-1 cells treated with doxorubicin. The cells showed a more 
efficient use of glucose carbon, i.e. less lactate secretion and increase oxidative decarboxylation 
as well as a higher TCA-cycle flux. This increase might be the result of either formation of 
reactive oxygen species or electron shunting (uncoupling of respiration), and consequently, an 
attempt of the cells to compensate for ATP-depletion.  
 
In summary, the presented study shows that application of metabolic profiling and 13C metabolic 
flux analysis, combined with respiration measurement, allows the assessment of drug induced 
changes of cardiac energy metabolism. The presented results suggest that preclinical in vitro 
studies regarding drug-induced cardiotoxicity by electrophysiologically based methods should be 
complemented by assessment of cardiac energy metabolism. 
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Chapter 8 
Outlook 
Respiration measurement was carried out on HL-1 cells by using oxygen-sensitive fluorescent 
optodes. The EC50 dynamics of the considered drugs could partly be explained by current 
literature knowledge regarding their general toxicity or more specifically, their cardiotoxicity. 
However, when the EC50 dynamic of a new chemical/drug with unknown mechanism of toxicity 
is determined it will merely give information whether the onset of toxicity occurs either fast or 
slow. Prediction of its mechanism of general toxicity or cardiotoxicity might necessitate the 
screening of a rather extensive library of training compounds with known in vitro or in vivo 
toxicity/cardiotoxicity. Besides that, EC50 values should be determined as exactly as possible, i.e. 
the number of considered drug concentrations should be higher than the number considered in 
this study (6-9 drug concentrations). Such an approach would require a higher throughput format, 
such as 384–well plates or even higher. In addition to the potential prediction of the toxicity 
mechanism of a drug, one could also establish mathematical models that describe the 
relationships between drug concentrations, death kinetics, toxicity delay time and the course of 
dissolved oxygen. Such relationships might show distinct characteristics (linear, asymptotical, 
sigmoidal etc.) depending on the toxicity mechanism of a drug. Such information might be very 
useful for in vitro safety pharmacological studies, but could also be used for a more detailed 
determination of a drug´s toxicity mechanism.  
Metabolic profiling of culture supernatants containing HL-1 cells was carried out upon exposure 
to drugs. The metabolic profiles were dependant on the drug class, thereby allowing classification 
of drugs according to their mechanism of toxicity. However, the used data set in the present work 
was limited and included merely a set of ten drugs. The establishment of extensive models for 
prediction of completely unknown compounds classification would propably need a rather 
extended set of training compounds. Moreover, using a similar profiling approach with an 
extended set of drugs, the risk of unknown compounds/new pharmaceuticals for cardiac side 
effects might be reliably assessed when applying classification on the basis of clinically observed 
side effects, such as QT-prolongation or cardiac arrest.  
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13C metabolic flux analysis has shown a clear effect of the cardioactive drug verapamil on the 
central metabolism of HL-1 cardiomyocytes. The actual mechanism by which verapamil 
inhibited glucose uptake was not determined in this study, but may involve direct inhibition of 
glucose transporters. Additionally there is evidence that verapamil and other channel blockers 
inhibit expression of hypoxia inducible factor (HIF1) at normoxic and hypoxic conditions 
(Bharadwaj et al., 2002). Elevated glucose consumption, has been associated with elevated 
(HIF1-α) levels in human breast cancer cell lines, while depression of HIF1- α levels resulted in 
an inhibition of anaerobic glycolysis (Robey et al., 2005). This might be an explanation for 
verapamil induced reduction in glucose uptake, which, however, has not been studied so far to 
our knowledge and should be the focus of following research in this regard.  
The effect of doxorubicin on the central metabolism of HL-1 cells was determined by 13C 
metabolic flux analysis. In the presented work it was pointed out that either doxorubicin induced 
production of reactive oxygen species or a mechanism referred to as “electron shunting” might be 
responsible for increased TCA-cycle activity and respiration. Both effects would result in an 
uncoupling of electron transfer to oxygen from oxidative phosphorylation and thus, decreased 
ATP-production. While formation of reactive oxygen species is highly associated with 
doxorubicin-cardiotoxicity (Simunek et al., 2009), more recent studies have suggested that 
electron shunting is more likely to occur in vivo (Pointon et al., 2011). It will be interesting to 
determine whether formation of reactive oxygen species occurs in the tested experimental setup 
and whether the application of appropriate antioxidants compensates the observed effects.  
13C metabolic flux analysis on human embryonic stem cell derived cardiomyocytes revealed that 
these cells highly rely on anaerobic glycolysis. However, by using medium design strategies the 
metabolism of the hESC-CM potentially could be altered to a state which more reflects the 
metabolism of the adult human cardiomyocyte (i.e. aerobic metabolism). In the used medium, 
glucose was the dominating substrate and its concentration highly exceeded the concentration of 
other metabolites (e.g. amino acids) which might contribute to the observed high anaerobic 
glycolysis. In fact, glucose concentration in common culture media (e.g. DMEM) exceeds the 
blood glucose concentration in healthy, non-diabetic adults (Ceriello et al., 2008)). Future studies 
on hESC-CM energy metabolism should take into account an adequate glucose concentration. In 
addition, fatty acids and lipids are the main energy source in the human myocardium and it has 
been shown that the fatty acid concentration in culture medium containing FBS is much lower 
than in human plasma. Thus, when applying metabolic studies on hESC-CM, a higher 
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concentration of fatty acids should be used. An optimal ratio between fatty acids and glucose, 
which mimics the ratio in human plasma, might result in a substrate usage which more reflects 
the cardiac in vivo situation in man and thus, gives more reliable results, when the assessment of 
the effect of drugs on cardiac energy metabolism is desired. However, treatment of the cells with 
doxorubicin showed significant alterations of the intracellular metabolism, similar to HL-1 cells 
treated with doxorubicin. Though, besides ATP-measurement, it will be interesting to study 
whether the altered TCA-cycle activity is accompanied by altered cell respiration and whether 
ROS-formation plays a significant role in the observed effects.  
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Table S1: EC50 values of several drugs determined by continuous measurement of dissolved oxygen using 24 – well 
OxoDishes. Drugs were tested on HL-1 cardiomyocytes for 48 h. n.d.: not determined. 
 EC50 [µM] 
t [h] Terfenadin Verapamil Daunorubicin Amiodarone Diclofenac Desipramin Haloperidol Astemizol Doxorubicin 
20 5.3 44.3 0.8 18.8 596.8 63.5 87.7 4.6 3.5 
25 4.7 41.4 0.5 18.3 566.6 51.9 74.6 4.5 n.d. 
30 4.4 39.3 0.4 17.5 458.9 43.0 56.2 4.4 2.7 
35 4.3 38.8 0.3 16.4 409.7 38.0 47.0 4.4 1.4 
40 4.2 37.6 0.2 15.9 355.9 34.6 41.2 4.5 0.8 
45 4.3 35.1 0.2 15.5 312.0 33.6 38.0 4.5 0.6 
48 4.1 33.2 0.1 14.5 321.3 33.2 35.8 4.3 0.5 
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Figure S1: Concentration-response curves of amiodarone (B,F,J), desipramin (A,E,I), doxorubicin (C,G,K) and 
terfenadin (D,H,L) screened on HL-1 cells by using continuous oxygen measurement (A,B,C,D); sulforhodamine B 
proliferation assay (E,F,G,H) and lactate dehydrogenase release assay (I,J,K,L). The concentration response was 
determined after 20 h (black symbols), 30 h (red symbols), 40 h (blue symbols) and 48 h (turquoise symbols) of 
exposure. Standard deviations were determined from triplicate measurement. 
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Chapter 4 
Text S1: Oxygen uptake rate measurement 
Specific oxygen consumption rate per cell (qO2) was estimated using the liquid phase balance: 
[ ] [ ]( ) ⋅ = ⋅ − − 2 sat 2L 2 2d O qO Xk a O Odt V   
[O2sat] is the dissolved oxygen concentration at saturation in culture medium while [O2] 
represents the actual dissolved oxygen concentration, X the number of cells per well and V the 
liquid volume per well. kLa is the oxygen transfer coefficient. It was additionally assumed that 
oxygen uptake follows Michaelis-Menten Kinetics. Additionally, exponential growth of cells was 
considered resulting in the set of equations (MATLAB listing) 
OUR = (qo2*X)*(O/(KO+O)); 
DODT = KLA*(OS-O) - OUR/Volume; 
DXDT = mue*X; 
KO was set to 0.001 mM, X was the experimentally determined cell number, OS is the saturation 
concentration of dissolved oxygen as taken from Oeggerli et al. (1995) and Volume is the volume 
per well.  
Equation (6) was integrated using MATLAB (routine od15s) and statistical errors were estimated 
using Monte Carlo simulation. Experimental data were fitted using least square criterion and the 
optimization routine fmincon of MATLAB. For each experiment two Monte-Carlo-runs (each 
with 200 simulations) were computed, one with a standard deviation of dissolved oxygen 
measurement of 5% and one with 10%. It was observed that the parameters kLa and qO2 are 
significantly correlated with each other. Therefore, combinations of parameter values estimated 
by the Monte-Carlo method were dependent on the specified measurement error. In parameter 
estimation the four parameters qO2, KLA, mue and the initial value of O, the dissolved oxygen 
concentration, were estimated simultaneously. 
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Figure S1: Experimental (symbols) and model calculated (full line) dissolved oxygen concentration profiles in 
untreated control and treated HL-1 cells (4 µM verapamil). 
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Figure S2: Monte-Carlo calculations of mass transfer coefficient, kLa, and specific oxygen uptake rate, qO2, in HL-1 
cells treated with 4 µM verapamil (A) and in untreated control (B).  Light (blue) columns represent estimations 
assuming 10% standard deviation of dissolved oxygen concentration and dark (red) columns estimations assuming 
5% error. Error bars show the resulting error in estimated parameters resulting from 200 Monte-Carlo runs. 
Appendix 
 128
C
o
n
c
e
n
tr
a
ti
o
n
 [
µ
M
]
t [h]
0 50 100
0
5×10
5
10×10
5
Cells
0 50 100
0
12500
25000
GLC
0 50 100
0
7500
15000
LAC
0 50 100
0
50
100
PYR
0 50 100
0
500
1000
ALA
0 50 100
0
200
400
ARG
0 50 100
0
150
300
ASN
0 50 100
0
200
400
ASP
0 50 100
0
400
800
GLU
0 50 100
0
1000
2000
GLN
0 50 100
0
300
600
GLY
0 50 100
0
100
200
HIS
0 50 100
0
400
800
ILE
0 50 100
0
400
800
LEU
0 50 100
0
500
1000
LYS
0 50 100
0
150
300
MET
0 50 100
0
200
400
PHE
0 50 100
0
750
1500
PRO
0 50 100
0
400
800
SER
0 50 100
0
400
800
THR
0 50 100
300
600
TYR
0 50 100
0
500
1000
VAL
 
Figure S3: Concentrations of all considered metabolites versus time in culture medium of untreated (filled symbols) 
and in HL-1 cells treated with 4 µM verapamil (open symbols). Error bars represent standard deviations from 
triplicate measurement. 
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Figure S4: Concentrations of all considered metabolites versus cell number at each time point of the cultivation in 
culture medium of untreated HL-1 cells (filled symbols) and in HL-1 cells treated with 4 µM verapamil (open 
symbols). The slope of each plot represents the yield coefficient (Yi) which was used for calculation of uptake and 
production rates (see Tab. 1, Chapter 4) according to equation 5 (Chapter 4). The correlation coefficients for each 
yield are shown in Tab. S2. Error bars represent standard deviations determined from triplicate measurement.  
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Figure S5: Calculated (simulated) intracellular fluxes and mass distributions as compared to experimentally 
measured fluxes and mass distributions in untreated controls (A and B) and in HL-1 cells treated with 4 µM 
verapamil (C and D).  
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Table S1: List of reactions in the metabolic network model used for the calculation of intracellular fluxes showing 
reactants, products, carbon transfer atom products and the metabolic pathway.  
Atomic mechanism
reactant product reactant carbon product carbon pathw ay
G6Pi n F6Pi n [1*2*3*4*5*6] [1*2*3*4*5*6] Glycolysis
F6Pi n G6Pi n [1*2*3*4*5*6] [1*2*3*4*5*6] Glycolysis
F6Pi n GAPi n [1*2*3*4*5*6] [4*5*6] Glycolysis
F6Pi n GAPi n [1*2*3*4*5*6] [3*2*1] Glycolysis
GAPi n 3PGi n [1*2*3] [1*2*3] Glycolysis
3PGi n PYRi n [1*2*3] [1*2*3] Glycolysis
PYRi n mACA i n [1*2*3] [2*3] TCA-cycle
mOAA i n mCITi n [1*2*3*4] [4*3*2*0*0*1] TCA-cycle
mACA i n mCITi n [1*2] [0*0*0*2*1*0] TCA-cycle
mCITi n mAKGi n [1*2*3*4*5*6] [1*2*3*4*5] TCA-cycle
mAKGi n mSUCi n [1*2*3*4*5] [2*3*4*5] TCA-cycle
mSUCi n mOAA i n [1*2*3*4] [1*2*3*4] TCA-cycle
mSUCi n mOAA i n [1*2*3*4] [4*3*2*1] TCA-cycle
mOAA i n mSUCi n [1*2*3*4] [1*2*3*4] TCA-cycle
mOAA i n PYRi n [1*2*3*4] [1*2*3] Anaplerosis
PYRi n mOAA i n [1*2*3] [1*2*3*0] Anaplerosis
mCITi n mOAA i n [1*2*3*4*5*6] [6*3*2*1] Intracellular
mCITi n ACA i n [1*2*3*4*5*6] [4*5] Intracellular
mOAA i n mCITi n [1*2*3*4] [4*3*2*0*0*1] Intracellular
ACA i n mCITi n [1*2] [0*0*0*2*1*0] Intracellular
PYRi n LACi n [1*2*3] [1*2*3] Intracellular
mOAA i n ASPi n [1*2*3*4] [1*2*3*4] Intracellular AA M etabolism
ASPi n mOAA i n [1*2*3*4] [1*2*3*4] Intracellular AA M etabolism
GLUi n mAKGi n [1*2*3*4*5] [1*2*3*4*5] Intracellular AA M etabolism
mAKGi n GLUi n [1*2*3*4*5] [1*2*3*4*5] Intracellular AA M etabolism
PYRi n ALA i n [1*2*3] [1*2*3] Intracellular AA M etabolism
ALA i n PYRi n [1*2*3] [1*2*3] Intracellular AA M etabolism
3PGi n SERi n [1*2*3] [1*2*3] Intracellular AA M etabolism
SERi n 3PGi n [1*2*3] [1*2*3] Intracellular AA M etabolism
SERi n GLY i n [1*2*3] [1*2] Intracellular AA M etabolism
GLY i n SERi n [1*2] [1*2*0] Intracellular AA M etabolism
GLNi n GLUi n [1*2*3*4*5] [1*2*3*4*5] Intracellular AA M etabolism
GLUi n GLNi n [1*2*3*4*5] [1*2*3*4*5] Intracellular AA M etabolism
GLUi n PROi n [1*2*3*4*5] [1*2*3*4*5] Intracellular AA M etabolism
PROi n GLUi n [1*2*3*4*5] [1*2*3*4*5] Intracellular AA M etabolism
ILEi n mACA i n [1*2*3*4*5*6] [5*6] Intracellular AA M etabolism
ILEi n mSUCi n [1*2*3*4*5*6] [0*2*3*4] Intracellular AA M etabolism
LEUi n mACA i n [1*2*3*4*5*6] [1*2] Intracellular AA M etabolism
LEUi n mACA i n [1*2*3*4*5*6] [3*4] Intracellular AA M etabolism
LEUi n mACA i n [1*2*3*4*5*6] [5*6] Intracellular AA M etabolism
VALi n mSUCi n [1*2*3*4*5] [2*3*4*5] Intracellular AA M etabolism
LYSi n mACA i n [1*2*3*4*5*6] [2*3] Intracellular AA M etabolism
LYSi n mACA i n [1*2*3*4*5*6] [4*5] Intracellular AA M etabolism
PHEi n TYRi n [1*2*3*4*5*6*7*8*9] [1*2*3*4*5*6*7*8*9] Intracellular AA M etabolism
TYRi n mOAA i n [1*2*3*4*5*6*7*8*9] [6*7*8*9] Intracellular AA M etabolism
TYRi n mACA i n [1*2*3*4*5*6*7*8*9] [4*5] Intracellular AA M etabolism
TYRi n mACA i n [1*2*3*4*5*6*7*8*9] [2*3] Intracellular AA M etabolism
LACi n LACex [1*2*3] [1*2*3] Secret ion
PYRi n PYRex [1*2*3] [1*2*3] Secret ion
ALA i n ALAex [1*2*3] [1*2*3] Secret ion
GLUi n GLUex [1*2*3*4*5] [1*2*3*4*5] Secret ion
GLY i n GLYex [1*2] [1*2] Secret ion
SERi n SERex [1*2*3] [1*2*3] Secret ion
GLCex G6Pi n [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake
GLNex GLNi n [1*2*3*4*5] [1*2*3*4*5] Uptake
ILEex ILEi n [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake
LEUex LEUi n [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake
VALex VALi n [1*2*3*4*5] [1*2*3*4*5] Uptake
ASPex ASPi n [1*2*3*4] [1*2*3*4] Uptake
PROex PROi n [1*2*3*4*5] [1*2*3*4*5] Uptake
LYSex LYSi n [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake
PHEex PHEi n [1*2*3*4*5*6*7*8*9] [1*2*3*4*5*6*7*8*9] Uptake
TYRex TYRi n [1*2*3*4*5*6*7*8*9] [1*2*3*4*5*6*7*8*9] Uptake
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Table S2: Correlation coefficients of metabolite yields (see Fig. S4, Chapter 4) 
Metabolite Untreated control 4 µM Verapamil
GLC -0.998 -0.96244
LAC 0.974 -0.84193
PYR 0.420 -0.57672
ALA 0.999 0.99936
ARG -0.994 -0.99544
ASN -0.972 -0.97336
ASP -0.467 -0.26242
GLU 0.985 0.92923
GLN -0.998 -0.99641
GLY 0.986 0.082844
HIS -0.926 -0.98624
ILE -0.997 -0.99307
LEU -0.991 -0.96915
LYS -0.977 -0.99958
MET -0.986 -0.99524
PHE -0.995 -0.96709
PRO -0.984 -0.15852
SER 0.955 0.92734
THR -0.984 -0.91537
TYR -0.971 -0.97156
VAL -0.990 -0.9765
correlation coefficients (d[M]/d[N])
 
 
Table S3: Mass isotopomer distribution of alanine in untreated control and HL-1 cells treated with 4 µM verapamil 
derived from [U-13C5] glutamine. Mass distribution of alanine, which was secreted by the cells into the culture 
medium, was analysed in samples by GC/MS. The data was used for calculation of mass isotopomer yields, as shown 
in Fig. 3. 
 alanine mass distribution [%] in untreated control 
t [h] m+0 m+1 m+2 m+3 
0 95.8 ± 1.02 3.74 ± 0.12 0.46 ± 0.23 0 ± 0.21 
24 94.65 ± 0.07 4.19 ± 0.09 0.14 ± 0.11 1.01 ± 0.04 
48 93.14 ± 0.1 4.56 ± 0.1 0.62 ± 0.07 1.69 ± 0.06 
72 92.46 ± 0.09 5.02 ± 0.13 0.69 ± 0.14 1.82 ± 0.09 
96 92.04 ± 0.35 5.33 ± 0.14 0.96 ± 0.07 1.67 ± 0.14 
 alanine mass distribution [%] in treated cells 
t [h] m+0 m+1 m+2 m+3 
0 95.8 ± 1.57 3.74 ± 0.21 0.46 ± 0.22 0 ± 0.11 
24 94.42 ± 0.5 3.99 ± 0.2 0.33 ± 0.24 1.26 ± 0.06 
48 92.12 ± 0.12 4.58 ± 0.05 0.9 ± 0.05 2.4 ± 0.03 
72 89.77 ± 0.15 5.49 ± 0.19 1.63 ± 0.01 3.12 ± 0.03 
96 87.79 ± 0.35 6.36 ± 0.21 2.2 ± 0.11 3.65 ± 0.03 
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Table S4: Mass isotopomer distribution of glutamate in untreated control and HL-1 cells treated with 4 µM 
verapamil derived from [U-13C5] glutamine. Cells were incubated for 96 h. Mass distribution of alanine, which was 
secreted by the cells into the culture medium, was analysed in samples by GC/MS. The data was used for calculation 
of mass isotopomer yields, as shown in Fig. 4 (Chapter 4). 
 glutamate mass distribution [%] in untreated control 
t [h] m+0 m+1 m+2 m+3 m+4 m+5 
0 94.05 ± 1.34 4.55 ± 0.17 0.00 ± 0.00 0.03 ± 1.47 0.03 ± 0.04 0.20 ± 0.28 
24 85.16 ± 0.39 7.15 ± 0.03 1.96 ± 0.17 0.64 ± 0.05 0.33 ± 0.01 4.77 ± 0.14 
48 84.85 ± 0.21 5.81 ± 0.04 0.95 ± 0.01 1.10 ± 0.02 0.53 ± 0.01 6.74 ± 0.16 
72 81.40 ± 0.14 6.54 ± 0.18 1.26 ± 0.10 1.61 ± 0.04 0.70 ± 0.01 8.47 ± 0.14 
96 79.90 ± 0.12 6.25 ± 0.1 1.39 ± 0.10 2.18 ± 0.01 0.71 ± 0.02 9.54 ± 0.1 
 glutamate mass distribution [%] in cells treated with 4 µm verapamil 
t [h] m+0 m+1 m+2 m+3 m+4 m+5 
0 94.05 ± 1.34 4.55 ± 0.17 0.00 ± 0.00 0.03 ± 1.47 0.03 ± 0.04 0.20 ± 0.28 
24 88.30 ± 0.28 5.37 ± 0.01 0.57 ± 0.05 0.53 ± 0.02 0.38 ± 0.02 4.89 ± 0.21 
48 82.90 ± 0.28 5.80 ± 0.02 0.95 ± 0.11 1.08 ± 0.02 0.70 ± 0.00 8.60 ± 0.16 
72 80.25 ± 1.48 5.69 ± 0.65 1.14 ± 0.30 1.59 ± 0.02 0.83 ± 0.09 10.55 ± 0.49 
96 75.65 ± 1.91 6.03 ± 0.64 1.79 ± 0.40 2.12 ± 0.03 1.00 ± 0.04 13.45 ± 0.78 
 
Table S5: Correlation coefficients of alanine mass isotopomer yields (see Fig. 3) 
 correlation coefficients (d[M]/d[N]) 
Mass isotopomer Untreated control 4 µM Verapamil 
m+0 0.999 0.999 
m+1 0.996 0.993 
m+2 0.995 0.989 
m+3 0.973 1.000 
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Table S6: Correlation coefficients of glutamate mass isotopomer yields (see Fig. 4) 
 correlation coefficients (d[M]/d[N]) 
Mass isotopomer Untreated control 4 µM Verapamil 
m+0 0.97 0.93 
m+1 0.78 0.99 
m+2 0.95 1.00 
m+3 1.00 1.00 
m+4 0.89 0.99 
m+5 0.97 1.00 
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Table S7: Intracellular rates of main catabolic pathway in untreated control and in cells treated with 4 µM 
verapamil. Metabolic fluxes were estimated from uptake and production rates and the mass isotopomer distribution 
of alanine and glutamate, derived from [U-13C5] glutamine. Standard deviations were calculated from Monte-Carlo 
simulation (see methods in Chapter 4). Rates were considered significantly different when p < 0.05, as calculated 
from two-tailed t-test. 
 Specific rate [fmol cell-1 h-1]  
Reaction 
untreated 
control 
± s. d. 4 µM verapamil ± s. d. p 
G6PF6P 218.0 0.1 90.4 0.4 <0.001 
F6PGAP 218.0 0.1 90.4 0.4 <0.001 
GAP3PG 434.5 0.2 179.1 1.0 <0.001 
3PGPYR 420.3 0.5 163.4 2.5 <0.001 
PYRACA 228.9 39.3 191.9 13.1 n.s. 
OAA+ACACIT 246.2 39.2 207.6 12.4 n.s. 
CITAKG 211.4 39.4 165.9 15.4 n.s. 
AKGSUC 235.8 38.6 195.7 20.1 n.s. 
SUCOAA 247.2 44.4 205.7 21.3 n.s. 
OAAPYR 35.6 4.3 38.4 6.9 n.s. 
CITOAA 34.7 0.7 41.7 4.6 <0.05 
PYRLAC 209.8 40.2 -8.5 8.0 <0.01 
OAAASP 1.6 0.5 2.4 0.5 <0.05 
GLUAKG 24.4 2.6 29.8 5.9 n.s. 
PYRALA 16.3 0.6 19.0 2.4 n.s. 
3PGSER 14.2 0.4 15.7 1.5 n.s. 
SERGLY 7.0 0.4 7.8 0.9 n.s. 
GLNGLU 29.4 1.9 37.3 5.0 <0.05 
GLUPRO 0.1 1.6 1.0 1.6 n.s. 
ILEACA 7.2 0.8 6.7 2.3 n.s. 
LEUACA 2.4 0.6 2.3 1.2 n.s. 
VALSUC 4.1 1.0 3.3 1.2 n.s. 
LYSACA 0.0 0.0 0.0 0.1 n.s. 
PHETYR 0.5 0.2 0.3 0.3 n.s. 
TYROAA 1.4 0.2 1.1 0.7 n.s. 
NAD++2H++2e- 
NADH+H+ 
1207 208 1008 88 n.s. 
FAD+2H++2e-FADH2 256 46 214 25 n.s. 
4e- +O2 2O2- 750 127 630 60 n.s. 
ADP+PiATP 5640 760 4150 340 <0.05 
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Figure S1: Concentration of glucose, lactate, pyruvate and 20 amino versus time in culture medium of untreated HL-
1 cardiomyocytes (●) and cells treated with 0.01 µM (○) and 0.02 µM (∆) Doxorubicin. Error bars indicate standard 
deviations from four biological replicates. 
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Table S1: Specific uptake and production rates of metabolites in HL-1 cardiomyocytes upon exposure of cells to 
doxorubicin at different sub-toxic concentrations. Cells were incubated for 34 h (n=4).  
 Specific rate [fmol cell-1 h-1] 
Metabolite Untreated control 0.01 µM DXR 0.02 µM DXR 
Glc -299.7 ± 107.9 -288.2 ± 96.7 -262.1 ± 68.6 
Lac 641.5 ± 150.4 604.3 ± 94.3 603.0 ± 94.0 
Pyr -9.5 ± 5.6 -5.2 ± 5.4 -7.6 ± 7.3 
Ala 20.0 ± 4.1 18.2 ± 2.8 19.3 ± 2.5 
Arg -6.0 ± 2.3 -6.7 ± 1.9 -4.2 ± 1.4 
Asn -1.2 ± 0.7 -1.1 ± 0.6 -0.8 ± 0.8 
Asp 0.1 ± 1.1 1.1 ± 1.4 0.2 ± 0.9 
Cys -0.1 ± 0.7 0.3 ± 1.0 -1.1 ± 1.1 
Glu 5.9 ± 2.4 6.5 ± 2.4 6.6 ± 1.9 
Gln -45.6 ± 17.0 -44.5 ± 14.7 -38.4 ± 13.6 
Gly -1.4 ± 2.6 -4.9 ± 4.4 0.7 ± 2.1 
His -1.8 ± 1.0 -2.4 ± 0.8 -1.4 ± 1.1 
Ile -4.2 ± 2.7 -2.8 ± 2.4 -3.1 ± 1.9 
Leu -7.5 ± 4.0 -6.7 ± 2.2 -4.7 ± 2.4 
Lys -5.7 ± 3.2 -5.7 ± 2.1 -3.0 ± 2.9 
Met -1.5 ± 0.8 -1.5 ± 0.5 -0.9 ± 0.6 
Phe -0.7 ± 1.2 -0.3 ± 0.9 0.7 ± 1.1 
Pro 8.6 ± 3.3 6.0 ± 2.8 6.6 ± 3.4 
Ser 1.5 ± 1.4 1.5 ± 0.9 2.9 ± 1.3 
Thr 0.6 ± 3.3 0.7 ± 2.5 1.4 ± 2.3 
Trp 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.5 
Tyr -0.9 ± 2.1 -0.8 ± 1.3 0.7 ± 1.6 
Val -1.2 ± 2.6 0.0 ± 2.8 -0.8 ± 2.1 
Oleic acid 0.16 ± 0.09 0.29 ± 0.06 0.25 ± 0.1 
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Table S2: Mass isotopomer distribution of secreted lactate in untreated HL-1 cardiomyocytes and in cells treated 
with 0.01 µM and 0.01 µM DXR derived from [U-13C6]glucose. Mass distribution of secreted lactate was analysed 
by GC/MS. The data was used for calculation of mass isotopomer yields 
  Lactate mass distribution in untreated control 
t [h] m+0 m+1 m+2 m+3 
2 0.952 0.042 0.006 0.001 
10 0.928 0.037 0.004 0.031 
24 0.861 0.039 0.009 0.091 
34 0.826 0.039 0.010 0.124 
  Lactate mass distribution (0.01 µM DXR) 
t [h] m+0 m+1 m+2 m+3 
2 0.952 0.042 0.006 0.000 
10 0.930 0.038 0.005 0.028 
24 0.855 0.038 0.009 0.097 
34 0.822 0.038 0.010 0.130 
  Lactate mass distribution (0.02 µM DXR) 
t [h] m+0 m+1 m+2 m+3 
2 0.953 0.042 0.006 0.000 
10 0.929 0.037 0.004 0.030 
24 0.861 0.038 0.008 0.093 
34 0.822 0.038 0.010 0.129 
 
 
m+0= unlabeled lactate, m+1= single labeled lactate, m+2= double labeled lactate, m+3= fully labeled lactate 
 
Table S3: Mass isotopomer distribution of secreted lactate in untreated HL-1 cardiomyocytes and in cells treated 
with 0.01 µM and 0.02 µM DXR derived from [1,2-13C2]glucose. Mass distribution of secreted lactate was analysed 
by GC/MS. The data was used for calculation of mass isotopomer yields.  
  Lactate mass distribution in untreated control 
t [h] m+0 m+1 m+2 m+3 
2 0.952 0.042 0.007 0.000 
10 0.943 0.039 0.018 0.000 
24 0.905 0.040 0.055 0.000 
34 0.888 0.042 0.070 0.000 
  Lactate mass distribution (0.01 µM DXR) 
t [h] m+0 m+1 m+2 m+3 
2 0.952 0.042 0.006 0.000 
10 0.943 0.038 0.019 0.000 
24 0.907 0.040 0.052 0.000 
34 0.888 0.042 0.070 0.001 
  Lactate mass distribution (0.02 µM DXR) 
t [h] m+0 m+1 m+2 m+3 
2 0.953 0.041 0.006 0.000 
10 0.942 0.038 0.020 0.000 
24 0.902 0.040 0.057 0.000 
34 0.887 0.042 0.070 0.001 
 
 
m+0= unlabeled lactate, m+1= single labeled lactate, m+2= double labeled lactate, m+3= fully labeled lactate 
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Table S4: Mass isotopomer distribution of secreted lactate in untreated HL-1 cardiomyocytes and in cells treated 
with 0.01 µM and 0.02 µM DXR derived from [U-13C5]glutamine. Mass distribution of secreted lactate was analysed 
by GC/MS. The data was used for calculation of mass isotopomer yields.  
  Lactate mass distribution in untreated control 
t [h] m+0 m+1 m+2 m+3 
2 0.952 0.042 0.006 0.000 
10 0.949 0.041 0.005 0.004 
24 0.942 0.044 0.007 0.007 
34 0.940 0.045 0.008 0.007 
  Lactate mass distribution (0.01 µM DXR) 
t [h] m+0 m+1 m+2 m+3 
2 0.953 0.042 0.006 0.000 
10 0.951 0.041 0.005 0.004 
24 0.942 0.044 0.007 0.007 
34 0.940 0.045 0.008 0.007 
  Lactate mass distribution (0.02 µM DXR) 
t [h] m+0 m+1 m+2 m+3 
2 0.953 0.041 0.005 0.000 
10 0.950 0.041 0.005 0.004 
24 0.942 0.044 0.007 0.007 
34 0.940 0.045 0.008 0.007 
 
 
m+0= unlabeled lactate, m+1= single labeled lactate, m+2= double labeled lactate, m+3= fully labeled lactate 
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Table S5: Intracellular fluxes in HL-1 cardiomyocytes upon exposure to doxorubicin at different sub-toxic 
concentrations. Cells were incubated for 34 h. Rates were determined by implementing 13C mass isotopomer 
fractions in lactate, obtained from incubating cells with [U-13C6]glucose and [1,2-13C6]glucose and [U-
13C5]glutamine, into a metabolic network model. Rates were considered significantly different at p < 0.05. 
 specific rate [fmol cell-1 h-1] 
reaction untreated control 0.01 µM P 0.02 µM P 
v1 298.4 ± 0.17 286.9 ± 0.12 <0.001 260.8 ± 0.4 <0.001 
v2 298.2 ± 0.07 286.5 ± 0.05 <0.001 260.4 ± 0.2 <0.001 
v3 595.4 ± 0.10 572.1 ± 0.07 <0.001 519.8 ± 0.3 <0.001 
v4 591.1 ± 0.76 571.3 ± 0.97 <0.001 513.2 ± 1.4 <0.001 
v5 30.7 ± 12.99 60.6 ± 15.16 <0.05 73.4 ± 55.8 n.s. 
v18 16.0 ± 1.63 15.5 ± 1.23 <0.01 19.9 ± 3.1 n.s. 
v20 14.6 ± 0.12 13.7 ± 0.63 <0.05 12.1 ± 2.8 n.s. 
v21 560.7 ± 6.55 466.2 ± 13.97 <0.001 390.8 ± 36.3 <0.01 
v23 4.3 ± 0.72 0.8 ± 0.95 <0.01 6.6 ± 1.4 <0.05 
v30 0.3 ± 0.64 -2.6 ± 0.88 <0.01 2.3 ± 0.9 <0.05 
v5 30.7 ± 12.99 60.6 ± 15.16 <0.05 73.4 ± 55.8 n.s. 
v6 61.0 ± 7.02 142.6 ± 16.61 <0.01 148.0 ± 38.5 <0.05 
v11 104.3 ± 8.18 163.5 ± 16.41 <0.01 167.6 ± 39.0 <0.05 
v12 86.2 ± 8.18 144.1 ± 16.50 <0.01 147.5 ± 39.1 <0.05 
v13 103.6 ± 9.09 176.2 ± 19.19 <0.01 177.7 ± 43.1 <0.05 
v14 117.8 ± 9.29 183.2 ± 19.06 <0.01 181.8 ± 42.9 <0.05 
v27 17.3 ± 1.56 32.1 ± 2.98 <0.001 30.2 ± 6.7 <0.05 
v15 30.2 ± 13.64 81.9 ± 18.69 <0.01 74.6 ± 40.7 n.s. 
v35 4.9 ± 0.62 2.1 ± 0.59 <0.01 2.1 ± 1.1 <0.05 
v33 6.0 ± 0.57 2.9 ± 0.54 <0.001 1.1 ± 0.9 <0.001 
v31 8.2 ± 0.53 4.1 ± 0.62 <0.001 3.0 ± 1.3 <0.01 
v32 8.5 ± 0.64 4.2 ± 0.64 <0.001 4.2 ± 1.4 <0.01 
v28 20.4 ± 1.10 35.4 ± 2.71 <0.001 37.8 ± 5.2 <0.01 
v34 5.3 ± 0.61 5.3 ± 0.50 n.s. 2.9 ± 1.2 <0.05 
v32 8.5 ± 0.64 4.2 ± 0.64 <0.001 4.2 ± 1.4 <0.01 
v24 16.4 ± 13.44 62.1 ± 17.00 <0.05 61.3 ± 38.7 n.s. 
v26 18.1 ± 0.30 19.4 ± 0.27 <0.01 20.2 ± 1.1 <0.05 
v25 -0.4 ± 0.26 -0.1 ± 0.30 n.s. 0.9 ± 0.3 <0.01 
v16 1.7 ± 13.34 -42.7 ± 17.10 <0.05 -41.1 ± 39.2 n.s. 
v7 0.4 ± 0.16 0.4 ± 0.12 n.s. 0.4 ± 0.4 n.s. 
v8 -0.1 ± 0.05 -0.2 ± 0.04 n.s. -0.2 ± 0.1 n.s. 
v9 -0.1 ± 0.05 -0.2 ± 0.04 n.s. -0.2 ± 0.1 n.s. 
v10 -0.1 ± 0.05 -0.2 ± 0.04 n.s. -0.2 ± 0.1 n.s. 
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Table S6: List of reactions in the metabolic network model used for calculation of intracellular fluxes showing 
reactants, products, carbon transfer atom products and the metabolic pathway. 
   Atomic mechanism  
reactant product flux reactant carbon product carbon pathway 
G6Pin F6Pin v1 [1*2*3*4*5*6] [1*2*3*4*5*6] Glycolysis 
F6Pin GAPin v2 [1*2*3*4*5*6] [4*5*6] Glycolysis 
F6Pin GAPin v2 [1*2*3*4*5*6] [3*2*1] Glycolysis 
GAPin 3PGin v3 [1*2*3] [1*2*3] Glycolysis 
3PGin gPYRin v4 [1*2*3] [1*2*3] Glycolysis 
gPYRin mPYRin v5 [1*2*3] [1*2*3] Glycolysis 
mPYRin gPYRin v5r [1*2*3] [1*2*3] Glycolysis 
G6Pin P5Pin v7 [1*2*3*4*5*6] [2*3*4*5*6] PPP 
P5Pin GAPin v8 [1*2*3*4*5] [0*0*0] PPP 
P5Pin GAPin v8 [1*2*3*4*5] [3*4*5] PPP 
P5Pin S7Pin v8 [1*2*3*4*5] [0*0*1*2*3*4*5] PPP 
P5Pin S7Pin v8 [1*2*3*4*5] [1*2*0*0*0*0*0] PPP 
GAPin P5Pin v8r [1*2*3] [0*0*0*0*0] PPP 
S7Pin P5Pin v8r [1*2*3*4*5*6*7] [3*4*5*6*7] PPP 
GAPin P5Pin v8r [1*2*3] [0*0*1*2*3] PPP 
S7Pin P5Pin v8r [1*2*3*4*5*6*7] [1*2*0*0*0] PPP 
GAPin F6Pin v9 [1*2*3] [0*0*0*1*2*3] PPP 
S7Pin F6Pin v9 [1*2*3*4*5*6*7] [1*2*3*0*0*0] PPP 
GAPin E4Pin v9 [1*2*3] [0*0*0*0] PPP 
S7Pin E4Pin v9 [1*2*3*4*5*6*7] [4*5*6*7] PPP 
F6Pin S7Pin v9r [1*2*3*4*5*6] [1*2*3*0*0*0*0] PPP 
E4Pin S7Pin v9r [1*2*3*4] [0*0*0*1*2*3*4] PPP 
F6Pin GAPin v9r [1*2*3*4*5*6] [4*5*6] PPP 
E4Pin GAPin v9r [1*2*3*4] [0*0*0] PPP 
P5Pin F6Pin v10 [1*2*3*4*5] [1*2*0*0*0*0] PPP 
E4Pin F6Pin v10 [1*2*3*4] [0*0*1*2*3*4] PPP 
P5Pin GAPin v10 [1*2*3*4*5] [3*4*5] PPP 
E4Pin GAPin v10 [1*2*3*4] [0*0*0] PPP 
F6Pin P5Pin v10r [1*2*3*4*5*6] [1*2*0*0*0] PPP 
GAPin P5Pin v10r [1*2*3] [0*0*1*2*3] PPP 
F6Pin E4Pin v10r [1*2*3*4*5*6] [3*4*5*6] PPP 
GAPin E4Pin v10r [1*2*3] [0*0*0*0] PPP 
mPYRin mACAin v6 [1*2*3] [2*3] TCA 
mOAAin mCITin v11 [1*2*3*4] [4*3*2*0*0*1] TCA 
mACAin mCITin v11 [1*2] [0*0*0*2*1*0] TCA 
mCITin mAKGin v12 [1*2*3*4*5*6] [1*2*3*4*5] TCA 
mAKGin mSUCin v13 [1*2*3*4*5] [2*3*4*5] TCA 
mSUCin mOAAin v14 [1*2*3*4] [1*2*3*4] TCA 
mSUCin mOAAin v14 [1*2*3*4] [4*3*2*1] TCA 
mOAAin mSUCin v14r [1*2*3*4] [1*2*3*4] TCA 
mOAAin mPYRin v15 [1*2*3*4] [1*2*3] Anaplerosis 
mPYRin mOAAin v15r [1*2*3] [1*2*3*0] Anaplerosis 
CO2ixx mOAAin v15r [1] [0*0*0*1] Anaplerosis 
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OAAin gPYRin v16 [1*2*3*4] [1*2*3] Anaplerosis 
gPYRin OAAin v16r [1*2*3] [1*2*3*0] Anaplerosis 
CO2ixx OAAin v16r [1] [0*0*0*1] Anaplerosis 
OAAin mOAAin v24 [1*2*3*4] [1*2*3*4] Intracellular 
mOAAin OAAin v24r [1*2*3*4] [1*2*3*4] Intracellular 
mCITin OAAin v26 [1*2*3*4*5*6] [6*3*2*1] Intracellular 
mCITin ACAin v26 [1*2*3*4*5*6] [4*5] Intracellular 
OAAin mCITin v26r [1*2*3*4*5*6] [4*3*2*0*0*1] Intracellular 
ACAin mCITin v26r [1*2] [0*0*0*2*1*0] Intracellular 
PYRin gPYRin v20 [1*2*3] [1*2*3] Intracellular Pyr 
ALAin gPYRin v18 [1*2*3] [1*2*3] Intracellular Pyr 
gPYRin ALAin v18r [1*2*3] [1*2*3] Intracellular Pyr 
gPYRin LACin v21 [1*2*3] [1*2*3] Intracellular Pyr 
mOAAin ASPin v25 [1*2*3*4] [1*2*3*4] AA Metabolism 
ASPin mOAAin v25r [1*2*3*4] [1*2*3*4] AA Metabolism 
GLUin mAKGin v27 [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
mAKGin GLUin v27r [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
3PGin SERin v23 [1*2*3] [1*2*3] AA Metabolism 
SERin 3PGin v23r [1*2*3] [1*2*3] AA Metabolism 
SERin GLYin v30 [1*2*3] [1*2] AA Metabolism 
GLYin SERin v30r [1*2] [1*2*0] AA Metabolism 
MTFixx SERin v30r [1] [0*0*1] AA Metabolism 
GLNin GLUin v28 [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
GLUin GLNin v28r [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
GLUin PROin v29 [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
PROin GLUin v29r [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
ILEin mACAin v31 [1*2*3*4*5*6] [5*6] AA Metabolism 
CO2ixx mACAin v31 [1] [0*0] AA Metabolism 
ILEin mSUCin v31 [1*2*3*4*5*6] [0*2*3*4] AA Metabolism 
CO2ixx mSUCin v31 [1] [1*0*0*0] AA Metabolism 
LEUin mACAin v32 [1*2*3*4*5*6] [1*2] AA Metabolism 
LEUin mACAin v32 [1*2*3*4*5*6] [3*4] AA Metabolism 
LEUin mACAin v32 [1*2*3*4*5*6] [5*6] AA Metabolism 
VALin mSUCin v33 [1*2*3*4*5] [2*3*4*5] AA Metabolism 
ARGin GLUin v34 [1*2*3*4*5] [1*2*3*4*5] AA Metabolism 
LYSin mACAin v35 [1*2*3*4*5*6] [2*3] AA Metabolism 
LYSin mACAin v35 [1*2*3*4*5*6] [4*5] AA Metabolism 
LACin LACex vext1 [1*2*3] [1*2*3] Secretion 
ALAin ALAex vext2 [1*2*3] [1*2*3] Secretion 
GLUin GLUex vext3 [1*2*3*4*5] [1*2*3*4*5] Secretion 
PROin PROex vext4 [1*2*3*4*5] [1*2*3*4*5] Secretion 
SERin SERex vext5 [1*2*3] [1*2*3] Secretion 
GLNex GLNin vinp2 [1*2*3*4*5] [1*2*3*4*5] Uptake 
ARGex ARGin vinp3 [1*2*3*4*5] [1*2*3*4*5] Uptake 
ASPex ASPin vinp4 [1*2*3*4] [1*2*3*4] Uptake 
GLYex GLYin vinp5 [1*2] [1*2] Uptake 
ILEex ILEin vinp6 [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake 
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LEUex LEUin vinp7 [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake 
LYSex LYSin vinp8 [1*2*3*4*5*6] [1*2*3*4*5*6] Uptake 
PYRex PYRin vinp9 [1*2*3] [1*2*3] Uptake 
VALex VALin vinp10 [1*2*3*4*5] [1*2*3*4*5] Uptake 
 
 
Chapter 6 
Table S1: List of reactions in the metabolic network model used for calculation of intracellular fluxes in untreated 
hESC-CM showing reactants, products, carbon transfer atom products and the metabolic pathway. 
   Atomic mechanism  
reactant product flux reactant carbon product carbon pathway 
G6Pin F6Pin v1 [1*2*3*4*5*6] [6*6] Glycolysis 
F6Pin G6Pin v1r [1*2*3*4*5*6] [6*6] Glycolysis 
F6Pin GAPin v2 [4*5*6] [6*3] Glycolysis 
F6Pin GAPin v2 [3*2*1] [6*3] Glycolysis 
GAPin 3PGin v3 [1*2*3] [3*3] Glycolysis 
3PGin PYRin v4 [1*2*3] [3*3] Glycolysis 
PYRin mACAin v5 [2*3] [3*2] TCA 
mOAAin mCITin v6 [4*3*2*0*0*1] [4*6] TCA 
mACAin mCITin v6 [0*0*0*2*1*0] [2*6] TCA 
mCITin mAKGin v7 [1*2*3*4*5] [6*5] TCA 
mAKGin mSUCin v8 [2*3*4*5] [5*4] TCA 
mSUCin mOAAin v9 [1*2*3*4] [4*4] TCA 
mSUCin mOAAin v9 [4*3*2*1] [4*4] TCA 
mOAAin mSUCin v9r [1*2*3*4] [4*4] TCA 
mOAAin PYRin v10 [1*2*3] [4*3] Anaplerosis 
PYRin mOAAin v10r [1*2*3*0] [3*4] Anaplerosis 
CO2ixx mOAAin v10r [0*0*0*1] [1*4] Anaplerosis 
mCITin mOAAin v11 [6*3*2*1] [6*4] Intracellular 
mCITin ACAin v11 [4*5] [6*2] Intracellular 
mOAAin mCITin v11r [4*3*2*0*0*1] [4*6] Intracellular 
ACAin mCITin v11r [0*0*0*2*1*0] [2*6] Intracellular 
PYRin LACin v12 [1*2*3] [3*3] Intracellular 
mOAAin ASPin v13 [1*2*3*4] [4*4] AA metabolism 
ASPin mOAAin v13r [1*2*3*4] [4*4] AA metabolism 
GLUin mAKGin v14 [1*2*3*4*5] [5*5] AA metabolism 
mAKGin GLUin v14r [1*2*3*4*5] [5*5] AA metabolism 
PYRin ALAin v15 [1*2*3] [3*3] AA metabolism 
ALAin PYRin v15r [1*2*3] [3*3] AA metabolism 
3PGin SERin v16 [1*2*3] [3*3] AA metabolism 
SERin 3PGin v16r [1*2*3] [3*3] AA metabolism 
SERin GLYin v17 [1*2] [3*2] AA metabolism 
GLYin SERin v17r [1*2*0] [2*3] AA metabolism 
MTFixx SERin v17r [0*0*1] [1*3] AA metabolism 
GLNin GLUin v18 [1*2*3*4*5] [5*5] AA metabolism 
GLUin GLNin v18r [1*2*3*4*5] [5*5] AA metabolism 
GLUin PROin v19 [1*2*3*4*5] [5*5] AA metabolism 
PROin GLUin v19r [1*2*3*4*5] [5*5] AA metabolism 
LEUin mACAin v21 [1*2] [6*2] AA metabolism 
LEUin mACAin v21 [3*4] [6*2] AA metabolism 
LEUin mACAin v21 [5*6] [6*2] AA metabolism 
Appendix 
 144
LYSin mACAin v23 [2*3] [6*2] AA metabolism 
LYSin mACAin v23 [4*5] [6*2] AA metabolism 
PHEin TYRin v24 [1*2*3*4*5*6*7*8*9] [9*9] AA metabolism 
TYRin mOAAin v25 [6*7*8*9] [9*4] AA metabolism 
TYRin mACAin v25 [4*5] [9*2] AA metabolism 
TYRin mACAin v25 [2*3] [9*2] AA metabolism 
ARGin GLUin v34 [1*2*3*4*5] [5*5] AA metabolism 
ALAin ALAex vext1 [1*2*3] [3*3] Secretion 
GLUin GLUex vext2 [1*2*3*4*5] [5*5] Secretion 
LACin LACex vext3 [1*2*3] [3*3] Secretion 
PROin PROex vext4 [1*2*3*4*5] [5*5] Secretion 
PYRin PYRex vext5 [1*2*3] [3*3] Secretion 
GLClab G6Pin vinp1 [1*2*3*4*5*6] [6*6] Norm Uptake 
ARGnon ARGin vinp2 [1*2*3*4*5] [5*5] Uptake 
ASPnon ASPin vinp3 [1*2*3*4] [4*4] Uptake 
HISnon HISin vinp4 [1*2*3*4*5*6] [6*6] Uptake 
LEUnon LEUin vinp5 [1*2*3*4*5*6] [6*6] Uptake 
LYSnon LYSin vinp6 [1*2*3*4*5*6] [6*6] Uptake 
PHEnon PHEin vinp7 [1*2*3*4*5*6*7*8*9] [9*9] Uptake 
SERnon SERin vinp8 [1*2*3] [3*3] Uptake 
TYRnon TYRin vinp9 [1*2*3*4*5*6*7*8*9] [9*9] Uptake 
GLNnon GLNin vinp10 [1*2*3*4*5] [5*5] Uptake 
GLYnon GLYin vinp11 [1*2] [2*2] Uptake 
 
Table S2: List of reactions in the metabolic network model used for calculation of intracellular fluxes in hESC-CM 
treated with doxorubicin showing reactants, products, carbon transfer atom products and the metabolic pathway. 
   Atomic mechanism   
reactant product flux reactant carbon product carbon pathway 
G6Pin F6Pin v1 [1*2*3*4*5*6] [6*6] Glycolysis 
F6Pin G6Pin v1r [1*2*3*4*5*6] [6*6] Glycolysis 
F6Pin GAPin v2 [4*5*6] [6*3] Glycolysis 
F6Pin GAPin v2 [3*2*1] [6*3] Glycolysis 
GAPin 3PGin v3 [1*2*3] [3*3] Glycolysis 
3PGin PYRin v4 [1*2*3] [3*3] Glycolysis 
PYRin mACAin v5 [2*3] [3*2] TCA 
mOAAin mCITin v6 [4*3*2*0*0*1] [4*6] TCA 
mACAin mCITin v6 [0*0*0*2*1*0] [2*6] TCA 
mCITin mAKGin v7 [1*2*3*4*5] [6*5] TCA 
mAKGin mSUCin v8 [2*3*4*5] [5*4] TCA 
mSUCin mOAAin v9 [1*2*3*4] [4*4] TCA 
mSUCin mOAAin v9 [4*3*2*1] [4*4] TCA 
mOAAin mSUCin v9r [1*2*3*4] [4*4] TCA 
mOAAin PYRin v10 [1*2*3] [4*3] Anaplerosis 
PYRin mOAAin v10r [1*2*3*0] [3*4] Anaplerosis 
CO2ixx mOAAin v10r [0*0*0*1] [1*4] Anaplerosis 
mCITin mOAAin v11 [6*3*2*1] [6*4] Intracellular 
mCITin ACAin v11 [4*5] [6*2] Intracellular 
mOAAin mCITin v11r [4*3*2*0*0*1] [4*6] Intracellular 
ACAin mCITin v11r [0*0*0*2*1*0] [2*6] Intracellular 
PYRin LACin v12 [1*2*3] [3*3] Intracellular 
mOAAin ASPin v13 [1*2*3*4] [4*4] AA metabolism 
ASPin mOAAin v13r [1*2*3*4] [4*4] AA metabolism 
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GLUin mAKGin v14 [1*2*3*4*5] [5*5] AA metabolism 
mAKGin GLUin v14r [1*2*3*4*5] [5*5] AA metabolism 
PYRin ALAin v15 [1*2*3] [3*3] AA metabolism 
ALAin PYRin v15r [1*2*3] [3*3] AA metabolism 
3PGin SERin v16 [1*2*3] [3*3] AA metabolism 
SERin 3PGin v16r [1*2*3] [3*3] AA metabolism 
SERin GLYin v17 [1*2] [3*2] AA metabolism 
GLYin SERin v17r [1*2*0] [2*3] AA metabolism 
MTFixx SERin v17r [0*0*1] [1*3] AA metabolism 
GLNin GLUin v18 [1*2*3*4*5] [5*5] AA metabolism 
GLUin GLNin v18r [1*2*3*4*5] [5*5] AA metabolism 
GLUin PROin v19 [1*2*3*4*5] [5*5] AA metabolism 
PROin GLUin v19r [1*2*3*4*5] [5*5] AA metabolism 
LEUin mACAin v21 [1*2] [6*2] AA metabolism 
LEUin mACAin v21 [3*4] [6*2] AA metabolism 
LEUin mACAin v21 [5*6] [6*2] AA metabolism 
LYSin mACAin v23 [2*3] [6*2] AA metabolism 
LYSin mACAin v23 [4*5] [6*2] AA metabolism 
PHEin TYRin v24 [1*2*3*4*5*6*7*8*9] [9*9] AA metabolism 
TYRin mOAAin v25 [6*7*8*9] [9*4] AA metabolism 
TYRin mACAin v25 [4*5] [9*2] AA metabolism 
TYRin mACAin v25 [2*3] [9*2] AA metabolism 
ARGin GLUin v34 [1*2*3*4*5] [5*5] AA metabolism 
ALAin ALAex vext1 [1*2*3] [3*3] Secretion 
GLNin GLNex vext2 [1*2*3*4*5] [5*5] Secretion 
GLUin GLUex vext3 [1*2*3*4*5] [5*5] Secretion 
GLYin GLYex vext4 [1*2] [2*2] Secretion 
LACin LACex vext5 [1*2*3] [3*3] Secretion 
PROin PROex vext6 [1*2*3*4*5] [5*5] Secretion 
PYRin PYRex vext7 [1*2*3] [3*3] Secretion 
GLClab G6Pin vinp1 [1*2*3*4*5*6] [6*6] Norm Uptake 
ARGnon ARGin vinp2 [1*2*3*4*5] [5*5] Uptake 
ASPnon ASPin vinp3 [1*2*3*4] [4*4] Uptake 
HISnon HISin vinp4 [1*2*3*4*5*6] [6*6] Uptake 
LEUnon LEUin vinp5 [1*2*3*4*5*6] [6*6] Uptake 
LYSnon LYSin vinp6 [1*2*3*4*5*6] [6*6] Uptake 
PHEnon PHEin vinp7 [1*2*3*4*5*6*7*8*9] [9*9] Uptake 
SERnon SERin vinp8 [1*2*3] [3*3] Uptake 
TYRnon TYRin vinp9 [1*2*3*4*5*6*7*8*9] [9*9] Uptake 
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